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General abbreVIaTIOnS
AF = amniotic fluid
ART = assisted reproductive technologies
BMI = body mass index
BPD = bronchopulmonary dysplasia
BV = bacterial vaginosis
Ca = calcium
CD4/8 = cluster of differentiation 4/8
COX = cyclo-oxygenase
CP = cerebal palsy
DNA = Deoxyribonucleic acid
ECM = extracellular matrix
ELBW = extremely low birth weight
fFN = foetal fibronectin
FIRS = foetal inflammatory response syndrome
GA = gestational age
IAI = intra-amniotic infection
Ig = immunoglobulin
IUI = intrauterine infection
IVF = in-vitro fertilisation
IVH = intravetricular haemorrhage
LBW = low birth weight
LPS = lipopolysaccharide
LR+ = positive likelihood ratio
LR- = negative likelihood ratio
MHC = major histocompatibility complex
MIAC = microbial invasion of the amniotic cavity
NEC = necrotizing enterocolitis
NICU = neonatal intensive care unit
PAMP = pathogen-associated molecular patterns
PCR = polymerase chain reaction
PDA = patent ductus arteriosus
PGE2 = prostaglandin E2
PPROM = preterm prelabour rupture of the membranes
PROM = prelabour rupture of the membranes
PRR = pattern recognition receptors
PTB = preterm birth
PTL = preterm labour
QoL = quality of life
RDS = respiratory distress syndrome
RNA = ribonucleic acid
ROM = rupture of membranes
ROP = retinopathy of prematurity
SGA = small for gestational age
SNP = single nucleotide polymorphism
SPE = studiecentrum voor perinatale epidemiologie
TH cells = T-helper cells
TLR = toll-like receptor
TREG = regulatory T-cells
TVS = transvaginal sonography
VLBW = very low birth weight
WHO = World Health Organization
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InFlaMMaTOry MarKerS
β-hCG = beta human chorionic gonadotrophin
CRP = C-reactive protein
EGF = epidermal growth factor
fFN = foetal fibronectin
FGF = fibroblast growth factor
G-CSF = granulocyte colony-stimulating factor
GM-CSF =  granulocyte-macrophage colony-stimulating 
factor
HGF = hepatocyte growth factor
IFN = interferon
IGFBP-1 = insulin-like growth factor binding protein-1
IL = interleukin
IP-10 = interferon gamma induced protein 10
MCP = monocyte chemoattractant protein-1
MIG = monokine induced gamma interferon
MIP = macrophage inflammatory protein
MMP = matrix metalloproteinase
PAMG-1 = placental alpha-microglobulin-1
PAPP-A = placental associated plasma protein A
phIGFBP-1 =  phosphorylated insulin-like growth factor 
binding protein-1
RANTES =  Regulated on Activation, Normal T-cell Expressed 
and Secreted
SP-A = surfactant proteins A
sTREM =  soluble triggering receptor expressed on myeloid 
cells
TIMP = tissue inhibitor of metalloproteinase
TNF-α = tumor necrosis factor-alpha
VEGF = vascular endothelial growth factor
aCrOnyM ClInICal TrIalS anD STUDIeS
APOSTEL I/II trial:  Alleviation of Pregnancy Outcome by Suspending of Tocolysis in Early Labour
EPIBEL study:  Extremely Preterm Infants in BELgium 
MOSAIC study:  Models of OrganiSing Access to Intensive Care for very preterm births
NICHD-MFMU trial:  National Institute of Child Health & Human Development-Maternal Fetal Medicine Unit
ORACLE I and II trial:  Overview of the Role of Antibiotics in Curtailing Labour and Early delivery
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Preterm birth (PTB) is a major perinatal health problem because 
it is the leading cause of perinatal morbidity and mortality 
worldwide (Beck et al., 2010; Goldenberg, Culhane, Iams & Rome-
ro, 2008; Gotsch et al., 2009). Technological advances and the 
collaborative efforts of obstetricians and neonatologists surviv-
al rates markedly have improved over the last 15 years (Davey, 
Watson, Rayner & Rowlands, 2011; Goldenberg et al., 2008). How-
ever these infants have an increased risk of neurodevelopmental 
impairments and respiratory and gastrointestinal complications 
(Goldenberg et al., 2008). The serious effects of PTB on parents, 
infant and society make PTB an important issue to public health 
worldwide (Khan & Honest, 2007).
1.1 Definition, inciDence anD prevalence
Preterm birth, as defined by the World health organization (Who), refers to all births occurring before 37 
completed weeks of gestation (up to 36 weeks 6 days) or fewer than 259 days since the first day of the last 
menstrual period (Beck et al., 2010; Blencowe et al., 2012; Kramer et al., 2012; Moutquin, 2003; steer, 2005b). 
This Who definition does not specify a lower gestational age (Ga) boundary. The lower Ga limit used for dis-
tinguishing PTB from spontaneous abortion, varies internationally (Goldenberg et al., 2008; Tucker & McGuire, 
2004) and ranges from 13 to 24 weeks of gestation (Mazaki-Tovi et al., 2007). Most countries base their PTB 
rate on live births from 20 (or 22) to 36 completed weeks. This lower and upper Ga boundary for defining PTB 
is quite arbitrary since infants born before 20 weeks or at 37 or 38 weeks share many etiological and prognostic 
features with birth at 20-36 weeks (Kramer et al., 2012). 
In 2005, the World health organization (Who) has estimated the global incidence of PTB at 9.6% of all births, 
with 13 million PTBs occurring annually (Beck et al., 2010). In 2010, the global average PTB rate (based on 
184 countries) was 11.1%, giving a worldwide total of 14.9 million (Blencowe et al., 2012). The burden of PTB 
is disproportionately concentrated in africa and asia where about 60 to 85% of all PTBs occur (Beck et al., 
2010; Blencowe et al., 2012). The high levels of PTB in developing regions are not only linked to the greater 
number of deliveries in those regions, but probably due to infection, poor maternal nutrition, heavy physical 
work, lack of availability of drugs (such as tocolytic agents) or lack of basic obstetric and neonatal care (Beck 
et al., 2010; steer, 2005a; Tucker & McGuire, 2004). PTB affects 12-13% of all pregnancies in the united states 
(Beck et al., 2010; Goldenberg et al., 2008). europe has the lowest rate of PTB worldwide (Beck et al., 2010). 
The prevalence varies widely in the european union, from 5.5% to 11.4% of all live births, with an average of 
7.1%, representing around 500,000 births annually (Keller, Mader, Thiele, saugstad & van steenbrugge, 2011). 
differences in definitions, classifications and measurement of Ga as well as the absence of routinely collected 
data on PTB in many countries may also explain the great disparity in PTB rates between countries (Blencowe 
et al., 2012; Kramer et al., 2012) and consequently limited the understanding of the size of the burden of PTB 
globally (Blencowe et al., 2012).
despite advances in perinatal medicine (e.g. assisted ventilation, prophylactic antenatal steroids, surfactant 
therapy, transfer to tertiary care, etc.) (chandiramani et al., 2011; Khan & honest, 2007; Tucker & McGuire, 
2004), improved perinatal health indicators (such as infertility, still birth and infant mortality) (Kramer et al., 
2012) and extensive research efforts to increase knowledge of risk factors and mechanisms related to preterm 
labour (Goldenberg et al., 2008), PTB rates have increased in most industrialized and many developing coun-
tries (Beck et al., 2010; Blencowe et al., 2012; Goldenberg et al., 2008; Keller et al., 2011). The usa rate has 
increased from 9.5% in 1981 to 12.7% in 2005 (Goldenberg et al., 2008). existing data show also an increase in 
PTB across europe during the last 10 years (Keller et al., 2011). contrary to the overall rise in the incidence of 
PTB, the rate of PTB before 32 weeks gestation is almost unchanged at 1-2%. This upward trend in PTB rate can 
be partially explained by increases in the proportion of iatrogenic (preterm) birth (Berghella, Baxter & hendrix, 
2009; Goldenberg et al., 2008), which is closely linked with the increased age of pregnant women (Beck et al., 
2010), the rise in multiple pregnancies (Beck et al., 2010; Berghella et al., 2009; Goldenberg et al., 2008; Tucker 
& McGuire, 2004), the greater use of assisted reproductive technologies (arT) (Beck et al., 2010; Berghella et 
al., 2009; Tucker & McGuire, 2004) and changes in registration (Berghella et al., 2009) and obstetric practice 
(Beck et al., 2010; Blencowe et al., 2012; Tucker & McGuire, 2004). for example, the greater use of elective 
caesarean section (Beck et al., 2010) and improved measurement methods for estimating Ga (ultrasonography 
vs. last menstrual period) (Beck et al., 2010; Berghella et al., 2009; Blencowe et al., 2012; Kramer et al., 2012).
Preterm birth has no specific functional basis and should be clearly distinguished from the concept of ‘prema-
turity’, which represents the lack of development of various organ systems at the time of birth (steer, 2005b).
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of regular contractions (Goldenberg et al., 2008). some studies do not require a minimum duration of rupture 
of membranes prior to onset of contractions, but based the classification on careful questioning the mother 
(Kramer et al., 2012). about 25-30% of the PTBs are related to PProM (Beck et al., 2010; Berghella et al., 2009; 
Goldenberg et al., 2008; Moutquin, 2003). Preterm labour implies regular contractions, accompanied by cer-
vical changes at less than 37 weeks gestation (Goldenberg et al., 2008). Preterm labour accounts for 45-50% 
of the PTBs and is sometimes called “idiopathic” (Beck et al., 2010; Berghella et al., 2009; Goldenberg et al., 
2008; Moutquin, 2003). 
The subdivision in preterm labour and PProM lacks robustness, because it is sometimes difficult to distinguish 
both conditions by history and it is often impossible to determine which occurred first. Moreover, each may 
result from more than one etiological pathway (Kramer et al., 2012). 
1.2.2 Gestational age
Birth at less than 28 weeks gestation is defined as severely (or extremely) preterm. Very preterm refers to birth 
at 28-31 weeks. The majority of PTBs occur between 32-36 weeks and are classified as mild preterm, subdi-
vided in moderate (32-33 weeks) and late preterm (or near term) (34-36 weeks) (Goldenberg et al., 2008; M. 
Keller et al., 2011; Moutquin, 2003). Mild preterm accounts for the great majority of all PTBs (Moutquin, 2003). 
In 2010, an estimated 0.78 million preterm babies were extremely preterm, 1.6 million were very preterm and 
most were moderate or late preterm (84%, 12.6 million) (Blencowe et al., 2012)
1.2.3 Birth weight
although birth weight is closely linked with gestational age, it cannot be used interchangeably (Blencowe et 
al., 2012; Tucker & McGuire, 2004), since there is a range of “normal” birth weight for a given gestational age 
and sex (Blencowe et al., 2012). Birth weight is classified into low birth weight (<2500g, lBW), very low birth 
weight (<1500g, VlBW) and extremely low birth weight (<1000g, elBW). only around two thirds of low birth 
weight infants are preterm. Preterm infants may also be small for gestational age (sGa) (usually defined as 
below the 10th percentile of birth weights) (Tucker & McGuire, 2004). Babies who are both preterm and sGa 
have a higher risk of death than babies of the same birth weight born sGa at term (Blencowe et al., 2012). 
outcomes improve with increasing gestational age, although for any given length of gestation survival varies 
with birth weight (Tucker & McGuire, 2004).
1.2 classification
existing classification including subdivisions by Ga, clinical presentation and birth weight. 
1.2.1 clinical presentation
according to its clinical presentation, PTB can be broadly classified into two groups (Beck et al., 2010; Blencowe 
et al., 2012; Goldenberg et al., 2008; Goldenberg, hauth & andrews, 2000; Kramer et al., 2012; Mazaki-Tovi et 
al., 2007; Moutquin, 2003): 
1.2.1.1  Medically indicated or provider initiated preterm birth (iatrogenic or 
elective) 
This category is etiologically and prognostically heterogeneous and includes both maternal and foetal compli-
cations which require labour induction or primary caesarean section before 37 weeks of gestation (Blencowe et 
al., 2012; Goldenberg et al., 2008; Kramer et al., 2012; Mazaki-Tovi et al., 2007). The most common indications 
are pregnancy-induced hypertension or preeclampsia (Kramer et al., 2012; Mazaki-Tovi et al., 2007; Moutquin, 
2003; Tucker & McGuire, 2004), intrauterine growth restriction (Kramer et al., 2012; Moutquin, 2003; Tucker & 
McGuire, 2004), nonreassuring tests of foetal well-being (Kramer et al., 2012; Moutquin, 2003), small for ges-
tational age (sGa) (Mazaki-Tovi et al., 2007) and antepartum haemorrhage (Kramer et al., 2012). These foetal 
and maternal complications can occur together, but may also be considered as separate clinical categories. 
some etiological risk factors can have opposite effects on maternal and foetal complications for indicated 
PTB (Kramer et al., 2012). approximately 15 to 30% of the PTBs are attributed to medically indicated PTB 
(Beck et al., 2010; Berghella et al., 2009; Goldenberg et al., 2008; Moutquin, 2003; Tucker & McGuire, 2004). 
The numbers of provider-initiated PTB have increased over time in many high and middle-income countries, 
but are very low in the highest burden countries such as african countries (Blencowe et al., 2012). one reason 
for this increase is that the indication threshold has fallen as obstetric care has become more aggressive and 
interventional (Kramer et al., 2012). 
1.2.1.2 Spontaneous preterm birth
Preterm births after preterm prelabour rupture of the membranes (PProM) and preterm labour with intact 
membranes are designated as spontaneous preterm births. Preterm prelabour rupture of the membranes is 
defined as spontaneous rupture of the membranes before 37 weeks gestation at least 1 h prior to the onset 
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fIGure 1:      PhenoTYPIc coMPonenTs of The PreTerM BIrTh sYndroMe
froM VIllar eT al. The PreTerM BIrTh sYndroMe. aM J oBsTeT GYnecol 2012
 
 
1.2.4 a prototype phenotypic classifi cation
The above mentioned categorizations are easy to adopt, but have not proven particularly useful in the identifi-
cation of causes or preventive interventions. Preterm birth is a syndrome, defined by time, not by a distinctive 
clinical phenotype, which at least partly explains why not much progress have been made in understand-
ing its aetiology. recently, it was proposed that the most useful classification would be by phenotype rather 
than focussing on suspected causes. The phenotype of PTB is complex and defining what phenotypic subtypes 
should be considered in the classification is far challenging, at least because the obstetric landscape is rapidly 
changing. The proposed classification (figure 1) is based on clinical phenotypes that are defined as ≥ 1 char-
acteristics of the mother, the foetus, the placenta, the signs of parturition, and the pathway to delivery and 
considered any birth (including stillbirths and pregnancy terminations) that occurs after 16 weeks gestation 
and before term (i.e. 39 weeks gestation). The phenotypic classification includes only conditions that are found 
in the index pregnancy, but no risk factors and mode of delivery. These data should be collected systematically 
in the clinical records. It is recognized that, in any single case, more than one phenotype may exist because of 
overlapping conditions and presentations. This classification system will improve understanding of the cause 
and improve surveillance across populations, since it does not force any particular case into a predefined phe-
notype and allows all relevant conditions to become part of the phenotype (Goldenberg et al., 2012; Kramer 
et al., 2012; Villar et al., 2012). The PTB phenotype can best be illustrated by an example. a patient delivered 
at 29 weeks gestation might have an abnormal foetal heart rate (from the foetal list), evidence of abruption 
(from the placental list), no signs of spontaneous parturition, with a pathway to delivery that was initiated by 
the provider because of foetal distress and suspected abruption. 
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Table 1 summarizes the number of PTBs in flanders according to gestational age. about 1% of all live births 
(n=731) were before 32 weeks gestation in 2011. about 5.8 % of the PTBs occur at less than 28 weeks and 
about 9% at 28-31 weeks. 
TaBle 1:      PreTerM BIrTh In flanders accordInG To GesTaTIonal aGe (2011)  
froM sTudY cenTre for PerInaTal ePIdeMIoloGY
The increase in absolute numbers from 1991 to 2002 was largest in mildly PTBs (32-36 weeks), but severely and 
very PTBs also increased (figure 3). however, the proportions of each category remained constant about 85% 
mild, 10% moderate and 5% severe (Keirse et al., 2009).
1.3 trenDs in preterm Birth in flanDers
The study centre for Perinatal epidemiology (sPe) (cammu, Martens, Martens, Van Mol & Jacquemyn, 2011) 
registers perinatal data on every birth in flanders (northern Belgium). This voluntary and anonymously peri-
natal registration, initiated by the flemish society of obstetrics and Gynaecology, is population-based (with 
currently 66 cooperating maternities) and covers all flemish births. The register makes a distinction between 
the number of births and deliveries. Births only refer to infants (babies of at least 500 g and 22 weeks of ges-
tation), while pregnancies and deliveries refer only to women, delivering from one or more infants of at least 
500 g. Preterm birth is defined as a delivery before 37 weeks of gestation. 
In flanders, 7.1% of the babies were born preterm in 2011. figure 2 shows the incidence of PTBs in flanders over 
an 21-year period. similar to other countries, the rate of PTB has increased from 5.3% in 1991 to 7.1% in 2011, 
but the number remained relatively stable the last 10 years (2001-2011). Keirse, hanssens & devlieger (2009) 
examined the pattern of PTB over a 12-year period (1991-2002) and showed that there was an almost linear 
increase in PTB rate of 0.23% a year (Keirse, hanssens & devlieger, 2009).
In singleton pregnancies about 6.3% of the deliveries (n=4197) occur preterm, while in multiple pregnancies, 
accounting for 1.8% of the deliveries in flanders,  55.6% (n=696) ended preterm.
fIGure 2:      PercenTaGe of all PreTerM BIrThs In flanders (1991-2011) 
froM sTudY cenTre for PerInaTal ePIdeMIoloGY
 
seVerITY of PTB GesTaTIonal aGe sInGleTon delIVerY
(n= 67098)
MulTIPle delIVerY
(n= 1254)
ToTal PTBs
(n=4893)
n % n % n %
severely preterm less than 28 weeks 239 0.4 42 3.3 281 5.8
Very preterm 28-316 385 0.6 100 8.1 485 9.9
Moderately preterm* 32-336 449 0.7 129 10.3 578 11.8
late preterm* 34-366 3124 4.7 425 33.9 3549 72.5
*Moderately +  late PTB  = mild PTB (32-366 weeks)
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1.4  preDiction of preterm laBour 
anD preterm Birth
The diagnosis of preterm labour and accurate prediction of preterm delivery is notoriously difficult. obtaining an 
accurate history of previous pregnancy events and underlying risk factors of PTB is the first step to identifying 
women at risk for PTB (chandiramani et al., 2011). an increasing number of maternal and foetal risk factors have 
been associated with PTB. risk factors for PTB can be classified as primary and secondary predictors (Goffinet, 
2005; leitich, 2005) and are summarized in table 2. The precise mechanisms by which risk factors are related to PTB 
are often unknown (davey et al., 2011; Goldenberg et al., 2008). however, defining risk factors associated with PTB 
is important to identify high risk women for initiating prevention and studying specific interventions. Identifica-
tion of risk factors might also provide important insights into mechanisms leading to PTB (Goldenberg et al., 2008). 
TaBle 2:     rIsK facTors for PreTerM BIrTh* 
fIGure 3:      Increase In The PercenTaGe of PreTerM, VerY PreTerM and seVerelY PreTerM BIrThs 
In flanders (1991-2002) 
froM KeIrse M, hanssens M, deVlIeGer h. Paediatr Perinat epidemiol. 2009
 
Keirse et al. (2009)  found a marked increase in flanders (1991-2002) in the frequency of known contributors 
to the PTB rate, including twin pregnancies, advanced maternal age, assisted reproduction and obstetric inter-
vention. after accounting for these factors, there was still a significant annual increase in the PTB rate. More 
importantly, they also observed a steady increase in PTB in an optimal cohort (i.e. women with none of these 
contributors factors). This indicates that changes in the known risk predictors are insufficient to explain the 
increase in PTB rate over more than a decade (Keirse et al., 2009). 
 
constant at about 85% mild, 10% moderate (28–31
weeks) and 5% severe. These proportions were also
remarkably similar for twins and singletons (Table 2).
Twin pregnancy
Twin pregnancies gradually increased from 1.5% to
2.0% between 1991 and 1997 to remain at that level
thereafter. Average frequencies in 1991–93 and 2000–02
were respectively 1.6% [95% CI 1.5, 1.7] and 1.9% [95%
CI 1.8, 1.9]. The percentag of naturally conceived
twins remained fairly constant throughout at 1.2% of
all pregnancies, the increas over time being ue
mainly to assisted conceptions. These accounted for
40% of twin pregnancie in the second alf f the
study period. Twin pregnancies were least frequent
among mothers aged <20 years (0.8%) increasing with
age to 2.6% in the 35–39 years group and declining to
1.8% in those aged 40 or more. Table 1 shows the mag-
nitude of the increases in preterm and very preterm
birth in twin pregnancies over the four triennia
(P < 0.001).
Parity
Primiparae and secundiparae accounted for respec-
tively 46% and 35% of the population. There was no
change in the parity distribution over time with 51%
of twin mothers being primiparous compared with
46% of singleton mothers. The preterm delivery rate
was much higher in primiparae (7.5%; [95% CI 7.4,
7.5]) than in secundiparae (5.2%; [95% CI 5.1, 5.2]),
whose rate was also lower than in women with
higher parity (6.0%; [95% CI 5.9, 6.2]). Increasing
parity seemed to offer some protection against
preterm delivery in twin but not in singleton preg-
nancies, with rates of 55.8%, 47.5% and 41.8%, respec-
tively, for primi-, secundi- and further multiparae in
twins and 6.5%, 4.4% and 5.4% in singletons. Similar
trends were observed for very preterm birth with
rates of 9.7%, 6.7% and 5.8 for primi-, secundi- and
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Figure 1. Increase in the percentage of preterm (<37 weeks), very
preterm (<32 weeks) and severely preterm (<28 weeks) births;
Flanders, 1991–2002.
Table 2. Frequency distributions of subcategories of preterm birth in singleton and twin pregnancies in Flanders, 1991–2002
No. of
pregnancies
% of
pregnancies
% of
preterm
% in age groups
% from assisted
conception
% due to obstetric
intervention<20 20–34 35
Singleton pregnancies
Severely preterm (<28 weeks) 1865 0.3 5.0 0.7 0.5 0.4 6.4 46.8
Moderately preterm (28–31 weeks) 3429 0.5 9.1 1.1 0.5 0.7 5.6 52.8
Mildly preterm (32–36 weeks) 32 227 4.8 85.9 7.0 4.7 5.4 4.7 32.0
Very preterm (<32 weeks) 5294 0.8 14.1 1.6 0.7 1.0 5.9 50.6
All preterm (<37 weeks) 37 431 5.6 100.0 8.7 5.4 6.5 4.9 34.7
Twin pregnancies
Severely preterm (<28 weeks) 332 2.6 5.3 8.6 2.7 2.2 38.3 24.4
Moderately preterm (28–31 weeks) 670 5.3 10.6 8.6 5.4 4.6 36.4 37.2
Mildly preterm (32–36 weeks) 5327 42.4 84.2 44.4 42.9 39.2 38.2 42.3
Very preterm (<32 weeks) 1002 8.0 15.8 17.1 8.1 6.8 37.0 32.9
All preterm (<37 weeks) 6329 50.4 100.0 61.5 50.9 45.9 38.1 40.8
Preterm births in Flanders: a problem growing beyond reach 525
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PRIMARY RISK FACTORS SECONDARY RISK FACTORS
socIo-deMoGraPhIc facTors BIoPhYsIcal PredIcTors
Black race
low socioeconomic and educational status
low (<18 years) and high (> 40 years) maternal age
single marital status
digital examination
short cervix
absence of foetal breathing movements
lIfesTYle, PsYchosocIal and enVIronMenTal facTors BIocheMIcal PredIcTors (non-exhaustive)
smoking, cocaine and heroin use
heavy alcohol consumption
hard working conditions
anxiety, stress and depression
low and high prepregnancy body-mass index (BMI)
cervicovaginal foetal fibronectin (ffn)
cerviovaginal phosphorylated form of insulin-like growth factor 
binding protein 1 (phIGfBP-1)
cervicovaginal β-human chorionic gonadotrophin (β-hcG)
cervicovaginal interleukin-8 (Il-8)
Plasma matrix metalloproteinase-9 (MMP-9)
Maternal serum and amniotic fluid c-reactive protein (crP)
amniotic fluid interleukin-6 (Il-6)
Insulin-like growth factor binding protein 1 (IGfBP-1)
Placental alpha macroglobulin-1 (PaMG-1)
oBsTeTrIcal hIsTorY and PreGnancY characTerIsTIcs
Previous pr term birth
second trimester pregnancy loss
Multiple pregnancy and higher order pregnancy
short interpregnancy interval (< 6 months)
singleton pregnancy after in-vitro fertilisation
Inadequate prenatal care
low gestational weight gain
Vaginal bleeding
Infection/inflammation
extreme amniotic fluid volume (oligo- or polyhydramnios)
abdominal surgery in the 2nd or 3rd trimester
cervical procedures
uterus anomalies
* Modified after Goffinet, F. BJOG, 2005; Goldenberg, RL et al. Lancet, 2008; Honest, H. et al. Health Technol Assess, 2009.
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specific working conditions (e.g. long hours, hard physical labour under stressful conditions) are related to PTB 
(Goffinet, 2005; Goldenberg et al., 2008; Iams et al., 2008). several studies report an association between PTB 
and anxiety, psychological or social stress and depression. Mothers exposed to objectively stressful condition 
such as domestic violence, housing instability and severe material hardship have increased risk of PTB. al-
though the results are inconsistent, several reports suggest a relation between depression and PTB (Goffinet, 
2005; Goldenberg et al., 2008).
1.4.1.2 Obstetrical history 
history of previous PTB or second trimester pregnancy loss are the most important risk factors of PTB (chan-
diramani et al., 2011; Goffinet, 2005; Goldenberg et al., 2008; Moutquin, 2003), with a recurrence risk ranging 
from 15% to more than 50% (Goldenberg et al., 2008). This risk is inversely related to the gestational age 
of the previous PTB (Goldenberg et al., 2008; Iams et al., 2008) and increases with the number of previous 
events (flood & Malone, 2012; Goffinet, 2005; Iams et al., 2008). however, a previous PTB is non-existent for 
the majority of all PTBs among primigravidae (Goffinet, 2005; Moutquin, 2003). only 10-15% of women who 
deliver preterm have a prior PTB (Berghella, 2009). The risk of recurrence is increased for both spontaneous and 
indicated PTBs (Iams et al., 2008; Parry, simhan, elovitz & Iams, 2012). 
other obstetrical risk factors associated with an increased risk of PTB include uterine and cervical anomalies 
(chandiramani et al., 2011; Goldenberg et al., 2008; Moutquin, 2003), maternal medical complications which 
are often related to indicated PTB (Goldenberg et al., 2008; Moutquin, 2003). Prepregnancy medical risk factors 
can be identified in as many as 40% of PTBs, which suggests that these women might benefit from preconcep-
tional interventions such as control of diabetes, seizures, asthma, or hypertension (Iams et al., 2008). 
1.4.1.3 Current pregnancy characteristics
a short interpregnancy interval (less than 6 months) incurs a two-fold increased risk of PTB and might be 
explained by a decreased opportunity to resolve the inflammatory status and to replenish nutrients associated 
with the previous pregnancy. This risk is even higher in women whose first birth was preterm (Goldenberg et 
al., 2008). The absence or minimal prenatal care is also associated with elevated PTB rates (Goffinet, 2005)
Multiple gestations carry a substantial risk for preterm delivery: 2 to 3% multiple birth rate accounts for up 
to 15 to 20% of all PTBs (Goldenberg et al., 2008; Moutquin, 2003). nearly 60% of twins and nearly all higher 
multiple gestations will result in preterm delivery. uterine overdistension is believed to be the causative mech-
anism (Goldenberg et al., 2008). 
Vaginal bleeding caused by placental abruption or placenta praevia or bleeding in the first and second trimes-
ter trimester in the absence of placental pathology is associated with a risk of PTB (Goldenberg et al., 2008).
Infection is a frequent and important mechanism leading to PTB. out of all of the suspected causes of PTB, 
infection is the only pathological process for which both a firm causal link with PTB has been established and 
1.4.1 primary risk factors
Primary risk factors are referred to preconceptional and conceptional characteristics. These risk factors are 
known before the onset of pregnancy or early in pregnancy and used to estimate the baseline risk of PTB. They 
include socio-demographic, ethnic, environmental, psychological and lifestyle factors and information on re-
productive history and baseline characteristics of the current pregnancy (davey et al., 2011; Goffinet, 2005; 
leitich, 2005). recognition of primary risk factors early or late in pregnancy remains a fundamental part of 
prenatal care (davey et al., 2011; Goffinet, 2005; Khan & honest, 2007). If women can be identified to be at high 
risk of PTB in early pregnancy, they can be targeted for more intensive antenatal surveillance and prophylactic 
interventions (primary prevention) (Khan & honest, 2007; leitich, 2005), which has been an important topic in 
public health for many years (leitich, 2005). however, several risk factors such as history of PTB are difficult to 
modify (Moutquin, 2003) and more than 50% of PTBs arise in pregnancies without obvious risk factors (Iams, 
romero, culhane & Goldenberg, 2008).
Many risk factor based scoring systems for identifying women at risk of PTB have been developed over the last 
40 years (davey et al., 2011). These risk scoring systems, awarding a score for each risk factor, have been shown 
to be adequate for distinguishing between low- and high-risk pregnancies, but their predictive value is low 
as they only identify a minority of women delivering preterm (Goffinet, 2005; Krupa, faltin, cecatti, surita & 
souza, 2006). The implementation of risk scoring in routine antenatal care involved some ethical issues. The 
attribution of a high risk label may result in unnecessary interventions and may have an adverse effect on the 
psychosocial well-being of the pregnant woman (davey et al., 2011).
1.4.1.1 Maternal baseline characteristics
Maternal demographic characteristics associated with PTB include low socio-economic and educational status 
(Goffinet, 2005; Goldenberg et al., 2008; Moutquin, 2003), low and high maternal ages and single marital 
status (Goffinet, 2005; Goldenberg et al., 2008). The risk of PTB is three times higher in black women. These 
women are also three to four times more likely to have a very early PTB (Goffinet, 2005; Goldenberg et al., 
2008). The nutritional status, described by indicators of body size, such as body-mass-index (BMI), might also 
affect PTB. underweight women have increased risks of PTB (Goffinet, 2005; Goldenberg et al., 2008; han, 
Mulla, Beyene, liao & Mcdonald, 2011; Moutquin, 2003) and low birth weight infants (han, Mulla, Beyene, liao 
& Mcdonald, 2011). overweight and obese women have higher risks of induced PTB and overall PTB (Mcdonald, 
han, Mulla & Beyene, 2010). The effect of high BMI is greater in primigravidae and might be mediated by an 
increase in pre-eclampsia, resulting in provider-initiated PTB (Blencowe et al., 2012). Women with low total 
gestational weight gain have a higher risk on PTB (Goffinet, 2005; han et al., 2011) and low birth weight in-
fants (han et al., 2011), with the lower the gain, the higher the risk (han et al., 2011). Tobacco use increases the 
risk of PTB (Goffinet, 2005; Goldenberg et al., 2008; Moutquin, 2003). heavy alcohol consumption (Goffinet, 
2005; Goldenberg et al., 2008) and cocaine or heroin use are associated with PTB (Goldenberg et al., 2008). 
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2003). however, these criteria have suboptimal sensitivity and specificity, since >70% of patients diagnosed 
with symptoms of and/or treated for preterm labour ultimately deliver at or near term (defranco et al., 2012; 
Iams, 2003; sanchez-ramos, delke, Zamora & Kaunitz, 2009). 
1.4.2.2 Biophysical predictors
(a)   DIGITAL VAGINAL EXAMINATION
cervical changes are associated with PTB. studies have indicated poor efficacy of digital cervical evaluation 
and the Bishop score in predicting PTB (Krupa et al., 2006). digital examination has some limitations: it is a 
subjective assessment lacking precision and reproducibility (Glanc et al., 2011; Goffinet, 2005), it tended to 
underestimate the cervix length compared to vaginal ultrasound (Glanc et al., 2011; larma & Iams, 2012), the 
morphology of the internal os cannot be evaluated (Glanc et al., 2011; Goffinet, 2005) and it involves potential 
risk of infection and membrane rupture (Glanc et al., 2011). 
(b)   ULTRASOUND MEASUREMENT OF THE CERVIX LENGTH
Traditionally, the cervix has been viewed in dichotomous terms, either as capable of maintaining pregnancy 
until term or not, which have been considered as cervical insufficiency or incompetence. however, cervical 
function is now viewed as a continuum, related to cervix length and pregnancy history (doyle & Monga, 2004; 
Glanc et al., 2011; Iams et al., 1996; larma & Iams, 2012; Wax, cartin & Pinette, 2010). The most objective and 
effective method for evaluating the cervix is transvaginal sonography (TVs) (Berghella, Baxter & hendrix, 
2013). Transvaginal sonography is more accurate than digital examination (Krupa et al., 2006) and transab-
dominal ultrasound (doyle & Monga, 2004; hernandez-andrade et al., 2012; Iams et al., 1996; Krupa et al., 
2006), because of the increased reproducibility of the complete cervix, the significantly improved visualisation 
and the high degree of standardisation (doyle & Monga, 2004; Goffinet, 2005; hernandez-andrade et al., 2012; 
larma & Iams, 2012). Technical pitfalls for abdominal ultrasound include the position of the cervix, bladder 
distension as well as myometrial contractions, giving a falsely normal cervical appearance (doyle & Monga, 
2004; Glanc et al., 2011; Krupa et al., 2006). 
cervical length measurement by TVs is one of the best predictors of PTB in all populations studied so far (Ber-
ghella et al., 2013). a number of studies have been carried out in symptomatic and asymptomatic pregnant 
women showing a wide variation in thresholds of cervical length and Ga at which TVs was carried out (honest 
et al., 2009; Krupa et al., 2006; larma & Iams, 2012). however, they all found that shortened cervical length 
determined by TVs was associated with a significantly increased risk of PTB. The length of the cervix (Berghel-
la, 2009; Berghella et al., 2013; Goldenberg et al., 2008; Iams et al., 1996; larma & Iams, 2012) and the Ga at 
cervical length measurement (Berghella, 2009; Berghella et al., 2009, 2013) are inversely correlated with the 
risk of PTB. cervical shortening precedes spontaneous PTB at a similar rate for four or more weeks, regardless 
of its clinical presentation (Iams, cebrik, lynch, Behrendt & das, 2011). 
a molecular pathophysiology defined (romero, espinoza, Goncalves et al., 2006). The role of infection in PTB 
is further discussed in chapter 3.
specific maternal bacterial infections have been shown to be associated with an increased risk of PTB in-
cluding bacterial vaginosis and probably other genital infections (such as trichomonas, syfillis, chlamydia and 
gonorrhoea), urinary tract infections (such pyelonephritis, cystitis, asymptomatic bacteria) and periodontal 
infections (Goldenberg et al., 2008; Klein & Gibbs, 2005). Bacterial vaginosis (BV) is characterized by a change 
in the microbial ecosystem of the vagina (Goldenberg et al., 2008; honest et al., 2009; lamont et al., 2011), re-
sulting from a reduction in the lactobacilli with an overgrowth of facultative anaerobic and anaerobic bacteria 
including Gardnerella vaginalis, atopobium vaginae, Mycoplasma hominis and Mobiluncus species (honest et 
al., 2009; h. M. Mcdonald, Brocklehurst & Gordon, 2007). Its presence is associated with an increased risk of 
PTB and intra-amniotic infection (honest et al., 2009; lamont et al., 2011; leitich, 2005). usually asymptom-
atic, BV is present in up to 35% of pregnancies (honest et al., 2009). Black women are three times more likely 
to have BV than are white women and this might explain 50% of the excess PTBs in black women (Goldenberg 
et al., 2008). 
There is sparse evidence that viral infections predispose to PTB, however, the role of viral infection in PTB has 
been inadequately studied (Goldenberg et al., 2008).
other obstetrical risk factors include extreme amniotic fluid volumes (oligo- or polyhydramnios) (Goldenberg 
et al., 2008), maternal abdominal surgery in the second or third trimester (Goldenberg et al., 2008) and single-
ton pregnancies after in-vitro fertilization (IVf) (chandiramani et al., 2011; Goffinet, 2005; Goldenberg et al., 
2008; Moutquin, 2003; Tucker & McGuire, 2004). after a history of PTB, assisted reproduction is the strongest 
predictor of PTB in singleton pregnancies (Keirse et al., 2009). 
1.4.2 secondary risk factors
secondary predictors are based on examinations, signs and symptoms during the current pregnancy and may 
allow a more accurate risk assessment of PTB in an individual woman during the course of pregnancy. screen-
ing for early signs of spontaneous preterm labour has always been an important topic in practical obstetric 
care (leitich, 2005).
1.4.2.1 Symptoms suggestive for preterm labour
early detection of preterm labour is difficult because initial symptoms and signs are often mild and may occur 
in normal pregnancies (Iams, 2003) and are therefore often dismissed by patients and clinicians. symptoms 
such as pelvic pressure, menstrual-like cramps, vaginal discharge, bleeding or spotting and lower back pain 
have been classically associated with impending PTB. The twin hallmarks of preterm labour are persistent 
uterine contractions accompanied by cervical effacement and dilatation (defranco, lewis & odibo, 2012; Iams, 
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(c)   AMNIOTIC FLUID SLUDGE
dense aggregates of particulate matter are frequently seen in the amniotic fluid in close proximity of the 
internal cervical os and are known as “amniotic fluid (af) sludge” (figure 4). The presence of af sludge is 
associated with impending PTB, PProM, microbial invasion of the amniotic cavity (MIac) and histologic chorio-
amnionitis in patients with spontaneous preterm labour and intact membranes (espinoza et al., 2005), among 
asymptomatic patients with a history of PTB (Kusanovic et al., 2007) and in those with cervical cerclage (rome-
ro, Kusanovic et al., 2007). hence, af sludge reflects a severe intra-amniotic infection-related inflammatory 
process (romero, Kusanovic et al., 2007). There is evidence that bacteria can form a microbial biofilm within 
the amniotic cavity and such biofilm was found in a case of intra-amniotic infection with af sludge (romero, 
schaudinn et al., 2008). Microbial biofilms are communities of sessile microorganisms formed by cells that are 
attached irreversibly to a substratum or interface or to each other. Biofilms are embedded in a hydrated matrix 
of extracellular polymeric substances. They play a major role in human disease and have been implicated in 
>80% of chronic infections. Bacteria in biofilms are more resistant to antimicrobial agents and to the host 
response to infection. Moreover, bacteria in biofilms are more difficult to isolate in culture, therefore these 
infections are often overlooked (romero, schaudinn et al., 2008).
fIGure 4:      TWo-dIMensIonal TransVaGInal ulTrasound IMaGe shoWs The Presence of aMnIoTIc 
fluId sludGe
froM roMero eT al. aM J oBsTeT GYnecol 2008;198:135e1-135.e5
asymptomatIc women
for predicting PTB before 34 weeks gestation in singleton pregnancies, measurement of the cervix length 
between 20-24 weeks gestation, using a threshold of 25 mm (the most common threshold evaluated at this 
gestation), had a summary likelihood ratio (lr)+ of 4.68 and summary lr- of 0.86 (honest et al., 2009). In the 
meta-analysis of domin, smith & Terplan (2010), the pooled lr+ and lr- was 6.3 and 0.65, respectively for 
predicting PTB before 35 weeks in singleton pregnancies with a cervical length ≤ 25 mm. Test performance 
was better with a cervical length of ≤ 20 mm (lr+ 12.4; lr- 0.74) and in low risk pregnancies (domin, smith & 
Terplan, 2010). In twin pregnancies, a cervix length of <20 mm at 20-24 weeks gestation was the most accu-
rate in predicting PTB before 32 and 34 weeks gestation (pooled lr+ and lr- 10.1 and 9.0, and 0.64 and 0.74, 
respectively) (conde-agudelo, romero, hassan & Yeo, 2010).
symptomatIc women
among symptomatic women, the most common threshold used was 15 mm (honest et al., 2009). In the me-
ta-analysis of sotiriadis, Papatheodorou, Kavvadias & Makrydimas (2010), the pooled lr+ was 5.71 and the 
pooled lr- 0.51, respectively for predicting PTB within 7 days of testing, using a threshold of 15 mm, but there 
was considerable heterogeneity across studies (sotiriadis, Papatheodorou, Kavvadias & Makrydimas, 2010). a 
cochrane review (Berghella et al., 2013) showed that knowledge of TVs cervical length was associated with 
a non-significant decrease in PTB before 37 weeks. The accuracy of cervix length for predicting PTB in twin 
pregnancies was low (conde-agudelo et al., 2010). 
ImplIcatIons for practIce
Transvaginal ultrasound measurement of cervical length is an effective tool in the prediction of PTB in as-
ymptomatic women. The clinical usefulness of cervical length assessment lies in its negative predictive value. 
a cervical length >30 mm generally excludes the likelihood of PTB and can be a reassuring sign (Goldenberg 
et al., 2008; larma & Iams, 2012; sotiriadis et al., 2010), since only 1% deliver in the next week (Goldenberg 
et al., 2008). hence, ultrasound measurement of the cervical length might be beneficial to avoid aggressive 
interventions (Berghella, 2009; di renzo et al., 2011) and to discharge women from hospital (larma & Iams, 
2012). cervical length assessment is also useful to identify women at risk for PTB who may benefit from tar-
geted interventions. There is growing evidence that prophylactic progesterone treatment in women with a 
short cervix reduces the frequency of PTB before 33-34 weeks gestation (fonseca et al., 2007; hassan et al., 
2011) and also improve neonatal outcome (hassan et al., 2011). Moreover, the combined approach of universal 
cervical length screening and progesterone treatment appears to be cost-effective (campbell, 2011; society for 
Maternal-fetal Medicine Publications committee, 2012). (see progesterone supplementation, p 32)
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2006; leitich, 2005; leitich & Kaider, 2003; ramsey & andrews, 2003; Wax et al., 2010). The proposed pathway 
for ffn release is believed to be disruption of the maternal-foetal decidual interface either mechanical, caused 
by uterine activity or generally related to localized inflammation (ascarelli & Morrison, 1997; Goffinet, 2005; 
leitich & Kaider, 2003; ramsey & andrews, 2003; Wax et al., 2010). The timely release of ffn in cervicovaginal 
secretions during pregnancy highlights its potential as an clinically important marker for PTB. a rapid bed-
side test for detection of ffn has been developed and a concentration of ≥ 50 ng/ml is required for a positive 
test. fibronectin evaluation is confounded by moderate or gross bleeding, ruptured membranes, recent sexual 
intercourse (<24 hours), recent cervical examination (either digital or ultrasound, <24 hours) and advanced 
cervical dilatation (≥ 3 cm), creating a false-positive result. lubricants, soaps, creams and disinfectants may 
cause a false-negative test (altinkaya, Gungor, ozat, danisman & Mollamahmutoglu, 2009; andersen, 2000). 
fIGure 5:      foeTal fIBronecTIn leVels ThrouGhouT PreGnancY 
froM ascarellI Mh, MorrIson Jc.oBsTeT GYnecol surV 1997;52:s1–12
a number of clinical studies have been published demonstrating clinical effectiveness and potential cost ben-
efits of ffn testing for risk assessment of PTB in both symptomatic and high-risk asymptomatic pregnant 
women (chandiramani et al., 2011). 
The prevalence of af sludge in normal pregnancies at term is 1%, whereas in patients with spontaneous 
preterm labour and intact membranes it is 22.6% (espinoza et al., 2005) which is similar to the prevalence 
of af sludge (23.5%) in asymptomatic high risk women between 13 and 29 completed weeks. Moreover, the 
shorter the cervical length, the greater the likelihood of af sludge (Kusanovic et al., 2007). debris seems to be 
a marker of microbial invasion as well as an independent risk factor for PTB in the setting of a short cervix. 
however, there is currently no evidence that management of a short cervix length should be altered by the 
presence of debris (larma & Iams, 2012). Midtrimester dense af sludge was present in 5% of asymptomatic low 
risk women undergoing amniocentesis and was associated with early PProM and spontaneous PTB, especially 
in patients with short cervix (himaya et al., 2011). 
1.4.2.3 Biochemical predictors 
Biological fluids (e.g. amniotic fluid, urine, cervical and vaginal secretions, serum or plasma and saliva) have 
been used to assess the value of biomarkers for the prediction of PTB. studies of biomarkers have improved the 
understanding of mechanisms of disease leading to spontaneous PTB, but few biomarkers have shown clinical 
usefulness (Goldenberg et al., 2008). during the last decades, several biochemical tests have been developed 
to predict PTB in either women with preterm labour or PProM. The most widely used biochemical tests will 
be discussed below.
(a)   FOETAL FIBRONECTIN
foetal fibronectin (ffn), a placental glycoprotein, is a major component of the extracellular matrix of the cho-
riodecidual junction (Berghella, hayes, Visintine & Baxter, 2008; leitich, 2005; ramsey & andrews, 2003; Wax 
et al., 2010), primarily produced by trophoblast (chandiramani et al., 2011; Goffinet, 2005; ramsey & andrews, 
2003). foetal fibronectin acts as a “glue” at the maternal-foetal interface, aiding in membrane adherence to 
the decidua (Wax et al., 2010). foetal fibronectin is believed to mediate implantation and choriodecidual at-
tachment throughout pregnancy (ramsey & andrews, 2003). figure 5 displays cervicovaginal ffn levels during 
normal pregnancy (ascarelli & Morrison, 1997). foetal fibronectin is commonly found in cervicovaginal secre-
tions before 20 weeks of gestation (andersen, 2000; ascarelli & Morrison, 1997; Goffinet, 2005; leitich, 2005; 
leitich & Kaider, 2003; ramsey & andrews, 2003), which can be explained by an incomplete fusion between the 
foetal membranes and the decidua (leitich, 2005; leitich & Kaider, 2003). after the fusion of the membranes 
at 22 weeks of gestation, ffn is rarely identified in cervicovaginal secretions, except in case of membranes 
rupture, and levels appear low (less than 50 ng/ml) until near term (andersen, 2000; ascarelli & Morrison, 
1997; Berghella et al., 2008; Goffinet, 2005; Goldenberg et al., 2008; Krupa et al., 2006; leitich, 2005; ramsey 
& andrews, 2003; Wax et al., 2010). cervicovaginal ffn between 24-34 weeks of gestation, at levels greater 
than or equal to 50 ng/ml, is associated with an increased risk of PTB (chandiramani et al., 2011; Krupa et al., 
a relatively high concentration within the extracellular makeup of this layer
[10]. Fetal ﬁbronectin has a role in establishing blastocyst implantation and
maintaining the integrity of the choriodecidual interface [11]. Cervicovagi-
nal secretions contain fetal ﬁbronectin early in gestation, and then again
just before term labor [12]. Concentrations are normally quite low in the
second and early th rd rimest r (Fig. 1). In a dition, fetal ﬁbronectin
does not appear to be a marker for inﬂa mation at any time during preg-
nancy [63].
U ility as preterm labor marker
The characteristics noted previously make fetal ﬁbronectin a logical
marker for threate ed or actual preterm labor. The precli ical onset of pre-
term labor see s to be ssociated with disruption of the chorio ecidu l
junction, which in turn releases fetal ﬁbronectin, which can be detected
in the cervicovaginal mucous. Quantitation of fetal ﬁbronectin can be per-
formed and its presence or absence can then aid in the diagnosis and ther-
apy of the patient. Initial clinical studies by Lockwood et al [9–11]
indicated that fetal ﬁbronectin was a sensitive marker for risk of preterm
delivery, and was also a very signiﬁcant tool when it was absent, because
there seemed a very low risk of preterm labor occurring in the next few
weeks.
Fig. 1. Cervicovaginal fetal ﬁbronectin levels during a normal pregnancy. Levels are normally
elevated before 20 weeks’ gestational age, and again near term. (From Ascarelli MH, Morrison
JC. Use of fetal ﬁbronectin in clinical practice. Obstet Gynecol Surv 1997;52:S1–12; with
permission.)
575BIOCHEMICAL MARKERS
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ImplIcatIons for practIce 
There are no guidelines for ffn use in Belgium and the uK. The american college of obstetricians and Gynecol-
ogists recommends ffn testing only for symptomatic women with high-risk pregnancies where preterm labour 
is suspected and the following criteria are met: intact membranes, minimum cervical dilation (<3 cm), and 
sampling between 24-34 weeks (chandiramani et al., 2011). The european association of Perinatal Medicine 
(study Group on PTB) encourages ffn testing as part of the routine clinical assessment of preterm labour and 
recommends to withheld tocolytic therapy and steroid prophylaxis when the ffn test is negative and the cervi-
cal length by transvaginal ultrasound is >2.5 cm (di renzo et al., 2011). screening for ffn is not recommended 
in pregnancies that are not at risk (Iams et al., 2008). further research is needed before widespread use can be 
encouraged in asymptomatic high risk women (chandiramani et al., 2011). 
(b)   PHOSPHORYLATED INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN I (PHIGFBP-1)
Insulin-like growth factor is a protein synthesized by the liver and is involved in the control of foetal growth 
and development. It is a major protein of human decidua and its binding protein (IGfBP-1) is found in different 
isoforms (Paternoster et al., 2007). The phosphorylation status of IGfBP-1 varies in different body fluids and 
tissues (Brik, hernandez, Pedraz & Perales, 2010; Paternoster et al., 2007). The non-phosphorylated isoform of 
IGfBP-1 predominates in amniotic fluid (see next paragraph). The highly phosphorylated isoform of IGfPB-1 
(phIGfBP-1) is produced by the decidua and is not present in amniotic fluid. It is commonly found in cervical 
secretions in the first and early second trimester (rahkonen, unkila-Kallio, rutanen & Paavonen, 2009), but 
rarely detected after 23 weeks of gestation until 37 weeks (Kekki et al., 2001). during cervical ripening and 
the onset of labour, phIGfBP-1 can be identified in cervicovaginal secretions probably due to the detachment 
of foetal membranes from the decidua. Therefore, the presence of phIGfBP-1 in cervical secretions after the 
23rd week may be a valuable tool for predicting PTB in symptomatic women (altinkaya et al., 2009; elizur et 
al., 2005; honest et al., 2009; rahkonen, unkila-Kallio, nuutila et al., 2009; Tanir, sener & Yildiz, 2009). a rapid 
bed-site test for the detection of phIGfBP-1 has been developed and a concentration of 30 µg/l is required for a 
positive result (Brik et al., 2010; elizur et al., 2005; honest et al., 2009). a negative phIGfBP-1 may identify low 
risk women that can be discharged at home. Thus, the main clinical value of the phIGfBP-1 test lies in the high 
negative predictive value, thereby avoiding unnecessary medical interventions (altinkaya et al., 2009; Tanir et 
al., 2009). The meta-analysis of honest et al. (2009) showed a lr+ of 4.17 and lr- of 0.21 for predicting PTB 
before 37 weeks gestation in asymptomatic women, but these lrs were based on the results of only one study. 
In symptomatic women, the accuracy of the phIGfBP-1 test for predicting PTB within 7 days yielded a lr+ 
of 3.29 and lr- of 0.20 (honest et al., 2009). These lrs are similar to those of ffn, indicating that both tests 
have approximately equivalent ability to predict PTB. however, the phIGfBP-1 test has some advantages with 
regard to the ffn test: it is unaffected by urine and seminal plasma, cervical dilatation and is less expensive. 
Vaginal bleeding may adversely affect the results of both tests (elizur et al., 2005; Paternoster et al., 2007). 
symptomatIc women
In particular, ffn appears to be one of the most effective biochemical markers for PTB identified to date, espe-
cially in symptomatic women (Berghella et al., 2008; Goldenberg et al., 2008; leitich, 2005; leitich & Kaider, 
2003; ramsey & andrews, 2003). The predictive power is stronger at earlier gestational age (andersen, 2000; 
Goffinet, 2005) and for short term prediction (within 7-10 days) (andersen, 2000; Krupa et al., 2006; leitich, 
2005; leitich & Kaider, 2003). a meta-analysis of sanchez-ramos, delke, Zamora and Kaunitz (2009) showed 
a sensitivity for ffn testing of 76.1%, a specificity of 81.9%, a positive predictive value of 25.9% and a neg-
ative predictive value of 97.6% within 7 days of testing in symptomatic singleton and multiple pregnancies. 
These observations confirmed that the clinical importance of ffn lies in the extremely high negative predictive 
values, thereby avoiding unnecessary interventions in low risk women (andersen, 2000; chandiramani et al., 
2011; ramsey & andrews, 2003) and guiding clinicians in decision-making regarding in utero transfer, admin-
istration of antenatal corticosteroid and/or tocolysis (chandiramani et al., 2011). The availability of ffn testing 
in symptomatic women has been shown to be cost-effective in terms of hospital admission, length of stay, 
medical interventions and overall costs in the management of preterm labour (chandiramani et al., 2011; Wax 
et al., 2010). nevertheless, the meta-analysis of sanchez-ramos et al. (2009) tempered the clinical usefulness 
of ffn as accurate short-term predictor in symptomatic patients, since likelihood ratios for ffn testing were 
rather moderate (lr+ 4.20; lr- 0.29) (sanchez-ramos et al., 2009). a meta-analysis of honest, forbes, duree, 
norman & duffy (2009) found similar overall ratios for predicting PTB within 7-10 days of testing, but included 
only singleton pregnancies (lr+ 4.10, lr- 0.35) (honest et al., 2009). similar results were observed in multiple 
pregnancies. a recent meta-analysis in symptomatic twin pregnancies showed that ffn testing is most accu-
rate in predicting PTB within 7 days of testing (lr+ 3.9; lr- 0.20). only 1.6% of women with twin pregnancies 
and threatened preterm labour who test negative for ffn will deliver within the next week (conde-agudelo & 
romero, 2010). a cochrane review found that PTB before 37 weeks was significantly decreased in symptomatic 
women with management based on knowledge of ffn results (15.6%) vs. controls without such knowledge. 
however all other obstetric and perinatal outcomes were not affected and therefore limited the value of ffn 
testing in the management of women with symptoms of preterm labour (Berghella et al., 2008). Moreover, the 
negative predictive value of the test decreases with time and re-evaluation should be considered if the patient 
continues to have symptoms of preterm labour (andersen, 2000).
asymptomatIc women
results in asymptomatic women were in agreement with those with symptoms in both singleton and multiple 
pregnancies. honest et al. (2009) reported likelihood ratios for positive and negative test results of 7.65 and 
0.80, respectively, for predicting PTB before 34 weeks gestation in singleton pregnancies. foetal fibronectin 
testing was most accurate in predicting PTB before 32 weeks gestation in asymptomatic multiple or twin 
pregnancies (lr+ 5.5 resp. 5.1; lr- 0.69 resp. 0.71) (conde-agudelo & romero, 2010). 
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1.5 prevention of preterm Birth
a number of strategies are used in an attempt to delay PTB. Interventions to reduce the morbidity and mor-
tality of preterm birth can be primary, secondary or tertiary (Iams et al., 2008). a single intervention may not 
be effective in all cases of preterm labour, since it results from several different pathophysiological processes 
(doyle & Monga, 2004).
1.5.1 primary prevention
Primary intervention is directed to all women before or during pregnancy to prevent and reduce the risk of 
PTB (flood & Malone, 2012; Iams et al., 2008; Khan & honest, 2007) These interventions focus on the overall 
health of women and include screening of low risk women, weight optimisation, nutritional supplementation, 
smoking cessation, improved access to prenatal care, and avoidance of late PTBs by elective caesarean section 
(flood & Malone, 2012; Iams et al., 2008). 
risk scoring systems for estimating the baseline risk of PTB in healthy women are largely based on a history of 
PTB and present pregnancy risk factors, but more than 50% of PTBs arise in pregnancies without obvious risk 
factors (Iams et al., 2008). several risk factors are difficult to modify (e.g. prior PTB, previous placenta praevia), 
while others may respond to targeted interventions (e.g. BMI, working conditions, smoking) (Kramer et al., 
2012; Moutquin, 2003). an overview of the risk factors were described in detail in chapter 1.
The role of nutritional supplementation is controversial, because controlled trials showed no benefits of mi-
cronutrients on PTB rates. nevertheless nutritional and lifestyle adjustments in the preconception period are 
recommended to ensure a prepregnancy BMI within the normal range (flood & Malone, 2012).
Pregnancy is an optimum time to encourage smoking cessation (Iams et al., 2008). The quit rate for smoking 
during pregnancy is up to eight times that of the general population (lumley et al., 2009). Moreover, smoking 
cessation programmes in pregnancy successfully reduce the incidence of PTB with 15% (lumley et al., 2009). 
Increased awareness of PTB as the leading cause of infant mortality might offer an opportunity to inform 
the public and medical profession about potentially avoidable risk factors (flood & Malone, 2012; Iams et al., 
2008). By contrast to public education strategies, policies adopted by government or medical bodies can exert 
a more immediate effect such as limitation of the number of embryos transferred (Iams et al., 2008). however, 
despite the growing prevalence and increasing costs, neonatal and preterm infant health rank low on the 
policy agendas of european member states (Keller et al., 2010). 
(c)    PLACENTAL ALPHA MACROGLOBULIN-1 (PAMG-1) AND INSULIN-LIKE GROWTH FACTOR 
BINDING PROTEIN-1 (IGFBP-1)
Prelabour rupture of the membranes (ProM) is defined as spontaneous rupture of membranes prior to the on-
set of labour and occurs in approximately 10% of term pregnancies and 20-40% of preterm deliveries. conven-
tional diagnostic methods such as visual pooling of af during sterile speculum examination, ph determination 
with nitrazine paper, microscopic evidence of ferning and/or ultrasound evidence of oligohydramnios, lack 
accuracy to enable a confident diagnosis. In addition to clinical examination, the diagnosis of ProM may be 
supported by biochemical tests. Very high concentrations of IGfBP-1 and PaMG-1 are present in amniotic fluid 
compared to blood and cervicovaginal secretions. Therefore, detection of IGfBP-1 or PaMG-1 in cervicovaginal 
secretions are indicative for ProM (albayrak, ozdemir, Koc, ankarali & ozen, 2011; f. c. chen & dudenhausen, 
2008; neil & Wallace, 2010; Tagore & Kwek, 2010). only three reported studies have compared the two test 
strips, showing that the PaMG-1 test performed better. The negative predictive value of the PaMG-1 test was 
93.9% and 89.5% for the IGfBP-1 test, the accuracy of the both test was 95% and 93%, respectively. The PaMG-
1 test may also be advantageous in its storage requirement than the IGfBP-1 test, but is approximately three 
times more expensive (albayrak et al., 2011). Both rapid strip tests have been shown to be more accurate than 
any single clinical method, but when compared with a combined clinical approach (vaginal pooling, ferning 
pattern and nitrazine) test accuracy was similar (albayrak et al., 2011). Therefore, these tests are clinical useful 
in women with doubtful diagnosis of ProM following a combination of conventional diagnostic methods (al-
bayrak et al., 2011; neil & Wallace, 2010). 
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(44%) compared to women in whom previous PTB is the only risk factor (25%). despite this difference in base-
line risk on PTB, the impact of cervical cerclage was very similar in history-indicated and ultrasound-indicated 
cerclage. no differences in terms of PTB or perinatal outcomes were identified between the two management 
strategies. These observations presumed that both management strategies might be equally safe, but further 
research is needed to ascertain whether it is better to perform a prophylactic cerclage early in pregnancy or to 
rely on serial transvaginal screening and wait on cervix shortening before performing cerclage (ultrasound-in-
dicated) (alfirevic et al., 2012; Berghella & Mackeen, 2011). Moreover, the cervical length at which to intervene 
is also controversial (flood & Malone, 2012).
multIple pregnancIes
It is well accepted that there is no role for cerclage for short cervix in multiple pregnancies, because it is asso-
ciated with an increased risk of PTB in twin pregnancies (flood & Malone, 2012; Iams et al., 2008). a cochrane 
review is going on to assess the use of cervical cerclage in multiple pregnancies. 
(b)   CERVICAL PESSARY
a cervical pessary has been used in the past 50 years to prevent PTB. Most of the reported studies (who were 
either retrospective or case controlled) used the arabin pessary which is a flexible, ring-like silicone device 
available in different sizes (abdel-aleem, shaaban & abdel-aleem, 2010; dharan & ludmir, 2009). The smaller 
diameter of the pessary is fitted around the cervix and the larger diameter faces the pelvic floor, thus rotating 
the cervix to the posterior vaginal wall and correcting the cervical angle (Goya et al., 2012). cerclage pessary 
is relatively noninvasive and easy alternative to cerclage for the treatment of a short cervix. It is an opera-
tor-independent and cost-effective outpatient procedure which does not require anesthesia and can be easily 
removed when necessary (abdel-aleem et al., 2010; dharan & ludmir, 2009). The study of Goya et al. (2012) 
is the first multicenter, randomized control trial investigating the use of a cervical pessary for PTB prevention 
in singleton pregnancies with a short cervix (25 mm or less) at 18-22 weeks of gestation. They found a lower 
PTB rate before 34 weeks of gestation in the pessary group. This indicates that the use of a cervical pessary 
is an effective intervention for prevention of PTB in at-risk pregnant women screened for cervical length as-
sessment at the midtrimester scan. further large multicenter trials in several countries are needed to confirm 
these results.
(c)   PROGESTERONE SUPPLEMENTATION
Progesterone has a role in maintaining pregnancy and is responsible for myometrial quiescence (dodd, flenady, 
cincotta & crowther, 2006; flood & Malone, 2012; romero et al., 2012; society for Maternal-fetal Medicine 
Publications committee, 2012). The precise mechanism of action of progesterone in preventing PTB is poorly 
understood, but several plausible mechanisms of action have been proposed including reduced gap-junction 
formation, oxytocin antagonism (leading to relaxation of smooth muscle), maintenance of cervical integrity, 
1.5.2 secondary prevention
secondary prevention efforts are directed to women who are already at higher risk of PTB on the basis of either 
obstetric history or present pregnancy risk factors (flood & Malone, 2012; Iams et al., 2008) and involved in-
terventions to attenuate, stop or reverse the progress of spontaneous preterm labour in its early stages (Khan 
& honest, 2007). 
(a)   CERVICAL CERCLAGE
cervical cerclage is a well-known surgical procedure carried out during pregnancy (alfirevic, stampalija, rob-
erts & Jorgensen, 2012; flood & Malone, 2012). It involves positioning of a suture (stitch) around the uterine 
cervix, aiming to give a mechanical support to the cervix and thereby preventing its opening (alfirevic et 
al., 2012; Berghella & Mackeen, 2011). The main indications for cervical cerclage are (1) a previous history of 
PTB, usually characterized by one or more early PTBs (history-indicated cerclage), (2) a short cervical length 
on transvaginal ultrasound screening in the second trimester (ultrasound-indicated cerclage) or (3) clinical 
judgement in emergency situations, for example when women with threatened miscarriage present at the 
hospital (physical examination-indicated cerclage) (alfirevic et al., 2012; Berghella, 2009; Berghella & Mack-
een, 2011). The effectiveness and safety of this procedure remains controversial (alfirevic et al., 2012). The 
pathophysiology of cervical shortening and the precise mechanism by which cerclage confers benefit remains 
largely unknown (flood & Malone, 2012). Moreover, cervical cerclage carries risks for the pregnancy such as 
myometrial contractions, bleeding or infection which may lead to miscarriage or preterm labour. These risks 
have to be carefully balanced against the benefit from mechanical support to the cervix (alfirevic et al., 2012).
 
sIngleton pregnancIes
a recent cochrane review (alfirevic et al., 2012) showed that compared to expectative management, cervical 
cerclage reduces the incidence of PTB with 20% in women at risk of recurrent PTB (history of PTB, cervical sur-
gery, short cervix on ultrasound or physical exam-detected cervical changes). This reduction in PTB was con-
sistent across all gestation time points and all clinical subgroups. There was no reduction in perinatal mortality 
and neonatal morbidity, but fewer perinatal deaths were observed in the cerclage group. cervical cerclage was 
associated with a higher rate of maternal side effects (vaginal discharge and bleeding, pyrexia). caesarean 
section is more likely in women who had cervical suture inserted during pregnancy.
The evidence for effectiveness of history-indicated cerclage compared to no cerclage is limited. The incidence 
of PTB was only reduced in women with three or more previous PTBs, second-trimester losses, or both (Ber-
ghella & Mackeen, 2011). conversely, ultrasound-indicated cerclage in women with a prior PTB and cervical 
length less than 25 mm reduces the incidence of PTB and perinatal mortality compared to no cerclage (Ber-
ghella, rafael, szychowski, rust & owen, 2011). There is limited data comparing a policy of history-indicated 
and ultrasound-indicated cerclage. Women with a short cervix on ultrasound are at much higher risk of PTB 
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benefit from progesterone. There is an ongoing individual data meta-analysis of randomized trials assessing 
the role of progesterone therapy to prevent PTB in twin pregnancies (schuit et al., 2012).
symptomatIc women
The role of progesterone for women with threatened preterm labour remains uncertain. a cochrane review 
(dodd et al., 2006) found a reduction in the risk of PTB less than 37 weeks, infant birth weight less than 2500 
grams, and respiratory distress syndrome. however, the number of trials comparing progestational agent and 
placebo or another tocolytic agent is very limited and these trials are of poor quality, with a small sample size 
and neonatal outcome has not been adequately addressed. Progesterone as primary, adjunctive or mainte-
nance tocolysis in women with threatened preterm labour has not been associated with a reduction in PTB 
rate neither was there an effect of progesterone in women with PProM (society for Maternal-fetal Medicine 
Publications committee, 2012). currently, there is insufficient evidence to advocate progestational agents as 
tocolytic therapy for women with preterm labour (society for Maternal-fetal Medicine Publications commit-
tee, 2012; su, samuel & chong, 2010). 
ImplIcatIons for practIce
Progesterone has not been uniformly beneficial in all populations at risk. Prophylactic administration of pro-
gesterone should be offered for the prevention of PTB in asymptomatic singleton pregnancies with a short 
cervix (≤ 20 mm) identified at ≤ 24 weeks or with a prior PTB (larma & Iams, 2012; society for Maternal-fetal 
Medicine Publications committee, 2012). It appears that progesterone administration could be an safe al-
ternative treatment to cerclage (romero et al., 2012). Moreover, vaginal progesterone is well-tolerated and 
treatment compliance is high (campbell, 2011; hassan et al., 2011). There are no differences in efficacy when 
a dose of either 90-100 or 200 mg/d of vaginal progesterone was used (romero et al., 2012). Therefore, the 
lowest dose is recommended, since information on childhood outcome after progesterone exposure in utero is 
lacking (dodd et al., 2006; society for Maternal-fetal Medicine Publications committee, 2012). There is grow-
ing evidence that universal screening of the cervical length in the midtrimester (19-24 weeks), followed by 
prophylactic progesterone administration to women with a short cervix is the best strategy to prevent PTB and 
reduce neonatal morbidity (campbell, 2011; da fonseca et al., 2009; hassan et al., 2011; romero et al., 2012). 
such a combined approach seems cost effective and can be easily implemented in practice during the existing 
routine midtrimester ultrasound scan (campbell, 2011).
(d)   ANTIBIOTIC TREATMENT
BacterIal vagInosIs (Bv)
routine screening for and treatment of BV to reduce PTB have been extensively studied. although antimicro-
bial therapy is highly effective at eradicating BV during pregnancy, treatment did not significantly reduce the 
risk of PTB before 37 weeks. Possible reasons for antibiotic failure to reduce PTB rate are that (1) trial protocols 
and anti-inflammatory effects (flood & Malone, 2012; Iams et al., 2008; society for Maternal-fetal Medicine 
Publications committee, 2012). 
low rIsk pregnancIes
currently there is insufficient evidence to determine the impact on PTB of progesterone (either intramuscularly 
or vaginally) in both singleton and multiple gestations with the absence of risk factors such as history of PTB 
or short cervix (society for Maternal-fetal Medicine Publications committee, 2012). 
sIngleton gestatIon In asymptomatIc women
Progesterone administration has been shown beneficial in preventing PTB in women with a prior PTB (dodd 
et al., 2006; society for Maternal-fetal Medicine Publications committee, 2012), but is likely to have a small 
impact on the overall rate of PTB because fewer than 10% of PTB occur in women with a previous history 
(campbell, 2011). Vaginal progesterone administration  to women with a sonographic short cervix (≤20 or 25 
mm) in the midtrimester has been associated with a reduction in PTB and perinatal morbidity and mortality 
(da fonseca, damiao & nicholaides, 2009; dodd et al., 2006; romero et al., 2012; society for Maternal-fetal 
Medicine Publications committee, 2012). The major effect of vaginal progesterone was a reduction in the rate 
of early PTB, irrespective of previous history but a fraction of late PTBs (34-366 weeks) can be prevented as well 
(romero et al., 2012). an important question is the range of cervical length in which vaginal progesterone is 
effective. It has been shown that progesterone is less effective in patients with a cervical length of <10 mm 
(fonseca et al., 2007; romero et al., 2012). one possible explanation is that women with a very short cervix 
are more likely to have intra-amniotic inflammation and may be less responsive to progesterone. however, 
no statistically significant effect could be observed according to cervical length (romero et al., 2012). further 
investigation is needed to determine the optimal management of women who have an extremely short cervix 
with some evidence of subclinical infection or inflammation (romero et al., 2012).
multIple gestatIon In asymptomatIc women
The role of progesterone in women with multiple pregnancies is less clear. a recent meta-analysis found a 
non-significant trend toward reduction of the rate of PTB <33 weeks of gestation in twin gestation with a 
short cervix. however, progesterone administration was associated with a significant decrease in neonatal 
mortality and morbidity (romero et al., 2012). a cochrane review observed a reduced risk of antenatal tocolysis 
when progesterone was administered in multiple pregnancies, but also no reduction in PTB rate or infant and 
maternal health outcomes (dodd et al., 2006). These observations suggest that there is insufficient evidence 
to recommend progesterone for prevention of PTB in multiple gestations with or without short cervix (fon-
seca et al., 2007; society for Maternal-fetal Medicine Publications committee, 2012). further research in twin 
gestations is needed to determine the efficacy of vaginal progesterone in women with a short cervix, since 
the meta-analysis of romero et al (romero et al., 2012), showed that this subset of twin gestations is likely to 
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(Widmer et al., 2011) found that a one-day regimen is significantly less effective than a seven-day regimen and 
concluded that women with asB in pregnancy should be treated by the standard regimen of antibiotics until 
more evidence from new trials (testing seven-day vs. three- or five-day regimens) are available.
1.5.3 tertiary prevention
Most of the interventions studied have been aimed at tertiary prevention, i.e. prevention once symptoms (e.g. 
preterm labour or PProM) develop (Berghella et al., 2009; Iams et al., 2008) and involves measures to reduce 
neonatal morbidity and mortality (Iams et al., 2008; Khan & honest, 2007). Tertiary prevention includes re-
gionalised perinatal care, antenatal transfer, tocolytic agents, antenatal administration of corticosteroids and 
antibiotics (Iams et al., 2008). 
(a)   TOCOLYSE
Tocolytic drugs are used to prolong pregnancy in women with acute risk of PTB mainly caused by active preterm 
labour and, less commonly, by ruptured membranes. Tocolysis has not been shown to reduce the rate of PTB, 
but temporally inhibits uterine contractions (abramovici, cantu & Jenkins, 2012; Iams et al., 2008). The main 
rationale for use of these drugs is a 48h delayed delivery that allows antenatal transfer and corticosteroids ad-
ministration to improve perinatal outcome (abramovici et al., 2012; anotayanonth, subhedar, Garner, neilson 
& harigopal, 2004; Iams et al., 2008). a wide variety of tocolytic agents have been advocated as suppressing 
uterine contractions including beta-agonists, calcium channel blockers, oxytocin receptor antagonists, pros-
taglandin synthetase inhibitors and magnesium sulphate. The ideal tocolytic agent should be easy to admin-
ister, inexpensive, without maternal, foetal or neonatal side effects, and effective at delaying PTB, at least 
long enough to permit the use of prenatal corticosteroids (crowther, hiller & doyle, 2002). a recent network 
meta-analysis of haas et al (haas, caldwell, Kirkpatrick, McIntosh & Welton, 2012) showed that , compared to 
other tocolytic agents, prostaglandin inhibitors and calcium channels had the highest probability of delaying 
delivery with 48 hours and reducing neonatal and maternal outcomes. however, there was no clear evidence 
for the relative effectiveness of any tocolytic agent versus placebo being beneficial for neonatal mortality, 
respiratory distress syndrome and maternal side effects . 
Beta-mImetIcs
Beta-mimetics (e.g. ritodrine) act on uterine β2-receptors to induce relaxation of smooth uterine muscles, in-
cluding the myometrium (abramovici et al., 2012; honest et al., 2009). Beta-mimetics versus placebo reduced 
the risk of PTB within 48 hours (anotayanonth et al., 2004; honest et al., 2009) and 7 days (honest et al., 2009) 
after treatment, but their was no reduction in PTB or perinatal outcome (anotayanonth et al., 2004; honest et 
al., 2009). Moreover, multiple maternal adverse effects ranging from moderate to severe cardiovascular and 
differ in many aspects (such as method of diagnose, timing, dose and choice of antibiotic, and period between 
screening and treatment) (Iams et al., 2008; lamont et al., 2011; Mcdonald, Brocklehurst & Gordon, 2007), 
(2) antibiotics might not effectively prevent or treat chorioamnionitis (Iams et al., 2008) or (3) host factors 
(such as smoking, diet) might influence the risk of infection-related PTB, irrespective of antibiotic treatment 
(flood & Malone, 2012; Iams et al., 2008). however, a recent meta-analysis (lamont et al., 2011) showed that 
early administration of clindamycin (<22 weeks) to women with abnormal vaginal flora reduces the rate of 
PTB before 37 weeks gestation and late spontaneous miscarriage. The mean gestational age at delivery was 
higher in the treatment group vs. placebo group. There were no overall differences in risk of PTB at <33 weeks 
of gestation, low birth weight, admission to neonatal intensive care unit, stillbirth, peripartum infection and 
other adverse effects. The reduction in the risk of PTB was only significant for oral but not for vaginal clinda-
mycin. The greater the degree of abnormal flora, the more effective the treatment. retreatment of BV was not 
found to have a significant effect on the rate of PTB (<37 weeks). although evidence is currently insufficient to 
support universal screening and treatment of asymptomatic BV in order to prevent PTB and its consequences, 
there is now evidence that some patients with BV may benefit from early treatment with oral clindamycin 
(lamont et al., 2011).
asymptomatIc BacterIurIa
asymptomatic bacteriuria (asB) is generally defined as the presence of significant bacteriuria without symp-
toms of acute urinary tract infection and occurs in 2% to 10-15% of pregnancies (lumbiganon, laopaiboon & 
Thinkhamrop, 2010; smaill & Vazquez, 2007; Widmer, Gulmezoglu, Mignini & roganti, 2011). If left untreated, 
up to 30% of the mothers will develop acute pyelonephritis which is associated with a 20% to 50% incidence 
of PTB (smaill & Vazquez, 2007). routine screening for asB with urine culture is recommended at 12-16 weeks 
gestation and will identify 80% of women who will ultimately have aBs in pregnancy (Guinto, de Guia, festin & 
dowswell, 2010; lumbiganon et al., 2010; smaill & Vazquez, 2007). quantitative culture of midstream or clean 
catch urine is currently the gold standard for diagnosis. The criterion for diagnosing asB is two (or more) con-
secutive clean-voided urine specimens both yielding positive cultures of the same bacterial strain in quantitive 
accounts of at least 105 colony-forming units (cfu)/ml (Guinto et al., 2010; lumbiganon et al., 2010; smaill & 
Vazquez, 2007). escherichia coli is the most common causative pathogen detected, representing at least 80% 
of isolates. other organisms include other gram negative bacteria and group B streptococci (Guinto et al., 2010; 
lumbiganon et al., 2010; smaill & Vazquez, 2007; Widmer et al., 2011). antibiotic treatment has been shown 
effective in clearing asB and reducing the incidence of pyelonephritis. a reduction in the incidence of low birth 
weight was also seen with treatment, but there was no reduction in PTB (smaill & Vazquez, 2007). Various 
antibiotics are available for treatment of asB in pregnancy and antibiotic preferences differ in different coun-
tries. however, there are no specific recommendations on the type of antibiotics clinicians should prescribe. 
Moreover, a recent cochrane review failed to identify the best single initial antibiotic regimen (Guinto et al., 
2010). Therefore, the choice of antibiotics should be guided by antimicrobial susceptibility testing, but also 
potential adverse foetal or neonatal side effects have to be taken into consideration. another cochrane review 
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able does not indicate that magnesium maintenance therapy after an episode of threatened preterm labour is 
effective (han, crowther & Moore, 2010; honest et al., 2009). 
prostaglandIn InhIBItors
cyclo-oxygenase (coX) enzymes are fundamental in the production of prostaglandins which have a crucial 
role in the onset of labour. Prostaglandin or coX inhibitors function as tocolytics through inhibition of the coX 
enzyme, leading to decreased uterine contractions (abramovici et al., 2012; King, flenady, cole & Thornton, 
2005). Indomethacin is the most widely used prostaglandin inhibitor to treat preterm labour (abramovici et 
al., 2012) and has been shown to be an effective tocolytic agent in preventing PTB within 48 hours or 7 days 
of treatment and before 37 weeks of gestation (honest et al., 2009; King et al., 2005). It is easy to administer 
(orally or rectally), inexpensive and has minimal maternal side effects (abramovici et al., 2012). however, the 
usefulness of coX inhibitors are limited by their effects on the foetus, primarily premature closure of the duc-
tus arteriosus, oligohydramnios and renal failure (abramovici et al., 2012; King et al., 2005). 
(b)   ANTENATAL ADMINISTRATION OF CORTICOSTEROIDS
That antenatal corticosteroids are effective in preventing neonatal morbidity is not in dispute (Brownfoot, 
crowther & Middleton, 2008). randomized trials and meta-analyses confirmed that treatment with antenatal 
corticosteroids reduces the risk of neonatal death, respiratory distress syndrome (rds), cerebroventricular hae-
morrhage, necrotising enterocolitis,  early sepsis, the need for respiratory support and neonatal intensive care 
unit admission (Iams et al., 2008; roberts & dalziel, 2006). Prenatal corticosteroids enhance the benefits of 
postnatal surfactant therapy and reduce the need for blood pressure support (crowther, McKinlay, Middleton & 
harding, 2011). Therefore, this life-saving therapy is now widely used throughout the world. however, it is not 
yet clear which regimen, route and type of corticosteroid performs best. further information is also required 
concerning the effects of corticosteroid therapy in multiple pregnancies, risk and benefits of repeat courses 
and long-term effects into adulthood (crowther et al., 2011; roberts & dalziel, 2006)
There is evidence to suggest benefit of antenatal corticosteroid therapy across a wide range of gestational ages 
from 26 to 346 weeks. antenatal corticosteroids should be administered routinely to accelerate foetal lung 
maturation in women at risk of PTB (roberts & dalziel, 2006). currently either betamethasone or dexametha-
sone are the recommended corticosteroid regimens used in clinical practice (Brownfoot et al., 2008)
(c)   ANTIBIOTIC TREATMENT 
Given the strong association between PTB and infection, prophylactic antibiotics seem a logical preventive 
strategy for PTB (subramaniam, abramovici, andrews & Tita, 2012). Because the causative organisms are gen-
erally unknown with PProM occurs, the optimal antibiotic regimen is unknown. Most studies have involved 
broad-spectrum antibiotic therapy given either intravenously or orally or as a combination of intravenous and 
biochemical disturbances must be considered and often result in discontinuation of therapy (abramovici et 
al., 2012; anotayanonth et al., 2004; honest et al., 2009). The evidence does not support the use of oral beta- 
mimetics for maintenance therapy after threatened preterm labour (honest et al., 2009). 
oxytocIn receptor antagonIsts
oxytocin antagonists (commonly atosiban) are used for tocolysis in several european countries (abramovici 
et al., 2012; Papatsonis, flenady & liley, 2009). oxytocin receptor antagonists block oxytocin receptors in the 
myometrium, preventing a rise in intracellular calcium and thereby relaxing the myometrium (abramovici 
et al., 2012; Papatsonis, flenady, cole & liley, 2005). atosiban was shown to have similar tocolytic efficacy 
in preventing PTB or improving neonatal outcomes to beta-mimetics and placebo (abramovici et al., 2012; 
honest et al., 2009; Papatsonis et al., 2005), although atosiban resulted to fewer maternal side effects than 
beta-mimetics (Papatsonis et al., 2005). The available evidence does not support the use of oxytocin receptor 
antagonists for maintenance therapy after a period of preterm labour (Papatsonis et al., 2009).
calcIum channel Blockers
calcium channel blockers or calcium antagonists (e.g. nifedipine) are non-specific smooth muscle relaxants, 
predominately used for the treatment of hypertension in adults. They exert their tocolytic effect by preventing 
the reuptake of extracellular calcium ions into muscle cells which leads to decreased myometrial contractility. 
The most widely used and studied calcium channel blocker is nifedipine which is mainly administered orally 
(abramovici et al., 2012; King, flenady, Papatsonis, dekker & carbonne, 2003). To date, no placebo-controlled 
trials of nifedipine have been published (abramovici et al., 2012; honest et al., 2009). compared to other toco-
lytics (mainly beta-mimetics), calcium channels blockers have been shown to be more effective in preventing 
PTB within 7 days as well as before 34 weeks (conde-agudelo, romero & Kusanovic, 2011; honest et al., 2009; 
King et al., 2003) with a significant improvement in some neonatal outcomes and less maternal side effects 
(conde-agudelo, romero et al., 2011; King et al., 2003). There is insufficient evidence for any form of main-
tenance nifedipine tocolysis (conde-agudelo, romero et al., 2011; Gaunekar & crowther, 2004; honest et al., 
2009; roos et al., 2013).
magnesIum sulfate
Magnesium sulfate is the most commonly used tocolytic agent in the united states (abramovici et al., 2012; 
crowther et al., 2002). The mechanism by which magnesium sulfate inhibits uterine contractions is not com-
pletely understood, although it is thought to be related to calcium antagonist activity, leading to decreased 
myometrial contractility (abramovici et al., 2012; crowther et al., 2002; honest et al., 2009). Magnesium has 
failed to show improved length of gestation, neonatal benefit or superior efficacy to other tocolytic agents 
(abramovici et al., 2012; crowther et al., 2002; honest et al., 2009). Maternal side effects, which range from 
mild to severe, are seen in up to 60% of exposed women (abramovici et al., 2012). The limited evidence avail-
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1.6 the BurDen of preterm Birth
1.6.1 neonatal outcome
Preterm births account for 75% of perinatal mortality and more than half the long-term morbidity (Goldenberg 
& culhane, 2003). PTB complications are estimated to be responsible for 35% of the world’s 3.1 million annual 
neonatal deaths, and are now the second most common cause of death after pneumonia in children under 5 
years old (Blencowe et al., 2012). There is little doubt that Ga exerts the greatest influence on outcomes of PTB 
(saigal & doyle, 2008). appreciation of Ga-based outcomes is particularly valuable for prenatal counselling and 
decision-making. however, decisions to provide active obstetric care and to initiate neonatal intensive care 
for the most immature infants remain controversial. rates of active obstetric and neonatal interventions and 
neonatal intensive care (e.g. prenatal steroid administration, caesarean section delivery, active resuscitation 
with ventilation in the delivery room) increased substantially in deliveries between 22 and 23 weeks (stoll 
et al., 2010). In general, most Belgian neonatal intensive care units (nIcu) do not recommend intensive care 
before 24-25 weeks of gestation. currently, the flemish tertiary referral hospitals are developing a guideline 
regarding foetal viability, Ga at in utero transfer and active treatment of preterm neonates.
1.6.1.1 Neonatal mortality
Increased survival rates of VlBW infants and extremely and very preterm infants have paralleled improve-
ments in prenatal, obstetric and neonatal care, including programs to regionalize perinatal care (saigal & 
doyle, 2008; stoll et al., 2010; Zeitlin et al., 2008). 
rates of death at ≤ 12 hours decreased with increasing Ga, from 85% of infants at 22 weeks to 2% infants at 
28 weeks (stoll et al., 2010). rates of survival to discharge increased with increasing Ga, from 6% at 22 weeks 
to 72% at 25 weeks and 92% at 28 weeks (stoll et al., 2010), with most early deaths occurring at 22 and 23 
weeks (allen, cristofalo & Kim, 2011; stoll et al., 2010). Infants born at 22 to 23 weeks had >3 times the risk 
of death, compared with infants born at 28 weeks (stoll et al., 2010). each additional week of Ga at birth has 
substantial survival advantage, with most marked changes between Gas of 22 and 25 weeks (stoll et al., 2010). 
The national ePIBel study (extremely Preterm Infants in Belgium) showed that the in-hospital mortality for 
extremely preterm infants was 54%. Mortality was high in the first few days at all Gas, but most impressive 
in infants below 24 weeks gestation (Vanhaesebrouck et al., 2004). The MosaIc study (Models of organising 
access to Intensive care for very preterm births) in 10 european regions in 2003 found an overall in-hospital 
mortality for very preterm infants of 14.2%. for infants born before 28 weeks, the 10 region average was 
36.3% and 5.2% for those born at ≥ 28 weeks of gestation (Zeitlin et al., 2008).
oral therapy (Mercer, 2012). The most recent cochrane review and meta-analysis (Kenyon, Boulvain & neilson, 
2010) found that antibiotic administration in women with PProM delayed delivery (within 48 hours and 7 
days) and reduced the risk of chorioamnionitis, neonatal infection and abnormal cerebral ultrasound before 
hospital discharge, but there was no reduction in perinatal mortality, although a trend towards a beneficial 
effect was observed in the treatment group. studies in this meta-analysis have been marked by a broad range 
of treatment and duration of therapy. The meta-analysis of Mercer (Mercer, 2012) evaluated only studies with 
broad-spectrum antibiotic treatment and initial parenteral therapy ≤34 weeks gestation. aggressive treat-
ment resulted in pregnancy prolongation and reduced infectious and gestational age-dependent morbidities 
without increasing perinatal complications. only the oracle I trial obtained a seven-year infant follow-up and 
found no evidence of either benefit or harm for children prenatally exposed to antibiotics in case of PProM 
(Kenyon et al., 2008). 
Based on these finding, antibiotic treatment of PProM should be restricted to pregnancies where pregnancy 
prolongation is likely to result in a reduction of newborn gestational age-dependent and infectious morbidi-
ties (Mercer, 2012). If antibiotics are subscribed, it is unclear which would be the antibiotic of choice (Kenyon 
et al., 2010). however, co-amoxiclav should be avoided because of the increased risk of neonatal necrotising 
enterocolitis (Kenyon et al., 2008). In current practice, PProM is managed conservatively by either oral eryth-
romycin for 10 days following the diagnosis of PProM (uK oracle trial) or 48 hours of intravenous ampicillin 
and erythromycin, followed by 5 days of oral amoxicillin and erythromycin (us nIchd-MfMu trial) (Kenyon, 
Taylor, Tarnow-Mordi & Group, 2001a; Mercer et al., 1997).
current evidence suggests that prophylactic antibiotics in the setting of preterm labour and intact membranes 
do not consistently prolong pregnancy, reduce the frequency of PTB or improve neonatal outcomes includ-
ing perinatal mortality (King & flenady, 2002; B. Mercer, 2012). Moreover, the oracle II trial observed more 
functional impairment and cerebral palsy in infants exposed to antibiotic treatment in utero (Kenyon, Taylor & 
Tarnow-Mordi, 2001b). Therefore, antibiotic treatment cannot be recommended in the routine management of 
women with preterm labour and intact membranes. since a fraction of women presenting with preterm labour 
have positive amniotic fluid cultures, antibiotic therapy might be potentially beneficial in a selected group, for 
example women with a short cervix length or positive foetal fibronectin. however, no randomized controlled 
trials have studied this hypothesis so far (Mercer, 2012).
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years (cammu et al., 2011). although the absolute incidence of neonatal mortality and morbidity is low in 
infants born late preterm, it is significantly increased as compared with term delivery. 
late-preterm infants were more likely to suffer poorer short-term outcomes. compared to term infants, they 
had higher rates of neonatal death (0-28 days) and were more likely to need mechanical ventilation and suf-
fer from respiratory distress syndrome, necrotizing enterocolitis and intraventricular haemorrhage (Teune et 
al., 2011). although mortality is less than 2% for near-term infants, it is three times higher than the global 
neonatal mortality of term infants (Van haesebrouck et al., 2008). other neonatal complications such as hy-
pothermia, hypoglycaemia, infections, apnoea, feeding problems, etc. are also more prevalent in late preterm 
infants (saigal & doyle, 2008; Teune et al., 2011). furthermore, late-preterm infants have a higher risk for 
infant mortality in de first year after birth and adverse long-term outcomes such as cerebral palsy and mental 
retardation. compared with their term counterparts, late preterm infants experience developmental delay 
and school-related problems, resulting in poorer school performance and learning difficulties (saigal & doyle, 
2008; Teune et al., 2011).
1.6.2 economic and emotional costs
While preterm labour is one of the most common reasons for prenatal hospital admission, prematurity is the 
main reason for admission to a neonatal intensive care unit (nIcu). In Belgium, PProM and preterm labour 
account for 10.8% respectively 11.1% of all admissions to maternal intensive care units (Van Parys et al., 
2008). sixty percent of all nIcu admissions in Belgium involve preterm infants of which two thirds are only 
mild preterm. extremely preterm infants represent only 0.2% of all live born infants and 2% of all preterm 
nIcu-admitted infants (Van haesebrouck et al., 2008). nevertheless, they continuously occupy at least 10% 
of all available nIcu-beds in Belgium (Vanhaesebrouck et al., 2004). The mean nIcu-stay was 57 and 84 days 
for VlBW-infants and elBW-infants, respectively (Van haesebrouck et al., 2008). as a consequence PTB has 
increasing cost implications for health services and the parents. 
The economic cost of PTB is high and has been estimated at 26.2 billion usd in 2005 or 51,600 usd per infant 
born preterm, with more than 85% of the costs provided during the first year of life (hodek, von der schulen-
burg & Mittendorf, 2011; Petrou, eddama & Mangham, 2011). a set of four main costs categories can be distin-
guished: direct medical costs, direct non-medical costs, indirect costs as well as intangible costs (in terms of 
emotional distress and reduced quality of life (qol)) (hodek et al., 2011). 
direct medical care services account for the majority of costs and can be divided into outpatients and inpa-
tients costs areas (hodek et al., 2011). In uK, it has been shown that hospital costs associated with the initial 
hospitalisation varied between £584 per term born infant and £317,166 per extremely preterm survivor (Pe-
trou et al., 2011). Initial hospitalisation and post-discharge costs are inversely related to Ga and birth weight 
(hodek et al., 2011; Petrou et al., 2011). neonatal costs tended to be higher for preterm survivors compared 
to non-survivors (hodek et al., 2011). other inpatients costs include costs for re-hospitalization (hodek et 
differences in mortality have also been noted by hospital level at birth. neonatal or predischarge mortality 
rate of high risk infants (e.g. VlBW, very preterm babies) are higher when born outside hospitals with a neo-
natal intensive care unit (level III unit) (lasswell, Barfield, rochat & Blackmon, 2010). In Belgium, 24.5% of 
the extremely preterm babies and 31.8 % of the very preterm were born in a maternity without intensive care 
facilities. overall 23.2% of the neonates with elBW and 29.8% of the VlBW were born in maternities without 
intensive care facilities (Van Parys et al., 2008).
1.6.1.2 Neonatal morbidity
although survival rates for very preterm births have greatly improved, they are at increased risk of neurode-
velopmental impairments and respiratory and gastro-intestinal complications (Goldenberg et al., 2008; saigal 
& doyle, 2008). common complications in preterm infants include respiratory distress syndrome (rds), chronic 
lung disease, necrotizing enterocolitis (nec), intraventricular haemorrhage (IVh), bronchopulmonary dysplasia 
(BPd), patent ductus arteriosus (Pda) and retinopathy of prematurity (roP) (allen et al., 2011; saigal & doyle, 
2008; simhan, Iams & romer, 2007). rates of morbidity also vary primarily by Ga, but are also affected by birth 
weight, foetal number (singleton vs. multifoetal), geographic location, proximity to neonatal intensive care 
and the maternal and/or foetal condition(s) that led to PTB (simhan et al., 2007). 
about a quarter of extremely preterm survivors (< 28 weeks) have substantial neurodevelopmental morbidity 
such as cerebral palsy, intellectual disability (formerly called mental retardation), visual and auditory impair-
ments and minor neuromotor dysfunction, with the highest rate in the most immature survivors (allen et al., 
2011; saigal & doyle, 2008). The prevalence of cerebral palsy is inversely related to Ga and birth weight catego-
ries, with the greatest increase at the lower limit of viability (allen et al., 2011). Preterm children demonstrate 
higher rates of cognitive dysfunction including lower mean intelligence quotient (Iq) scores, learning disabili-
ties, grade retention, special education and low teacher ratings than do peers who were born term. The higher 
rate of visual and auditory deficits have also a cumulative detrimental effect on the acquisition of language 
skills and learning at school. Behaviour problems such as attention-deficit disorders (add) and social-emotion-
al difficulties are also associated with prematurity (allen et al., 2011; saigal & doyle, 2008). Preterm birth is 
also associated with hospital readmissions in the first year of life, mostly as a result of respiratory illnesses, in-
creased use of outpatient health care and increased risk of chronic disease in adulthood (saigal & doyle, 2008). 
1.6.1.3 Late preterm births
late PTBs (32-36 weeks gestation) are five times more common than births before 32 weeks gestation (saigal 
& doyle, 2008). late-preterm infants account for about 74% of all PTBs and about 8% of all births in the us, 
by which they comprise the fastest increasing and largest proportion of singleton PTBs (Teune et al., 2011). In 
2011, 6% of all births in flanders occurred late preterm, accounting for 84% of all PTBs (cammu et al., 2011). 
The number of late PTBs increased from 1991 to 2002 (Keirse et al., 2009), but remained constant the last 10 
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al., 2011; Petrou et al., 2011) and rehabilitation (hodek et al., 2011). outpatients costs involve expenses for 
pharmaceutical and medical aids, home care and outpatient visits to physicians and non-physicians. costs 
for parental travelling and accommodation, home aid, special education and institutionalisation, home or car 
remodelling, care for siblings and loss of parental time are examples of direct non-medical costs (hodek et al., 
2011; Petrou et al., 2011). Indirect costs involve lost productivity, missed working days, parental wage losses. 
The birth of a preterm infant is a critical, stressful event in the life of parents and the rest of the family and im-
plies also intangible costs, in terms of reduced qol, such as the pain, fear, suffering, social isolation, emotional 
and psychological distress.
In Belgium, reliable and comprehensive cost data demonstrating the health-economic impact of PTB are lack-
ing (Keller et al., 2010). a flemish centre-based case control study evaluated the direct and indirect costs re-
lated to PTB before 34 weeks gestation from birth until two years. This study showed that PTB was associated 
with a significantly increased expense compared to term delivery, mainly caused by a longer maternal hospital 
and nIcu stay, but also by higher paternal travelling costs. Peripartal hospital costs for preterm delivery were 
three times as high as for term delivery (€ 6,960 and € 2,327, respectively). costs related to nIcu hospitalisation 
and post-discharge costs were inversely related to Ga and birth weight. The mean nIcu costs were estimated 
at € 20,950 for extremely preterm infants, € 12,017 for very preterm infants and € 4,072 for mild preterm 
infants. Medical costs after discharge until two years (reimbursed by the social insurance) were significantly 
higher for preterm compared to term infants (€ 13,521 for extremely preterm infants, € 8,819 for very preterm 
infants and € 4,628 for mild preterm infants compared to € 732 for term infants) (delaey, 2009).
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2.2  inflammation as a mechanism for term 
parturition
2.2.1 the spectrum of inflammation
Inflammation is the basic process by which tissues respond to injury (Blank, hirsch, challis, romero & lye, 2008; 
Gotsch et al., 2007; romero, Gotsch, Pineles & Kusanovic, 2007). clinical inflammation has been classically de-
fined by the presence of five cardinal signs, usually identified with the acronym PrIsh: pain (dolor), redness 
(rubor), impaired function or immobility (function laesa), swelling (tumor) and heat (calor), which reflect the 
effects of inflammatory mediators on local blood vessels and tissues. In contrast, histological inflammation is 
defined by infiltration of tissue by neutrophils, macrophages and lymphocytes (romero, espinoza, Goncalves 
et al., 2006). Pathological examination has been the gold standard for the diagnosis of inflammation. however, 
there is a window of time in which a molecular signature of inflammation is present before histologic evidence 
is observed. Moreover, most cases of histopathologic inflammation are subclinical in nature, likely occurring 
in the absence of systemic clinical signs (Gotsch et al., 2007; romero, Gotsch et al., 2007). Inflammation is 
part of the innate immune response, but has also been shown to orchestrate an appropriate adaptive immune 
response (Gotsch et al., 2007; romero, espinoza, Goncalves et al., 2006). at molecular level, inflammation is 
characterized by upregulation of chemokines, cytokines, or pattern recognition receptors (Blank et al., 2008). 
Inflammation is central to maintain tissue homeostasis (Gotsch et al., 2007; romero, espinoza, Goncalves et al., 
2006) and accomplishes three main goals: (1) to deliver cells (i.e. macrophages, neutrophils and lymphocytes) 
and molecules (i.e. antimicrobial peptides, cytokines, chemokines, prostaglandins, etc.) to the site of injury 
to suppress the infection; (2) to generate a physical barrier to prevent the spread of the microorganism, often 
accomplished by the activation of the coagulation system and formation of thrombi in blood vessels and (3) 
to promote repair of the injured tissue (Gotsch et al., 2007; Murphy, Travers & Walport, 2008; romero, Gotsch 
et al., 2007).
a major cause of inflammation is infection with microorganisms. however, inflammation can also be initiated 
by other stimuli such a trauma, foreign bodies (e.g. small splinter, suture materials, etc.), harmful immunolog-
ical reactions (e.g. allergy, auto-immune diseases), chemical agents and physical injuries (e.g. burn or radiation 
injury, frostbite) (rijkers, Kroese, Kallenberg & derksen, 2009). 
Inflammation can either be an acute or a chronic event. acute inflammation is characterized by its short dura-
tion (minutes-days) and includes 4 phases: (1) blood vessel dilatation and hyperaemia, (2) exudation of fluid 
and plasma proteins, (3) adhesion, extravasation (diapedesis) and emigration of leucocytes (mainly neutro-
phils) and (4) healing (resolution), scarring (fibrosis) or prolonged inflammation with the formation of granu-
loma, known as chronic inflammation. chronic inflammation is caused by either an exaggerated or prolonged 
inflammation or a lack of an adequate inflammatory response. It is characterised by an massive influx of mono-
2.1 the immunoloGy of preGnancy
Pregnancy is characterized by a complex cross-talk and tight regulation of inflammatory events regulated by 
both the innate and acquired immune system (MacIntyre, sykes, Teoh & Bennett, 2012). Pregnancy represents 
a unique immunological state where changes in the maternal immune system promote foetal allograft toler-
ance (s. J. chen, liu & sytwu, 2012; MacIntyre et al., 2012; orsi, 2008; sykes, Macintyre, Yap, Teoh & Bennett, 
2012). The foetus is an semi-allogeneic allograft, being the product of two histoincompatible individuals. This 
requires a degree of maternal immunosuppression while on the other hand maintaining the ability to fight off 
infection (sykes et al., 2012). This balance between immune tolerance and suppression is tightly regulated by 
a plethora of cytokines, in concert with hormones including progesterone (orsi, 2008; orsi & Tribe, 2008; sykes 
et al., 2012). successful pregnancy is characterized by a switch in the T-helper (Th)1:Th2 cytokine balance to 
a state of Th2 predominance (MacIntyre et al., 2012; orsi, 2008; sykes et al., 2012). This tendency appears to 
exist both at systemic level but even more significantly at the maternal-foetal interface (MacIntyre et al., 2012; 
saito, nakashima, shima & Ito, 2010; sykes et al., 2012). The Th1:Th2 bias is reversed toward term gestation, 
especially with the onset of labour (sykes et al., 2012). Th1:Th2 imbalances may lead to adverse pregnancy 
outcomes such as miscarriage, pre-eclampsia, preterm labour and foetal brain injury (orsi, 2008; orsi & Tribe, 
2008; sykes et al., 2012). In particular, activation of the Th1 profile, rather than suppression of the Th2 profile, 
seems to be more apparent in preterm labour (sykes et al., 2012). however, it has been shown that the Th1:Th2 
paradigm is now insufficient to explain complex and dynamic immunological processes such as pregnancy and 
a new Th1:Th2:Th17 and Treg cells paradigm has been proposed (saito et al., 2010).
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protein a (sP-a) secretion in amniotic fluid (Garcia-Verdugo, Tanfin & Breuiller-fouche, 2010; orsi, 2008; orsi 
& Tribe, 2008; romero, espinoza, Goncalves et al., 2006; Yadav, Madan & Bernal, 2011). The presence of sP-a is 
thought to be an indicator of foetal lung maturity (Garcia-Verdugo et al., 2010). sP-a targets foetal amniotic 
macrophages, which become activated and migrated to maternal uterus, where they produce Il-1β. This elicits 
an inflammatory cascade leading to uterine contractility (Garcia-Verdugo et al., 2010; orsi, 2008; orsi & Tribe, 
2008; romero, espinoza, Goncalves et al., 2006; Yadav et al., 2011). The mouse models do not seem to be appli-
cable to humans. In  humans, sP-a levels increase sharply in amniotic fluid towards term, but decrease during 
labour (Garcia-Verdugo et al., 2010; Yadav et al., 2011). It has been demonstrated that sP-a is present in human 
endometrium, placenta and foetal membranes (Yadav et al., 2011). however, it remains to be elucidated how 
sP-a gets in contact with myometrial cells in vivo and how it may be transported through foetal membranes 
(Garcia-Verdugo et al., 2010). other pathways leading to labour initiation implicate inflammatory decidual ac-
tivation (Goldenberg et al., 2008; hamilton et al., 2012) and oxytocin initiation (Goldenberg et al., 2008; Kamel, 
2010). The number of oxytocin receptors are increasing before labour. during labour, the foetus can produce 
substantial amounts of oxytocin that binds to its receptors and potentiates uterine contractions by increasing 
intracellular calcium through activation of phospholipase c. oxytocin has also been found to stimulate pros-
taglandin synthesis in chorion, decidua and amnion, thus assisting in cervical ripening process (Kamel, 2010). 
although synthetic oxytocin is used to augment uterine contractions, blood concentrations of oxytocin do not 
rise before labour and the clearance of oxytocin remains constant, thus oxytocin is unlikely to initiate labour 
(Goldenberg et al., 2008). decidual activation, involving prostaglandin and proinflammatory cytokine output, 
is proposed to be an integral early event in the labour cascade. recently, it has been demonstrated that de-
cidual macrophage infiltration is an important process in the labour cascade at term and preterm. Infiltration 
is significantly increased approximately 12h preceding labour in rat model, suggesting a coordinating role for 
the decidua at the maternal-foetal interface (hamilton et al., 2012). In many cases of early preterm labour, 
decidual activation seems to arise in the context of intrauterine bleeding or an occult intrauterine infection 
(Goldenberg et al., 2008). 
labour is associated with a core inflammatory response in all gestational tissues. leukocyte infiltration has 
been demonstrated in the myometrium, placenta, cervix, and the foetal membranes during labour (Gomez-lo-
pez, estrada-Gutierrez, Jimenez-Zamudio, Vega-sanchez & Vadillo-ortega, 2009; norman, Bollapragada, Yuan 
& nelson, 2007), featured by a release of inflammatory cytokines to amplify or initiate the process of partu-
rition (norman et al., 2007). The constraints on the maternal immune system will remove at term and permit 
the initiation of a mild inflammatory process and labour. It has been shown that peripheral blood leukocytes 
in the maternal circulation are primed in preparation for activation during labour (Yuan, Jordan, McInnes, har-
nett & norman, 2009), with subsequent invasion in the myometrium and cervix, thereby potentially initiating 
and propagating cervical ripening and uterine contractions (norman et al., 2007). Genome wide studies have 
indicated that spontaneous parturition at term is characterized by a molecular signature of inflammation in 
the myometrium, chorioamniotic membranes and cervix, even in the absence of histologic signs (Blank et 
al., 2008; romero, espinoza, Goncalves et al., 2006). This inflammatory signature was not observed in the 
nuclear cells (macrophages, lymphocytes and plasma cells), tissue destruction, fibrosis and necrosis. chronic 
inflammation can last for several months or years and can lead to several diseases (rijkers et al., 2009). 
2.2.2 inflammation in term labour
Inflammation plays a central role in physiological processes. successful reproduction is critically dependent on 
inflammatory processes. ovulation, menstruation, implantation, pregnancy and parturition are all inflamma-
tory phenomena (Blank et al., 2008; Gotsch et al., 2007; romero, Gotsch et al., 2007).
The common pathway of parturition has been defined as anatomical, physiological, biochemical, endocrino-
logical, immunological and clinical events that occur in the mother and/or foetus at the time of parturition, 
regardless of whether this occurs at term or preterm (Gotsch et al., 2009). The activation of the uterine com-
ponents of the common pathway is manifested clinically and involves three physiologically interdependent 
processes: (1) cervical remodelling leading to dilatation and effacement, (2) weakening and rupture of the 
membranes and (3) the initiation of uterine contractions leading to the expulsion of the foetus (Gotsch et al., 
2009; MacIntyre et al., 2012; orsi & Tribe, 2008; Peltier, 2003; romero, espinoza, Kusanovic et al., 2006). In most 
cases of spontaneous term labour, there is a physiological and synchronous activation of the pathway (Gotsch 
et al., 2009). a plethora of cytokines (e.g. Il-1β, Il-6, Il-8, GM-csf, Tnf-α) mediate this pathway, by induction 
of matrix metalloproteinases (MMPs), downregulation of tissue inhibitor of metalloproteinases (TIMPs), pro-
duction of coX-2 and prostaglandin e2 (PGe2) and increasing intracellular calcium (ca
2+) availability (Bowen, 
chamley, Keelan & Mitchell, 2002; orsi & Tribe, 2008; Peltier, 2003). MMPs are responsible for extracellular 
matrix remodelling and weakening through collagen breakdown, ultimately leading to membrane rupture and 
cervical ripening (cockle, Gopichandran, Walker, levene & orsi, 2007). Intracellular ca2+ signalling and PGe2 are 
triggers for uterine contractions (orsi & Tribe, 2008; Peltier, 2003). 
The underlying mechanisms that initiate normal labour are incompletely understood, but inflammatory path-
ways are likely integral (orsi, 2008; orsi & Tribe, 2008; unal, cierny, roedner, newman & Goetzl, 2011). several 
theories have been proposed to explain initiation of term labour. The functional progesterone withdrawal 
theory is generally accepted (Goldenberg et al., 2008; orsi, 2008; orsi & Tribe, 2008; Peltier, 2003). The endo-
crine system plays an important role in maintenance of uterine quiescence during pregnancy and in initiating 
uterine activity. sensitivity of the myometrium to progesterone and oestrogen hormones is regulated through 
alteration in the rate of expression of their receptors (Kamel, 2010). during pregnancy, progesterone has a 
suppressive effect on expression of oestrogen receptors, thereby reducing myometrial sensitivity to the high 
circulating levels of oestrogen (Kamel, 2010; orsi, 2008; Peltier, 2003). near parturition, more expression of 
progesterone receptors-a relative to progesterone-B leads to functional progesterone withdrawal and oes-
trogen activation, causing myometrial contractions by stimulating prostaglandin production (Kamel, 2010). 
The initiating signal for parturition may also arise from the foetus. Mouse models suggest that the process 
is also determined by foetal pulmonary maturation: the foetus triggers the onset of labour via surfactant 
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maternal circulation of women with spontaneous labour at term, suggesting that the inflammatory process is 
localised to the membranes (romero, espinoza, Goncalves et al., 2006). 
2.2.3 infection in term labour
The amniotic cavity is normally considered to be sterile for bacteria (Goldenberg et al., 2008; Goncalves, chai-
worapongsa & romero, 2002; romero, espinoza, Kusanovic et al., 2006; romero, Gotsch et al., 2007). less than 
1% of the amniotic fluid of at term pregnant women not in labour will contain bacteria (romero, espinoza, 
Goncalves et al., 2006; romero, Gotsch et al., 2007). labour is associated with an increased risk of microbial 
invasion of the amniotic cavity (MIac). In patients with term ProM or spontaneous labour with intact mem-
branes, positive amniotic fluid cultures were identified in 34% and 18% of the cases, respectively (Goncalves 
et al., 2002). The increased risk of MIac even in term labour and intact membranes may be explained by the 
assumption that uterine contractions exert a suction-like effect whereby vaginal fluid can ascend into the 
uterine cavity with contractions. labour was also associated with histologic chorioamnionitis in term pregnan-
cy with intact membranes. Moreover, the more advanced the cervical dilatation, the higher the risk of MIac. 
In contrast, foetal inflammation (funisitis) was not associated with the presence of labour or the degree of 
dilatation (seong, lee, Kang, romero & Yoon, 2008).
InFeCTIOn aS CaUSe OF
PreTerM labOUr
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chorioamnionitis are less commonly in late PTB, but present in most PTB cases occurring at less than 30 weeks 
(Goldenberg & culhane, 2003; Goldenberg et al., 2000).
figure 6 depicts the potential sites of bacterial infection within the uterus. Intrauterine infection can be classi-
fied into two broad groups according to the location of the microorganism: (1) extra-amniotic infection when 
the infection occurs in the choriodecidual space between maternal tissues and foetal membranes or in chorio-
amniotic space, thereby affecting the foetal membranes and leading to chorioamnionitis (documented by his-
tologic findings or culture). (2) intra-amniotic infection, which refers to amniotic fluid infection (amnionitis). 
Infection can also occur within the umbilical cord (funisitis). The most advanced and serious stage of ascending 
IuI is foetal infection. Bacterial infection of the placenta (villitis) is rarely observed (Goldenberg & culhane, 
2003; Goldenberg et al., 2000; Goncalves et al., 2002).
fIGure 6:      PoTenTIal sITes of BacTerIal InfecTIon WIThIn The uTerus
froM GoldenBerG rl eT al, lanceT, 2008
 
Based on the common features of uterine contractility, cervical 
dilatation and foetal membrane/decidua activation, both term 
an preterm labour are the same process except for the gestation-
al age at which they occur. Preterm parturition might represent 
an untimely and asynchronous activation of the normal labour 
process or the results of pathological insults (Goldenberg et al., 
2008; Gotsch et al., 2009; Orsi, 2008). 
Preterm parturition is now thought to be a syndrome initiated 
by multiple mechanisms, including infection or inflammation, 
uteroplacental ischemia or hemorrhage, uterine overdistension, 
stress, and other immunologically mediated processes.
3.1 intrauterine infection
3.1.1 potential sites, pathways and stages
Intrauterine infection (IuI), caused by bacteria, is a frequent and important mechanism leading to infec-
tion-associated PTB (Goldenberg et al., 2008; romero, espinoza, Kusanovic et al., 2006; romero, Gotsch et 
al., 2007). Intrauterine infection is the only pathological process for which a firm causal link with PTB has 
been established and for which a direct molecular pathophysiology is known (Blank et al., 2008; romero, 
espinoza, Kusanovic et al., 2006). The relation between infection and PTB is not consistent throughout gesta-
tion (Goldenberg & culhane, 2003; Goldenberg et al., 2000). Infection is more prevalent in the earlier cases of 
spontaneous PTB. The lower the gestational age at PTB, the higher the frequency of intra-amniotic infection 
(IaI) and histologic chorioamnionitis (Goldenberg & culhane, 2003; Goldenberg et al., 2008; Goncalves et al., 
2002; romero, espinoza et al., 2007; romero, espinoza, Kusanovic et al., 2006). Moreover, IuI and histological 
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that microbial invasion occurs during the latency period (romero, espinoza, Goncalves et al., 2006).
Microbiological studies suggest that infection may account for 25-40% of PTBs (Goldenberg et al., 2008; rome-
ro, espinoza, Kusanovic et al., 2006), but this might represent minimum estimates, because IuI is difficult 
to detect with conventional cultivation techniques. a positive culture is indicative for MIac, but a negative 
culture cannot definitively exclude the presence of microorganisms. a negative culture may indicate that the 
laboratory was not able to grow bacteria from the specimen, either because bacteria were absent or because 
the laboratory conditions did not support the growth of a specific microorganism. consequently, it seems 
that the true prevalence of MIac is much higher, because (1) the prevalence of MIac is higher when molecular 
techniques are used and evidence suggests that the presence of microbial footprints detected by polymerase 
chain reaction (Pcr) is associated with adverse outcomes, (2) it is difficult to obtain informative samples 
during pregnancy, in particular in asymptomatic patients, since diagnosis requires amniocentesis (3) the rate 
of microbial colonization in the chorioamniotic space is higher than observed in the amniotic cavity, but this 
location is not amenable to culture before delivery (Goldenberg et al., 2008; Goncalves et al., 2002; romero, 
espinoza et al., 2007). 
3.1.3 intrauterine infection as a chronic process
There is accumulating evidence that MIac represents a chronic process and exists for an extended period of 
time. Multiple observations have suggested that microbial invasion could be clinically silent in the midtri-
mester of pregnancy and so undetected for weeks until labour begins or the membranes rupture (Goldenberg 
& culhane, 2003; Goldenberg et al., 2008; Goldenberg et al., 2000; Goncalves et al., 2002; romero, espinoza 
et al., 2007; romero, espinoza, Kusanovic et al., 2006). Women with histological chorioamnionitis or women 
who have organism in the membranes will only exhibit signs of clinical chorioamnionitis 5 to 10% of the time 
(Goldenberg & culhane, 2003). non-pregnant women with bacterial vaginosis were more likely to have endo-
metrial colonization with bacteria. Therefore, it has been proposed that intrauterine colonization associated 
with preterm labour might be present at conception (Goldenberg & culhane, 2003; Goldenberg et al., 2000). 
3.1.4 microbiology of intrauterine infection
The most common microorganisms found in the amniotic cavity are genital Mycoplasma species, in particu-
lar, ureaplasma urealyticum, but many other organisms have been identified, including Mycoplasma hominis, 
streptococcus agalactiae, escherichia coli, fusobacterium species and Gardnerella vaginalis (Goldenberg & cul-
hane, 2003; Goldenberg et al., 2008; Goncalves et al., 2002; romero, espinoza et al., 2007; romero, espinoza, 
Goncalves et al., 2006). half of the patients with MIac have more than one microorganism isolated from the 
amniotic cavity. Microorganisms are isolated twice as frequently form the chorio-amniotic space than from the 
Microorganisms may gain access to the amniotic cavity and the foetus using any of the following pathways: 
(1) ascending from the vagina and the cervix; (2) haematogenous dissemination through the placenta (trans-
placental infection) (3) retrograde seeding from the peritoneal cavity through the fallopian tube; and (4) acci-
dental introduction during invasive procedures, such as amniocentesis, percutaneous foetal blood sampling, 
chorionic villus sampling, or shunting. The most common pathway of IuI is the ascending route, because the 
organisms most commonly found in the uterus are of vaginal origin (Goldenberg & culhane, 2003; Goldenberg 
et al., 2008; Goldenberg et al., 2000; Goncalves et al., 2002; romero, espinoza et al., 2007; romero, espinoza, 
Goncalves et al., 2006; romero, espinoza, Kusanovic et al., 2006).
In general, 4 stages of ascending infection can be distinguished. The first stage consists of a change in the vag-
inal or cervical microbial flora or the presence of pathologic organisms in the cervix. Vaginal organisms appear 
to ascend first into the choriodecidual space (stage II). Microorganisms may then reside in the chorion and 
amnion and cross the chorioamniotic membranes into the amniotic fluid, leading to intra amniotic infection 
(stage III). finally, the bacteria may gain access to the foetus by different points of entry (stage IV) (Goldenberg 
et al., 2000; Goncalves et al., 2002).
3.1.2 frequency and clinical significance 
as mentioned previously, the amniotic cavity is normally considered to be sterile for bacteria (Goldenberg et 
al., 2008; Goncalves et al., 2002; romero, espinoza, Kusanovic et al., 2006; romero, Gotsch et al., 2007). There-
fore isolation of bacteria in amniotic fluid is a pathologic finding (romero, espinoza et al., 2007; romero, espi-
noza, Goncalves et al., 2006). Most infections are subclinical and not detected without amniotic fluid analysis. 
a positive amniotic fluid culture has become the golden standard for the diagnosis of IuI and is also defined as 
‘microbial invasion of the amniotic cavity’ (MIac) (Goncalves et al., 2002; romero, espinoza, Kusanovic et al., 
2006; romero, Gotsch et al., 2007). Microbial invasion has been shown to be the result of advancing disease 
from the extra-amniotic to the intra-amniotic space (Goncalves et al., 2002).
Patients with MIac are more likely to deliver preterm, have spontaneous rupture of the membranes, devel-
op clinical chorioamnionitis and experience adverse perinatal outcome than patients with preterm labour or 
PProM with sterile amniotic fluid (romero, espinoza et al., 2007). Microbial invasion is frequently associated 
with intra-amniotic inflammation and a foetal inflammatory response (Goldenberg et al., 2008).
The frequency of MIac depends upon the clinical presentation and gestational age (romero, espinoza, Gon-
calves et al., 2006). Microbial invasion occurs in 12.8% of women with preterm labour and intact membranes 
and in 32.4% of women with PProM. The frequency of MIac among women with cervical insufficiency is up 
to 51% (Goncalves et al., 2002). In asymptomatic patients with a short cervix (<25mm sonographically) in the 
midtrimester, the rate of positive cultures is 9% (romero, espinoza, Goncalves et al., 2006). among patients 
with preterm labour and intact membranes who deliver preterm, the frequency is 22% (Goncalves et al., 2002). 
however, at the time of the onset of preterm labour, as many as 75% of patients will have MIac, suggesting 
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fIGure 7:      MechanIsM of PreTerM delIVerY due To InfecTIon
froM GoldenBerG rl eT al, lanceT, 2008
amniotic fluid (Goncalves et al., 2002). The genital mycoplasma and other organisms detected in the uterus 
before membrane rupture are typically of low virulence, probably accounting for both the chronicity of IuIs 
and the frequent absence of overt clinical signs of infection (Goldenberg & culhane, 2003; Goldenberg et al., 
2008). The significance of microorganisms in the membranes is less clear. Bacteria have been cultured for the 
chorio-amnion in 15% of non-labouring women with intact membranes undergoing elective caesarean section 
at term and bacterial dna has been detected in up to 70% of these women. These findings suggest that the 
presence of bacteria in the chorio-amnion alone cannot be sufficient to cause preterm labour and that micro-
bial colonization of the chorioamniotic membranes may not always elicit a foetal or maternal inflammatory 
response. nevertheless, bacteria are present in more than 80% of women in early preterm labour with intact 
membranes who underwent caesarean section as well as in women with PProM. Thus bacterial infection 
probably predisposes to PTB (Goldenberg et al., 2008; romero, espinoza, Goncalves et al., 2006). 
3.1.5 mechanism of preterm delivery due to infection
a consistent picture on how bacterial infection results in spontaneous PTB has been emerged from both animal 
and human studies (figure 7). Bacterial invasion of the choriodecidual space, acting through the release of 
endotoxins and exotoxins, activates the decidua and the foetal membranes to produce various cytokines in-
cluding Tnf-α, Il-1α, Il-1β, Il-6, Il-8 and G-csf. Microbial endotoxins and proinflammatory cytokines stimulate 
the production and release of prostaglandins and neutrophil activity and thereby the synthesis and release of 
matrix-degrading enzymes, called matrix metalloproteinases (MMPs). Prostaglandins stimulate uterine con-
tractility, whereas degradation of the extracellular matrix by MMPs in the foetal membranes leads to PProM 
and causes remodelling of the collagen in the cervix, leading to cervical ripening and dilatation. These pro-
cesses together will ultimately result in spontaneous PTB. a foetal inflammatory response may also occur, in 
which infection stimulates the production of corticotropin-releasing hormone in both foetal hypothalamus 
and placenta, resulting in increased foetal cortisol secretion and leading to increased production of prosta-
glandins. other pathways may have a role as well. for example, prostaglandin dehydrogenases in chorionic 
tissue inactivate prostaglandins produced in the amnion, preventing them from reaching the myometrium and 
causing contractions. during chorionic infection, the activity of these dehydrogenases are decreased, allowing 
increasing quantities of prostaglandins to reach the myometrium. however, the relative contributions of the 
maternal and foetal compartments to the overall inflammatory response are unknown (Goldenberg & culhane, 
2003; Goldenberg et al., 2000).
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ectodomain by matrix metalloproteinases (ford & McVicar, 2009; Jiyong et al., 2009; Klesney-Tait et al., 2006; 
sharif & Knapp, 2008). It has been demonstrated that sTreM-1 is involved in bacterial infection(Jiyong et al., 
2009) as well as in non-infectious inflammatory conditions (collins et al., 2009; Park et al., 2009). research in 
septic patients has shown great promise, demonstrating that sTreM is of substantial value for early diagnosis 
of bacterial infection (Jiyong et al., 2009), and represents an excellent biomarker for the prognosis of sepsis 
(Gibot et al., 2005), bacteraemia (su et al., 2012) and sepsis severity (Zhang, she, feng, Jia & Xie, 2011). More-
over, it has been shown that sTreM-1 levels reflect the infection status more accurately and specifically than 
c-reactive protein (crP) and procalcitonin (PcT) levels do (su et al., 2012). Measurement of sTreM-1 might 
especially be relevant in clinical practice for ruling out a possible infection and for its ability to facilitate deci-
sion-making regarding administration of antibiotics (Jiyong et al., 2009).
few studies have investigated the role of sTreM-1 in PTB (cobo, Kacerovsky, holst et al., 2012; cobo, Tsiartas 
et al., 2012; Kramer et al., 2010; Kusanovic et al., 2010; Menon & fortunato, 2008; Tsiartas et al., 2012; Vogel 
et al., 2007). Menon & fortunato (2008) demonstrated that both lipopolysaccharide (lPs) and preterm labour 
induced foetal membrane TreM-1 expression (Menon & fortunato, 2008). In the presence of IuI, amniotic fluid 
sTreM-1 concentrations were significantly higher in patients with preterm labour (Kusanovic et al., 2010; Me-
non & fortunato, 2008) or PProM (Kusanovic et al., 2010). however, amniotic fluid TreM-levels did not predict 
PTB within seven days in women with PProM (cobo, Kacerovsky, holst et al., 2012). elevated serum concen-
trations of sTreM-1 in the second trimester were associated with an increased risk of PTB in asymptomatic 
high risk patients (Vogel et al., 2007), but not in low risk women (Kramer et al., 2010). To our knowledge, only 
two studies (cobo, Tsiartas et al., 2012; Tsiartas et al., 2012) evaluated serum sTreM-1 concentrations  during 
preterm labour. however, these studies did not include women with term labour. There is accumulating evi-
dence that inflammation has also been implicated in the mechanism of spontaneous term parturition (agrawal 
& hirsch, 2012; romero, espinoza et al., 2007) and upregulation of sTreM-1 in myometrium and cervix has been 
demonstrated with the onset of term labour (Youssef et al., 2009). Therefore, the purpose of this study was to 
assess sTreM-1 concentrations in maternal serum during term and preterm labour. 
AIM 2:
To determine the maternal serum concentrations of MMP-3, MMP-9 and all four TIMPs as well as 
the MMP:TIMP ratios during term and preterm labour 
Matrix metalloproteinases (MMPs) are proteolytic, zinc-dependent enzymes, capable of degrading extracellu-
lar matrix (ecM) components, including collagen (amalinei, caruntu & Balan, 2007; Brew & nagase, 2010; chel-
ladurai, seeger & Pullamsetti, 2012; leeman, curran & Murray, 2002; raffetto & Khalil, 2008; Weiss, Goldman & 
shalev, 2007). The human MMP family currently consists of 23 members (amalinei et al., 2007). Based on their 
substrate specificity, MMPs can be subdivided into collagenases, gelatinases, stromelysins, matrilysins, mem-
4.1 oBjectives
Inflammation seems to be an underlying factor promoting labour. human labour is characterized by a massive 
influx of inflammatory cells in gestational tissues and increased release of inflammatory markers to amplify or 
initiate the process of parturition (Bowen et al., 2002; MacIntyre et al., 2012; orsi, 2008; sykes et al., 2012). Term 
and preterm labour share a common cytokine-mediated inflammatory pathway. While term labour results 
from a physiological activation of this pathway, preterm labour results from an untimely and asynchronous 
inflammatory activation, caused by multifactorial triggers including infection (orsi, 2008; romero, espinoza, 
Kusanovic et al., 2006). Most intra-uterine infections are chronic and subclinical in nature and consequently 
hard to diagnose before labour or rupture of the membranes. Therefore, inflammatory biomarkers, predom-
inately cytokines, have been extensively investigated during the last decades to explore their involvement in 
the mechanisms and pathophysiological pathways leading to PTB and to analyse their potential usefulness as 
predictive marker or diagnostic accuracy. despite these extensive research efforts, the puzzle of PTB seems far 
from being resolved, at least because the nature of PTB is heterogeneous and complex, associated with mul-
titudes of risk factors and overlapping pathways, but also because the process of term labour is poorly under-
stood. The best studied site of infection is amniotic fluid. although these studies increase our understanding 
in the foetal inflammatory response, it is unlikely that one will perform invasive procedures to test foetal bio-
markers for the prediction of PTB. a non-invasive approach (e.g. maternal blood, vaginal or cervical secretions) 
seems to be more relevant to clinical practice because of the feasibility and accessibility. however, the mater-
nal inflammatory response has been investigated to a lesser extent, thereby mainly focussing on patients with 
preterm labour. Therefore, the overall objective of this thesis was to determine several inflammatory markers 
in maternal serum from pregnant women in labour (either term or preterm) vs. non labouring controls. 
AIM 1: 
To assess sTreM-1 concentrations in maternal serum during term and preterm labour
recently, a family of cell surface receptors, the triggering receptor expressed on myeloid cells (TreM) pro-
teins, has been discovered that seems to play an important role in fine-tuning the immune response during 
infectious diseases. Triggering receptor expressed on myeloid cells-1 is a transmembrane glycoprotein, mainly 
expressed in monocytes and neutrophils and functions as an amplifier of the inflammatory response triggered 
by bacterial infection (Bouchon, facchetti, Weigand & colonna, 2001; colonna, 2003; ford & McVicar, 2009; 
Gibot, 2006; Jiyong, Tiancha, Wei & huahao, 2009; Klesney-Tait, Turnbull & colonna, 2006; sharif & Knapp, 
2008). during infection, soluble TreM-1 (sTreM-1) is generated through proteolytic cleavage of the TreM-1 
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however few studies have investigated MMPs or TIMPs in maternal serum. We hypothesized that aberrant 
MMP expressions at local level implicated in ecM degradation of the chorio-amnion and cervix, are associated 
with aberrant changes in circulating MMPs, resulting in imbalanced MMP:TIMP ratios and leading to preterm 
labour. We therefore sought to determine the maternal serum concentrations of MMP-3, MMP-9 and all four 
TIMPs as well as the MMP:TIMP ratios during term and preterm labour. 
AIM 3: 
To evaluate the maternal inflammatory response during term and preterm labour by 
simultaneous measurement of 30 biomarkers in maternal serum
human term and preterm parturition are inflammatory processes in which cytokines play a pivotal role. de-
regulated cytokine networks may lead to adverse pregnancy outcomes such as preterm labour. a number of 
studies have explored amniotic fluid cytokine profiles in women with PTB, but few studies have evaluated 
circulating cytokines during term and preterm labour. We hypothesized that inflammatory serum markers are 
differently expressed in labour, especially in women with preterm labour. Therefore, we sought to evaluate a 
panel of relevant maternal cytokines in labouring vs. non labouring women (either term or preterm) by using 
a multiplex immunoassay. This novel technological approach makes it possible to measure multiple proteins 
simultaneously thereby requiring only small sample volumes. 
brane type-MMPs and other MMPs (amalinei et al., 2007; Brew & nagase, 2010; chelladurai et al., 2012; Iyer, 
Patterson, fields & lindsey, 2012; Murray, 2001; nagase, Visse & Murphy, 2006). Matrix metalloproteinases are 
synthetized as inactive zymogen with an pro-peptide domain (commonly referred to as proMMPs). activation 
of these latent MMPs by removal of the propetide is an important regulatory step of MMP activity (chelladurai 
et al., 2012; Iyer et al., 2012; nagase et al., 2006). The MMP activity is regulated by tissue inhibitors of metal-
loproteinases (TIMPs) of which four have been identified, TIMP-1 through TIMP-4 (amalinei et al., 2007; chel-
ladurai et al., 2012; cockle et al., 2007; nagase et al., 2006; Vadillo-ortega & estrada-Gutierrez, 2005; Weiss et 
al., 2007; Woessner, 2001). Inhibition of MMP activity occurs in a 1:1 stoichiometric relationship (amalinei et 
al., 2007; Brew & nagase, 2010; fortunato, Menon & lombardi, 1999a; raffetto & Khalil, 2008). although TIMPs 
are broad-spectrum inhibitors which do not show high specificity for any particular MMP, there is some selec-
tivity. for example, there is an preferential binding of TIMP-2 with MMP-2 and TIMP-1 with MMP-9 . TIMP-2 
and -3 are weaker inhibitors than TIMP-1 for MMP-3 and MMP-7 (Brew & nagase, 2010; chelladurai et al., 2012; 
Iyer et al., 2012). The interactions with pro-MMPs are relatively specific: TIMP-2, -3 and -4 with pro-MMP-2 
and TIMP-1 or -3 with MMP-9 (Brew & nagase, 2010). The balance between collagenolysis and its inhibition is 
critical during ecM remodelling (amalinei et al., 2007; nagase et al., 2006). an imbalanced MMP:TIMP ratio has 
been involved in various medical conditions in humans including cancer, rheumatoid arthritis, osteoarthritis, 
endometriosis and vascular diseases (amalinei et al., 2007; Brew & nagase, 2010; raffetto & Khalil, 2008).
human pregnancy is characterized by a steady remodelling of the collagenous ecM in order to adapt foetal 
membranes and cervix to uterine and foetal growth as gestation progresses (Menon & fortunato, 2004; Weiss 
et al., 2007). Matrix metalloproteinases are undoubtedly involved in ecM remodelling during pregnancy as 
well as in the generation of labour through membrane weakening and rupture and cervical ripening and dila-
tation (cockle et al., 2007; Weiss et al., 2007). some MMPs (e.g. MMP-1, MMP-2 and MMP-3) are constitutively 
expressed during gestation, while the production of others (e.g. MMP-9) are induced by active labour (Bry-
ant-Greenwood & Yamamoto, 1995; cockle et al., 2007; Vadillo-ortega & estrada-Gutierrez, 2005; Yonemoto 
et al., 2006). aberrant ecM degradation by MMPs or imbalanced MMP:TIMPs ratios have been implicated in the 
pathogenesis of preterm labour. Intrauterine infection triggers MMP production via inflammatory mediators 
(Goldenberg et al., 2000). activation of the MMP cascade causes ecM degradation, predisposing membrane 
rupture and cervix ripening (cockle et al., 2007; Menon & fortunato, 2004, 2007). The involvement of MMP-9 in 
IuI and parturition has been clearly demonstrated in amniotic fluid (athayde et al., 1998; athayde et al., 1999; 
edwards, clark, locksmith Gregory & duff, 2001; fortunato & Menon, 2001; fortunato et al., 1999a; Goldman, 
Weiss, eyali & shalev, 2003; harirah, donia & hsu, 2002; locksmith, clark, duff, saade & schultz, 2001; Maymon 
et al., 2000; romero et al., 2002; Vadillo-ortega et al., 1996), but few studies (Bryant-Greenwood & Yamamoto, 
1995; fortunato, Menon & lombardi, 1999b; K. h. Park et al., 2003) have investigated MMP-3. a fully function-
al TIMP network has been demonstrated in foetal membranes, decidua and placenta (fortunato, Menon & 
lombardi, 1997, 1998; riley et al., 1999). The majority of studies focused only on TIMP-1 (athayde et al., 1998; 
athayde et al., 1999; fortunato et al., 1999a; locksmith et al., 2001; Vadillo-ortega et al., 1996) and TIMP-2 
(fortunato & Menon, 2001; fortunato et al., 1999a; Maymon et al., 2001) concentrations in amniotic fluid. 
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4.2.2 Definitions
Preterm labour was defined as having regular uterine contractions (six to twelve contractions in one hour) 
and documented cervical changes before 37 completed weeks of gestation. cervical changes include cervical 
effacement or dilatation, cervical shortening (<25 mm) and/or funnelling and were measured by vaginal ex-
amination or transvaginal sonography. Preterm prelabour rupture of the membranes (PProM) was defined as 
amniorrhexis before the onset of preterm labour. a confirmatory test (crystallization test on slide or rapid rup-
ture of membranes (roM) - test (amnisure, Boston, us)) was performed if PProM was suspected on the basis 
of fluid leakage or oligohydramnion. In case of a positive test, the diagnosis of PProM was considered. Preterm 
birth was defined as preterm labour and/or PProM, followed by a delivery before 34 weeks. Gestational age 
was determined based on last menstrual period corrected by early ultrasound before 20 weeks gestation.
4.2.3 sample collection
Blood samples of labouring women (either term or preterm) were collected by the attending midwife upon ad-
mission to the labour and delivery ward using serum separating tubes (gel + clot-activator, Venosafe® Plastic 
tube serum Gel, Terumo europe leuven, Belgium). Women at term not in labour were sampled prior to their 
caesarean section. Gestational age matched controls were enrolled from the prenatal clinic. These pregnant 
women were screened at 20-22 weeks (structural ultrasound) to verify whether they fulfilled the inclusion 
criteria. When they were eligible for participation and agreed with the study procedure, these women were 
matched for week of gestation with a PTB case. sampling was performed during a subsequent prenatal con-
sultation at the appropriate gestational age.
4.2.4 sample processing and analysis
samples were stored at 4°c until centrifugation. Blood samples were centrifuged at 1000 g for 10 minutes at 
room temperature to harvest serum. all samples were stored at -80 °c until analysis. samples used for this 
analysis were never thawed previously.
concentrations of sTreM-1 were determined using an enzyme-linked immunoassay in accordance with the 
manufacturer’s instructions (r&d systems, Minneapolis, Mn). The interassay and intra-assay coefficients of 
variation were 7.8% and 13.9%, respectively.
concentrations of MMP-3, -9 and -13 were determined using a human Matrix Metalloproteinases 3-Plex Panel 
(Invitrogen, Inc. carlsbad, ca). The 3-Plex was validated for serum by performing spike and recovery and lin-
earity-of-dilution experiments. serum concentrations of MMP-13 were undetectable using this method in all 
samples. at a twofold dilution of serum, concentrations were below the detection limit and recovery fell out-
4.2 methoDoloGy
4.2.1 study design and study population
an observational study was conducted to build a bank of biological samples and clinical data and to explore 
putative associations between inflammatory markers of term and preterm labour. The original study consisted 
of 768 pregnant women between 24 and 42 weeks gestation, presenting to the labour and delivery ward of 
Ghent university hospital. 
We complete a nested case-control study after the major outcomes (such as PTB before 34 weeks gestation) 
were determined. all subjects for this study, except patients from group 2, were selected from the original 
cohort. Group 2 was recruited at the prenatal clinic (see below). a convenience sample of singleton pregnancies 
was selected and divided into four groups according to gestational age (Ga) and labour status. Table 3 provides 
an overview of the study population and immunoassays for the different inflammatory markers (see page 81).
Group 1 consisted of women with preterm labour, allocated to the PTB group when delivered before 34 weeks 
gestation (=PTB), including patients with preterm prelabour rupture of the membranes (PProM) or with 
preterm labour and intact membranes. 
Group 2 consisted of women not in labour, attending the prenatal clinic of Ghent university hospital and 
matched for week of gestation with the PTB group. all these women had an uncomplicated pregnancy that 
proceeded to term delivery (Ga matched controls). 
Group 3 consisted of healthy pregnant women at term in labour (aT in labour), including patients in labour 
with intact membranes and women with prelabour rupture of the membranes (ProM). 
Group 4 consisted of healthy pregnant women at term not in labour, undergoing a primary caesarean section 
(=aT not in labour).
eligibility criteria included age ≥18 years, gestational age ≥24 weeks, absence of foetal (congenital) malfor-
mations, absence of infectious disease (hIV, syphilis, hepatitis B and c, cMV, toxoplasmosis) or acute infection 
and dutch speaking. 
data on maternal demographics, medical and obstetrical history and pregnancy outcome were recorded. 
Written informed consent was obtained from every patient. The study was approved by the ethical committee 
of Ghent university hospital (ec/2009/010).
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actions were considered between the covariates remaining in the model. The forward selection of interaction 
terms was performed with an inclusion criterion of p = 0.05. When no further interactions met this criterion, 
the final model was obtained for that outcome.
unless noted otherwise, all statistical analyses and tests were performed two-sided at the 5% significance 
level using sPss statistics 19 software (IBM, chicago, Illinois).
TaBle 3:      oVerVIeW of The sTudY PoPulaTIon and IMMunoassaYs for The dIfferenT 
InflaMMaTorY MarKers
side the range 70-130%. recovery and linearity-of-dilution were within the acceptable range for MMP-3 (97-
116%) and MMP-9 (74-114%). however, different serum dilutions were required to obtain fluorescence signals 
within the linear range of detection (an 80-fold dilution for MMP-9 and a 2-fold dilution for MMP-3). levels 
ofTIMP-1, -2, -3 and -4 were assessed using a human TIMP Multiplex Kit (r&d systems, Minneapolis, Mn). 
Multiple proteins were analysed using a multiplex bead immunoassay (human cytokine 30-plex Panel, Invitro-
gen, carlsbad, ca). The panel consisted of epidermal growth factor (eGf), eotaxin, basic fibroblast growth fac-
tor (fGf-basic), granulocyte colony-stimulating factor (G-csf), granulocyte macrophage colony-stimulating 
factor (GM-csf), hepatocyte growth factor (hGf), interferon alpha (Ifn-α), interferon gamma (Ifn-γ), interleu-
kin (Il) receptor antagonist (Il-1ra), Il-1β, Il-2, soluble Il-2 receptor (sIl2r), Il-4, Il-5, Il-6, Il-7, Il-8, Il-10, Il-12 
(p40/p70), Il-13, Il-15, Il-17, inducible protein-10 (IP-10), monocyte chemoattractant protein (McP)-1, mono-
kine induced by gamma interferon (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β, regulated on 
activation, normal T-cell expressed and secreted (ranTes), tumor necrosis factor alpha (Tnf-α), and vascular 
endothelial growth factor (VeGf). Protein levels were expressed as pg/ml. The mean intra-assay and interassay 
coefficients of variation were 6.0 and 4.4 %, respectively. 
all multiplexes (TIMP, MMP and 30-plex) were run on a luminex 200 platform (luminex corporation, austin, 
TX), equipped with Bio-Plex software (Bio-Plex Manager 4.1.1, Bio-rad, hercules, ca).
4.2.5 statistical analysis
univariate group differences were tested with χ² or fisher’s exact test for categorical and Mann-Whitney 
u-test or student’s t-test for continuous variables. as multiple markers were considered as outcome variables 
(e.g. multiplexes), we accounted for multiple testing by applying the Bonferroni correction: where appropri-
ate, adjusted p-values were obtained by multiplying with the total number of markers and ratios and used to 
evaluate significance. The normality of the continuous data was tested using the Kolmogorov-smirnov test 
and visual inspection of qq-plots. since the distribution of inflammatory markers were positively skewed, 
their natural log transformed values were used so as to have a normally distributed outcome variables for the 
multiple regression analysis, which was performed on the full dataset.
The subgroups were translated into three variables: preterm (vs. at term), labour (vs. not in labour) and rupture 
of membranes (roM) (vs. intact membranes). Because these key covariates were the focus of our investigation, 
they remained in the models regardless of their significance. To adjust for possible confounding effects, the 
following covariates were considered in the model selection procedure: maternal age, education level, marital 
status, smoking, BMI, history of PTB, storage time and time delay between sampling and processing (referred 
to as sample age). This set of covariates was included in the initial model of the selection procedure for each 
outcome. Model selection was carried out for each outcome independently and occurred in two steps. first, 
a backward selection of main terms was applied in which covariates were sequentially removed in order of 
increasing significance until only terms with p-value below 0.10 remained. In the second step, first order inter-
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sTreM-1 176 52 52 40 32 elIsa r&d systems, Minneapolis, Mn
MMP-9 166 47 47 40 32 luminex human Matrix Metalloproteinases 3-Plex Panel
Invitrogen, Inc. carlsbad, ca
TIMPs 166 47 47 40 32 luminex human TIMP Multiplex Kit
r&d systems, Minneapolis, Mn
MMP-3 116 34 34 27 21 luminex human Matrix Metalloproteinases 3-Plex Panel
Invitrogen, Inc. carlsbad, ca
Multiplex 144 39 39 34 32 luminex human cytokine 30-plex Panel
Invitrogen, Inc. carlsbad, ca
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Elevated Soluble Triggering Receptor Expressed on
Myeloid Cells (sTREM)-1 Levels in Maternal Serum during
Term and Preterm Labor
Inge Tency1*, Hans Verstraelen1, Bart Saerens2, Bruno Verhasselt2, Mario Vaneechoutte2,
Olivier Degomme3, Rita Verhelst3., Marleen Temmerman1,3.
1Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium, 2Department of Clinical Chemistry, Microbiology
& Immunology, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium, 3 International Centre for Reproductive Health, Department of Obstetrics and
Gynecology, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
Abstract
Background: Infection and inflammation are important mechanisms leading to preterm birth. Soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1) belongs to a family of cell surface receptors that seems to play an important role in
fine-tuning the immune response. It has been demonstrated that sTREM-1 is involved in bacterial infection as well as in non-
infectious inflammatory conditions. Few studies have investigated serum sTREM-1 expression during preterm labor.
Therefore, the purpose of this study was to assess sTREM-1 concentrations in maternal serum during term and preterm
labor.
Methods: This case control study included 176 singleton pregnancies in the following groups: patients in (1) preterm labor,
delivered before 34 weeks (PTB) (n = 52); (2) GA matched controls, not in labor, matched for gestational age (GA) with the
PTB group (n = 52); (3) at term in labor (n = 40) and (4) at term not in labor (n = 32). sTREM-1 concentrations were determined
by enzyme-linked immunoassay.
Results: sTREM-1 was detected in all serum samples. Median sTREM-1 concentrations were significantly higher in women
with PTB vs. GA matched controls (367 pg/ml, interquartile range (IQR) 304–483 vs. 273 pg/ml, IQR 208–334; P,0.001) and in
women at term in labor vs. at term not in labor (300 pg/ml, IQR 239–353 vs. 228 pg/ml, IQR 174–285; P,0.001). Women with
PTB had significantly higher levels of sTREM-1 compared to women at term in labor (P = 0.004). Multiple regression analysis,
with groups recoded as three key covariates (labor, preterm and rupture of the membranes), showed significantly higher
sTREM-1 concentrations for labor (+30%, P,0.001) and preterm (+15%, P = 0.005) after adjusting for educational level,
history of PTB and sample age.
Conclusions: sTREM-1 concentrations in maternal serum were elevated during spontaneous term and preterm labor and
sTREM-1 levels were significantly higher in preterm labor.
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Introduction
Preterm birth (PTB), defined as a delivery before 37 completed
weeks of gestation, remains a key issue in modern obstetrics. PTB
is the major cause of neonatal morbidity and mortality in
developed countries [1]. Infection and inflammation are important
mechanisms leading to PTB [2,3]. Intra-uterine infection caused
by bacteria is considered to be the primary cause of PTB [4–7]
and presumably evokes an immune response that involves the
release of cytokines and chemokines, prostaglandins and matrix-
degrading enzymes. These substances trigger uterine contractions,
membrane rupture and cervical ripening [4]. Evidence suggests
that most intra-uterine infections are chronic and subclinical in
nature and consequently hard to diagnose before labor or rupture
of membranes [1,4,5]. Therefore a diagnostic marker of subclin-
ical infection or inflammation would be most useful to identify
women at risk for PTB.
Recently, a family of cell surface receptors, the triggering
receptor expressed on myeloid cells (TREM) proteins, has been
discovered that seems to play an important role in fine-tuning the
innate immune response during infectious diseases. TREM-1 is a
transmembrane glycoprotein, mainly expressed in monocytes and
neutrophils [8–14]. Studies have shown that TREM-1 expression
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e56050
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on the full dataset (n = 176). A backward selection procedure was
applied in which covariates were sequentially removed in order of
increasing significance until only terms with p-value below 0.10
remained. The subgroups were translated into three variables:
preterm (vs. at term), labor (vs. not in labor) and rupture of the
membranes (ROM)(vs. intact membranes). These variables are
considered as key covariates and remained in the model regardless
of their significance. Other covariates considered in the model
selection were maternal age, educational level, marital status,
smoking, body mass index (BMI), history of PTB, storage time and
time delay between blood sampling and serum harvesting (further
described as sample age). After backward selection of main terms,
first order interactions were considered between all remaining
covariates, yielding the final model. Spearman correlation was
performed to estimate correlations between serum concentration
of sTREM-1 and the admission-to-delivery interval in the PTB
group. All statistical analyses and tests were performed two-sided
at the 5% significance level using SPSS statistics 19 software (IBM,
Chicago, Illinois).
Results
Demographic and Clinical Characteristics of the Study
Population
Demographic and clinical characteristics of the study popula-
tion are presented in Table 1. There were no significant
differences between groups regarding pre-pregnancy BMI, marital
status, ethnicity, conception, parity and history of PTB. Women
with PTB had a significantly lower education level than GA matched
controls (P = 0.003). Women AT not in labor were significantly older
than women AT in labor (P = 0.03). There were more smokers
among women AT not in labor and among women with PTB as
compared to women AT in labor (P = 0.04 respectively P= 0.005).
Serum sTREM-1 Concentrations
sTREM-1 was detected in all serum samples collected in this
study. Figure 1 shows sTREM-1 concentrations among the
different groups. Significantly higher median concentrations of
sTREM-1 were seen in women with PTB compared to GA matched
controls (367 pg/ml, interquartile range (IQR) 304–483 vs. 273 pg/
ml, IQR 208–334; P,0.001). Median sTREM-1 concentrations
were significantly increased in women AT in labor compared with
AT not in labor (300 pg/ml, IQR 239–353 vs. 228 pg/ml, IQR
174–285; P,0.001). Women with PTB had significantly higher
sTREM-1 levels than women AT in labor (367 pg/ml, IQR 304–
483 vs. 300 pg/ml, IQR 239–353; P= 0.004) (Figure 1).
For multiple linear regression, the covariates educational level,
history of PTB and sample age, met the significance criteria of the
backward selection and were retained in the final model, in
addition to the key covariates preterm, labor and rupture of the
membranes. No interaction effects were found to be significant.
Results of the final model are shown in Table 2. Since the model
used the natural log of sTREM-1 concentration as the dependent
variable, model coefficients reflect differences on the ln(concentra-
tion) scale. To allow interpretation on the original concentration
scale, we also provide exponentiated coefficients that reflect
relative (%) instead of absolute changes. The model showed that
labor (vs. not in labor) and preterm (vs. not preterm), but not
ROM (vs. intact membranes) remained significantly associated
with sTREM-1 concentration after adjusting for educational level,
history of PTB and sample age. On average, the sTREM-1
concentration was 30% higher in labor (vs. not in labor) and 15%
higher preterm (vs. at term). The average sTREM-1 concentration
was 14% higher in women with secondary education or less
compared to women with higher education and 28% lower in
women with a history of PTB versus no history. With other
covariates held constant, sTREM-1 concentrations multiplied with
a factor 1.004 for every additional hour of sample age.
Serum sTREM-1 Concentrations in PPROM vs. PTL and
Relation with Admission-to-Delivery Interval
In the PTB group, no differences in sTREM-1 concentrations
were observed between women with PPROM versus women with
PTL and intact membranes (372 pg/ml, IQR 303–494 vs.
342 pg/ml, IQR 303–436; P = 0.46). This result did not change
when using multiple regression analysis (data not shown). The
median admission-to-delivery interval in the PTB group was 3,5
days (IQR 3,5–7), in women with PPROM 4 days (IQR 0-7) and
in women with PTL and intact membranes 3 days (IQR 0–14,5).
The concentration of sTREM-1 was not related to the admission-
to-delivery interval in women with PTB (r = 0.17, P= 0.23) neither
in the subgroups (PPROM: r= 0.30, P= 0.08; PTL and intact
membranes: r = -0.11, P = 0.67).
Discussion
We have used a case control study to assess sTREM-1
concentrations in serum during term and preterm labor. In line
with previous observations in amniotic fluid [6], serum sTREM-1
levels are significantly increased in women with preterm labor
compared to GA matched controls. sTREM-1 levels were also
elevated in women at term in labor vs. those not in labor. Recent
studies have demonstrated that sTREM-1, although initially
described in microbial inflammation [8], is involved in non-
infectious inflammatory conditions as well [15,16]. There is
accumulating evidence that inflammation is also important in
spontaneous labor at term [3,25–27]. Moreover, it has been shown
that term labor is associated with an increased risk of microbial
invasion of the amniotic cavity (MIAC). The more advanced the
cervical dilatation, the greater the risk of MIAC [28,29]. Our
observation is consistent with Youssef et al [23] who demonstrated
increased TREM-1 mRNA expression in myometrium and cervix
after labor at term. In contrast, Kusanovic et al [6] found no
differences in amniotic fluid concentrations of sTREM-1 between
laboring and non-laboring women at term. These data suggest that
the maternal inflammatory response during labor may be different
from the fetal response. A large cross-sectional study is needed to
evaluate sTREM-1 concentrations in both compartments during
labor.
Since microbial invasion is more prevalent in PPROM [5,30],
we expected higher sTREM-1 levels in these women. Neverthe-
less, we found no differences in sTREM-1 concentrations between
patients with PPROM and those with PTL and intact membranes.
This finding may be attributed to the relative small number of
patients in both groups. In the presence of intra-amniotic
infection, sTREM-1 levels in amniotic fluid were higher in women
with PPROM vs. PTL and intact membranes [6]. This
observation suggests that sTREM-1 is probably a good marker
for intra-amniotic infection in amniotic fluid but not in maternal
serum which has been recently demonstrated by Cobo et al [21].
They evaluated 27 proteins in maternal serum of women with
PPROM or PTL and intact membranes and observed a weak
maternal inflammatory response in women with MIAC. In
particular, serum TREM-1 levels did not differ between women
with and without MIAC. Moreover, differences in protein levels
were only evident at early gestational age (less than 32 weeks of
gestation). Similar observations were made in amniotic fluid of
women with PPROM. TREM-1 concentrations did not differ
Serum sTREM-1 in Labor
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is upregulated in response to lipopolysaccharide (LPS) and other
microbial components [8–14]. TREM-1 synergizes with pathogen
recognition receptors, including Toll-like receptors (TLRs), which
in turn, increase cytokine production (e.g. IL-8, TNF-a and IL-
1a)[8–14]. Hence, TREM-1 functions as an amplifier of the
inflammatory response in the context of bacterial infection [8–14].
During infection, soluble TREM-1 (sTREM-1) is generated
through proteolytic cleavage of the TREM-1 ectodomain by
matrix metalloproteinases [10,14]. sTREM-1 is detectable in
various body fluids [10,12] and has been detected in plasma,
broncho-alveolar lavage fluid, pleural fluid, cerebrospinal fluid and
urine from intensive care patients with bacterial infections [12].
Recent studies have demonstrated that TREM-1 is also involved
in non-infectious inflammatory conditions such as rheumatoid
arthritis [15] and inflammatory bowel disease [16].
Few studies have investigated the role of sTREM-1 during PTB
[6,17–19]. Menon et al [18] demonstrated that both lipopolysac-
charide (LPS) and preterm labor induced fetal membrane TREM-
1 expression. In the presence of intra-uterine infection, amniotic
fluid sTREM-1 concentrations were significantly higher in patients
with preterm labour (PTL) [6,18] or preterm premature rupture of
the membranes (PPROM) [6]. However, amniotic fluid TREM-
levels did not predict PTB within 7 days in women with PPROM
[20]. Elevated serum concentrations of sTREM-1 in the second
trimester were associated with an increased risk of PTB in
asymptomatic high risk patients [19], but not in low-risk women
[17]. Furthermore, it has been shown that amniotic fluid
concentration of sTREM-1 increases with advancing gestational
age [6]. To our knowledge, only two studies [21,22] evaluated
serum sTREM-1 concentrations in patients with preterm labor.
Blood sampling has the advantage of being less invasive than
amniocentesis and is therefore a more appropriate method to
perform in pregnancy. However, these studies did not include
women with term labor. There is accumulating evidence that
inflammation has also been implicated in the mechanism of
spontaneous term parturition [2,7]. Youssef et al [23] demon-
strated that TREM-1 is expressed in myometrium and cervix at
term and found that sTREM-1 is upregulated in both tissues with
the onset of labor.
Therefore, the objective of the present study was to evaluate
whether sTREM-1 is upregulated in maternal serum during term
and preterm labor vs. non laboring controls and to assess a
possible relationship between sTREM-1 serum concentrations and
admission-to-delivery interval in women with PTB.
Materials and Methods
Ethics Statement
The study was approved by the Ethical Committee of Ghent
University hospital (EC/2009/010). All participants provided oral
and written informed consent.
Study Design and Population
We conducted a prospective cohort study at the Department of
Obstetrics and Gynecology of Ghent University Hospital in which
768 pregnant women between 24 and 42 weeks’ gestation,
presenting to the labor and delivery ward were enrolled, in order
to build a bank of biological samples and clinical data and to
explore putative associations between inflammatory markers of
term and preterm labor. [24]All subjects for this study were
selected from the prospective cohort except patients in group 2 (see
below). A convenience sample of 176 singleton pregnancies was
selected and divided into four groups according to gestational age
(GA) and labor status: (1) women with preterm labor (PTL), who
delivered before 34 weeks gestation (PTB) (n = 52). This group
consisted of 35 patients with preterm premature rupture of the
membranes (PPROM) and 17 with PTL and intact membranes.
All patients were in labor at the time of sampling; (2) women not in
labor, attending the prenatal clinic of Ghent University Hospital
and matched for GA with the PTB group. All these women had an
uncomplicated pregnancy that proceeded to term delivery (GA
matched controls) (n = 52); (3) healthy pregnant women at term in
labor (AT in labor) (n = 40). This group included patients in labor
with intact membranes (n = 20) and women with premature
rupture of the membranes (PROM) (n = 20). (4) healthy pregnant
women at term not in labor, undergoing a primary Caesarean
section (AT not in labor) (n = 32). Eligibility criteria included age
.18 years, gestational age$24 weeks, absence of fetal (congenital)
malformations, absence of maternal infectious disease (e.g. HIV,
hepatitis B) and Dutch speaking. Data on maternal demographics,
medical and obstetrical history and pregnancy outcome were
recorded.
Definitions
PTL was defined as having regular uterine contractions (six to
twelve contractions in one hour) and documented cervical changes
before 37 completed week’s gestation. Cervical changes include
cervical effacement or dilatation, cervical shortening (,25 mm)
and/or funneling and were measured by vaginal examination or
transvaginal ultrasonography. PPROM was defined as amnior-
rhexis at least 1 h before the onset of contractions. A confirmatory
test (crystallization test on slide or rapid rupture of membranes
(ROM) - test (Amnisure, Boston, US)) was performed if PPROM
was suspected on the basis of fluid leakage or oligohydramnion. In
case of a positive test, the diagnosis of PPROM was considered.
PTB was defined as PTL and/or PPROM, followed by a delivery
before 34 weeks. Gestational age was determined based on last
menstrual period corrected by early ultrasound before 20 weeks
gestation.
Sample collection and processing. Blood samples of
laboring women (either term or preterm) were collected by the
attending midwife upon admission to the labor and delivery ward.
Women at term not in labor were sampled prior to their
Caesarean section. GA matched controls were recruited from the
antenatal clinic. These pregnant women were screened at 20–22
weeks (structural ultrasound) to verify whether they fulfilled the
inclusion criteria. When eligible for participationthese women
were matched for week of gestation with a PTB case. Sampling
was performed during a subsequent prenatal consultation at the
appropriate gestational age. Samples were stored at 4uC until
processing. Blood samples were centrifuged at 1000 g for 10
minutes at room temperature to harvest serum. All serum samples
were stored at 280uC until analysis. Samples used for this study
were never thawed previously. sTREM-1 concentrations were
determined using an enzyme-linked immunoassay in accordance
with the manufacturer’s instructions (R&D systems, Minneapolis,
MN). All assay plates included samples from all groups. Both
standards and samples were measured in duplicate. The interassay
and intra-assay coefficients of variation were 7.8% and 13.9%,
respectively.
Statistical analysis. Univariate group differences were
tested with x2 or Fisher’s Exact test and Student’s t-test or
Mann-Whitney U-test when appropriate. The normality of the
continuous data was tested using the Kolmogorov-Smirnov test
and visual inspection of QQ-plots. Since the distribution of
sTREM-1 was positively skewed, their natural log transformed
values were used so as to have a normally distributed outcome
variable for the multiple regression analysis, which was performed
Serum sTREM-1 in Labor
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found that increased sTREM-1 levels in the second trimester were
associated with PTB in asymptomatic high risk patients, but not in
low risk women [17,19]. Further research is needed to establish the
value of sTREM-1 as a predictive marker of PTB. Second, no
Figure 1. Serum sTREM-1 concentrations among groups. Median sTREM-1 concentrations are significantly elevated in women in labor (either
term or preterm) vs. non-laboring controls. sTREM-1 levels are significantly higher in preterm vs. term labor. Horizontal bars denote the median value
for each study group.
doi:10.1371/journal.pone.0056050.g001
Table 2. Multiple regression model for ln(sTREM-1 concentration).
Parameter
Model coefficient
(95%CI) Exponentiated coefficient (95%CI) P-value
Intercept 5.416 [5.323, 5.508] 224.9 [205.1, 246.7] ,0.001
Preterm [vs. at term] 0.142 [0.043, 0.241] 1.152 [1.044, 1.272 0.005
Labor [vs. not in labor] 0.258 [0.126, 0.391] 1.295 [1.134, 1.479] ,0.001
ROM [vs. intact membranes] 20.021 [20.156, 0.113] 0.979 [0.856, 1.120] 0.76
Secondary education (or less) [vs. higher education] 0.128 [0.020, 0.236] 1.136 [1.020, 1.266] 0.02
History of PTB [vs. no history] 20.324 [20.542, 20.105] 0.724 [0.582, 0.900] 0.004
Sample age (in hours) 0.0039 [0.0003, 0.0076] 1.004 [1.000, 1.008] 0.04
Results of the model fitted on the full dataset (n = 176), obtained from the backward selection procedure outlined in the text. Covariates considered but not retained
were: maternal age, marital status, smoking, body mass index and storage time. Coefficients of the model (additive on the log scale) were exponentiated to
multiplicative factors, allowing interpretation on the concentration scale.
Sample age = time delay between blood sampling and processing.
CI, confidence interval; PTB, preterm birth; ROM, rupture of the membranes.
R2 = 0.28.
doi:10.1371/journal.pone.0056050.t002
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between women with and without MIAC [20], but higher levels
were observed in PPROM cases ,34 weeks in the presence of
both MIAC and histological chorioamnionitis [31]. This indicates
that TREM-1 may serve as a good marker for severe inflammation
in a subset of pregnant women at risk for PTB.
In addition, we observed significantly higher sTREM-1 levels in
preterm labor compared to term labor. The fact that microbial
invasion is more common in preterm birth could explain this
result. Another explanation could be that sTREM-1 levels alter
during pregnancy and may differ from the baseline in these
women. However, our study was not designed to evaluate
longitudinal changes in sTREM-1 concentrations. A study in
which sTREM-1 levels are serially assayed throughout gestation
and in non-pregnant women would be able to address this issue.
It is also recommendable to evaluate whether sTREM-1 levels
differ between women with PTL and intact membranes who
delivered preterm and those who delivered at term. We carried out
a preliminary evaluation, but found no significant differences in
sTREM-1 levels between both groups (data not shown). This result
must be interpreted cautiously since the number of patients with
PTL who delivered at term was rather low (n= 10). However,
Tsiartas et al [22] did not observed higher levels of TREM-1 in
women with PTL who delivered within 7 days vs. those delivering
later.
Variability in pre-analytical factors has been shown to influence
cytokine levels. Cytokine concentrations are most critically affected
by sample age i.e. the time lapse between blood collection and
processing [32–35]. The window between collection and process-
ing and the variability between samples has to be minimized, but is
not always feasible in practice [32,33]. The impact of sample age
on levels of inflammatory markers is often poorly addressed in
studies. Our model suggests that sample age can affect sTREM-1
measurements in serum, supporting the need to standardize
specimen processing as much as possible and/or to consider
differences due to sample age.
Some limitations of this study deserve consideration. First, the
case control study design did not allow investigating the value of
serum sTREM-1 to predict the onset of PTB. Previous studies
Table 1. Demographic and clinical characteristics of the study population.
Variables PTB (n =52)
GA matched
controls (n =52)
AT in labor
(n=40)
AT not in
labor (n=32)
Group 1
vs.
2 P-value
Group
3
vs.
4 P-value
Group 1
vs.
3 P-value
Maternal age (mean 6 SD, y) 28.765.6 29.864.1 29.164.6 31.464.4 0.26 0.03 0.69
Pre-pregnancy BMI (Me,
IQR, kg/m2)
21.5 [19.7–24.8] 21.8 [20.1–23.1] 21.9 [19.9–24.0] 21.6 [19.9–25.0] 0.98 0.43 0.77
Educational level (n, %) 0.002 0.58 0.09
Secondary education or less 24 (46.2) 9 (17.3) 11 (27.5) 7 (21.9)
Higher education 28 (53.8) 43 (82.7) 29 (72.5) 25 (78.1)
Marital status (n, %) 0.70 1.00 0.38
Married or cohabiting 47 (92.2) 48 (94.1) 39 (97.5) 31 (96.9)
Living alone 4 (7.8) 3 (5.9) 1 (2.5) 1 (3.1)
Smoking at recruitment 9 (17.3) 8 (15.4) 0 (0.0) 4 (12.5) 0.79 0.04 0.005
Ethnicity (n, %) 1.00 0.12 0.16
White/Caucasian 51 (98.1) 50 (96.2) 36 (90.0) 32 (100.0)
Other 1 (1.9) 2 (3.8) 4 (10.0) 0 (0.0)
GA at recruitment (Me,
IQR, wk)
29.0 [26.0–31.0] 29.0 [26.0–31.0] 40.0 [39.0–40.0] 38.0 [38.0–39.0] P = 1.00 ,0.001 0.001
Conception (n, %) 0.78 0.09 0.96
Spontaneous 44 (84.6) 45 (86.5) 34 (85.0) 31 (96.9)
Assisted reproductive
technology
8 (15.4) 7 (13.5) 6 (15.0) 1 (3.1)
Nullipara (n, %) 32 (61.5) 26 (50.0) 20 (50.0) 12 (37.5) 0.24 0.29 0.27
History of PTB 4 (7.7) 2 (3.8) 2 (5.0) 1 (3.1) 0.68 1.00 0.69
GA at delivery (Me, IQR, wk) 30.0 [28.0–32.0] 40.0 [39.0–40.0] 40.0 [39.0–40.0] 38.0 [38.0–39.0] ,0.001 ,0.001 ,0.001
Delivery mode (n, %) 0.21 ,0.001 = 0.38
Vaginal birth 48 (92.3) 43 (84.3) 39 (97.5) 0 (0.0)
Caesarean section 3 (5.9) 8 (15.7) 1 (2.5) 32 (100.0)
Birth weight (mean, 6SD, g) 1517.36514.4 3484.96498.0 3461.96396.2 3236.96360.0 ,0.001 0.01 ,0.001
Gender (n, %) 0.04 0.75 0.04
R 16 (30.8) 26 (51.0) 21 (52.5) 18 (56.3)
= 36 (69.2) 25 (49.0) 19 (47.5) 14 (43.8)
AT, at term; BMI, body mass index; GA, gestational age; IQR, interquartile range; Me, Median; PTB, preterm birth; SD, standard deviation.
X2 or Fisher’s Exact test for categorical variables; Student’s t-test or Mann-Whitney U-test for continuous variables.
doi:10.1371/journal.pone.0056050.t001
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Research, cosponsored by the American Society of Preventive Oncology 15:
1578–1581.
36. Gibot S, Cravoisy A, Kolopp-Sarda MN, Bene MC, Faure G, et al. (2005) Time-
course of sTREM (soluble triggering receptor expressed on myeloid cells)-1,
procalcitonin, and C-reactive protein plasma concentrations during sepsis.
Critical Care Medicine 33: 792–796.
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information could be obtained on the presence of intra amniotic
infection in patients with PPROM or PTL and sTREM-1 levels in
serum and amniotic fluid could not be compared, since
amniocentesis is not routinely performed in patients with preterm
labor. Finally, sTREM-1 concentrations were measured only once
upon admission. Evaluation of the time-course of plasma sTREM-
1 levels during sepsis showed that a progressive decline in sTREM-
1 concentration was associated with a favorable clinical evolution
[36]. It would be interesting to investigate the clinical informative
value of repeated determinations of serum sTREM-1 in hospital-
ized patients with preterm labor.
In conclusion, we found elevated sTREM-1 concentrations in
maternal serum during spontaneous parturition (either term or
preterm) and sTREM-1 levels were significantly higher in women
with preterm labor. Further studies are required to explore the role
of sTREM-1 in the inflammatory response during pregnancy and
labor.
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Imbalances between Matrix Metalloproteinases (MMPs)
and Tissue Inhibitor of Metalloproteinases (TIMPs) in
Maternal Serum during Preterm Labor
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Abstract
Background: Matrix metalloproteinases (MMPs) are involved in remodeling of the extracellular matrix (ECM) during
pregnancy and parturition. Aberrant ECM degradation by MMPs or an imbalance between MMPs and their tissue inhibitors
(TIMPs) have been implicated in the pathogenesis of preterm labor, however few studies have investigated MMPs or TIMPs
in maternal serum. Therefore, the purpose of this study was to determine serum concentrations of MMP-3, MMP-9 and all
four TIMPs as well as MMP:TIMP ratios during term and preterm labor.
Methods: A case control study with 166 singleton pregnancies, divided into four groups: (1) women with preterm birth,
delivering before 34 weeks (PTB); (2) gestational age (GA) matched controls, not in preterm labor; (3) women at term in labor
and (4) at term not in labor. MMP and TIMP concentrations were measured using Luminex technology.
Results: MMP-9 and TIMP-4 concentrations were higher in women with PTB vs. GA matched controls (resp. p = 0.01 and
p,0.001). An increase in MMP-9:TIMP-1 and MMP-9:TIMP-2 ratio was observed in women with PTB compared to GA matched
controls (resp. p = 0.02 and p,0.001) as well as compared to women at term in labor (resp. p = 0.006 and p,0.001). Multiple
regression results with groups recoded as three key covariates showed significantly higher MMP-9 concentrations, higher
MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios and lower TIMP-1 and -2 concentrations for preterm labor. Significantly higher
MMP-9 and TIMP-4 concentrations and MMP-9:TIMP-2 ratios were observed for labor.
Conclusions: Serum MMP-9:TIMP-1 and MMP-9:TIMP-2 balances are tilting in favor of gelatinolysis during preterm labor.
TIMP-1 and -2 concentrations were lower in preterm gestation, irrespective of labor, while TIMP-4 concentrations were
raised in labor. These observations suggest that aberrant serum expression of MMP:TIMP ratios and TIMPs reflect pregnancy
and labor status, providing a far less invasive method to determine enzymes essential in ECM remodeling during pregnancy
and parturition.
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Introduction
Matrix metalloproteinases (MMPs) are proteolytic, zinc-de-
pendent enzymes[1–6] capable of degrading extracellular matrix
(ECM) components, including collagen [1,4,5,7,8]. The human
MMP family currently consists of 26 members [1] and is classified
according to substrate specificity into collagenases, gelatinases,
stromelysines, matrilysins, membrane type-MMPs and other
MMPs [1,6,7,9]. More specifically, MMP-9, also known as
gelatinase B, plays a role in the remodeling of collagenous ECM
[1] and cleaves collagen type IV, the major basement membrane
component, collagen type V and elastin [1,2]. MMP-3 or
stromelysin-1 degrades a wide range of ECM proteins and
participates in proMMP activation [1,6]. Their activity is
regulated by tissue inhibitors of metalloproteinases (TIMPs) of
which four have been identified.[1–4,6,10]. Inhibition of MMP
activity occurs in a 1:1 stoichiometric relationship [1,7,8,11]. The
balance between collagenolysis and its inhibition is critical during
ECM remodeling [1,6]. An imbalanced MMP:TIMP ratio has
been involved in various medical conditions in humans including
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cancer, rheumatoid arthritis, osteoarthritis, endometriosis and
vascular diseases [1,7,8].
Human pregnancy is characterized by a steady remodeling of
the collagenous ECM in order to adapt fetal membranes and
cervix to uterine and fetal growth as gestation progresses [4,12].
MMPs play also a crucial role in birth-related events, including
cervical ripening and dilatation and membrane weakening and
rupture [2,4]. Some MMPs (e.g. MMP-1, MMP-2 and MMP-3)
are constitutively expressed during gestation, while the production
of others (e.g. MMP-9) are induced by active labor [2,3,13,14].
Aberrant ECM degradation by MMPs has been documented
during pregnancy complications including preterm birth. Preterm
birth (PTB), defined as a delivery before 37 completed weeks
gestation, is a multifactorial syndrome in which intrauterine
infection (IUI) is one of the most important mechanisms involved
[15,16]. IUI trigger MMP production via inflammatory mediators
[17]. Activation of the MMP cascade causes ECM degradation,
predisposing membrane rupture and cervix ripening [2,12,18].
A number of studies have shown that IUI[19–22], spontaneous
rupture of the membranes [11,21–27] and parturition[21–
24,26,28] either term or preterm are associated with elevated
MMP-9 concentrations in amniotic fluid, but few studies have
investigated the involvement of MMP-3 in labor and parturition.
Increased MMP-3 levels were found in amniotic fluid during term
as well as preterm parturition [13,29] and in cases of IUI [29,30].
A fully functional TIMP network has been demonstrated in fetal
membranes, decidua and placenta, irrespective of labor status[31–
33]. The majority of studies focused only on TIMP-1 and TIMP-
2. TIMP-1 concentrations in amniotic fluid were increased in the
presence of IUI [21,23] and in patients with rupture of the
membranes either term or preterm [11,23], but not in those with
spontaneous labor [11,24]. In contrast, TIMP-2 levels were
decreased in women with IUI, rupture of the membranes and
spontaneous labor [11,27,34]. Furthermore, it has been shown
that amniotic fluid levels of TIMP-1 decrease with advancing
gestational age [24,26] while those of TIMP-2 do increase [34].
We hypothesized that aberrant MMP expressions at local level
implicated in ECM degradation of the amniochorion and cervix,
are associated with aberrant changes in circulating MMPs,
resulting in imbalanced MMP:TIMP ratios and leading to preterm
labor. We therefore sought to determine the maternal serum
concentrations of MMP-3, MMP-9 and all four TIMPs as well as
the MMP:TIMP ratios during term and preterm labor.
Materials and Methods
Ethics Statement
The study was approved by the Ethical Committee of Ghent
University hospital (EC/2009/010). All participants provided oral
and written informed consent.
Study Design and Population
We performed a prospective cohort study (March 2009 to
December 2011) in which 768 pregnant women between 24 and
42 weeks’ gestation, presenting to the labor and delivery ward of
Ghent University hospital, a 1000-bed tertiary referral facility,
were enrolled in order to build a bank of biological samples and
clinical data and to explore putative associations between in-
flammatory markers of term and preterm labor. All subjects for
this study were selected from the prospective cohort, except
patients in group 2 (see below). A convenience sample of 166
singleton pregnancies was selected and divided into four groups
according to gestational age (GA) and labor status: Group 1 women
with preterm labor (PTL), allocated to the PTB group when
delivered before 34 weeks gestation (PTB) (n = 47). This group
included 32 patients with preterm premature rupture of the
membranes (PPROM) and 15 with PTL and intact membranes.
Group 2 consisted of women not in labor, attending the prenatal
clinic of Ghent University Hospital and matched for week of
gestation with the PTB group. All these women had an
uncomplicated pregnancy that proceeded to term delivery (GA
matched controls) (n = 47). Group 3 consisted of normal pregnant
women at term in labor (AT in labor) (n = 40). This group included
patients in labor with intact membranes (n = 20) and women with
rupture of the membranes (PROM) (n= 20). Group 4 consisted of
healthy pregnant women at term not in labor, undergoing
a primary Caesarean section (AT not in labor) (n = 32). Because of
logistic reasons, MMP-3 analyses were performed on a non-
selective sample of 116 singleton pregnancies, divided among the
subgroups as follows: 34 PTB, 34 GA matched controls, 27 AT in labor
and 21 AT not in labor. Inclusion criteria were age $18 years,
gestational age $24 weeks, absence of fetal (congenital) mal-
formations, absence of infectious disease (e.g. HIV, hepatitis B),
acute infection and Dutch speaking. Maternal demographic,
medical and obstetrical data were collected upon admission.
Definitions
PTL was defined as having regular uterine contractions (six to
twelve contractions in one hour) with cervical changes before 37
completed weeks of gestation. Cervical changes include cervical
effacement or dilatation, cervical shortening (,25 mm) and/or
funneling and were measured by vaginal examination or
transvaginal sonography. PPROM was defined as amniorrhexis
before the onset of PTL. A confirmatory test (crystallization test on
slide or rapid rupture of membranes (ROM) - test (Amnisure,
Boston, US)) was performed if PPROM was suspected on the basis
of fluid leakage or oligohydramnion. In case of a positive test, the
diagnosis of PPROM was considered. PTB was defined as PTL
and/or PPROM that led to a delivery before 34 weeks of
gestation. Gestational age was determined based on last menstrual
period, corrected by early ultrasound before 20 weeks gestation.
Sample Collection and Processing
Blood samples of laboring women (either term or preterm) were
collected by the attending midwife upon admission to the labor
and delivery ward. Women at term not in labor were sampled
prior to their Caesarean section. GA matched controls were enrolled
from the prenatal clinic. These pregnant women were screened at
20–22 weeks (structural ultrasound) to verify whether they fulfilled
the inclusion criteria. When they were eligible for participation,
the study was explained and they were matched for week of
gestation with a PTB case. Sampling was performed during
a subsequent prenatal consultation at the appropriate gestational
age.
Serum was obtained after coagulation of blood in the presence
of clot activator, followed by centrifugation for 10 minutes at
1000 g at room temperature and than frozen at minus 80uC until
analysis. Samples used for this analysis were never thawed
previously. MMP concentrations (MMP-3, -9 and -13) were
determined using a Human Matrix Metalloproteinases 3-Plex
Panel (Invitrogen, Inc. Carlsbad, CA). The 3-Plex was validated
for serum by performing spike and recovery and linearity-of-
dilution experiments. MMP-13 concentrations in maternal serum
were undetectable using this method in all samples. At a twofold
dilution of serum, concentrations were below the detection limit
and recovery fell outside the range 70–130%. Recovery and
linearity-of-dilution were within the acceptable range for MMP-3
(97–116%) and MMP-9 (74–114%). However, different serum
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well as all MMP-9:TIMP ratios were more than double preterm
while the average TIMP-1 and TIMP-2 concentrations were lower
(respectively 11% and 22%). Regression results show no significant
association between preterm and MMP-3 or any of the MMP-
3:TIMP ratios.
Labor vs. No Labor
The regression results showed that, after adjusting for other
covariates, MMP-9 concentrations and MMP-9:TIMP-2 ratios
were significantly higher for labor (vs. no labor, resp. P= 0.03 and
P=0.04), the same was true for TIMP-4 concentrations
(P,0.001). In particular, the average MMP-9 concentration and
MMP-9:TIMP-2 ratio were 51% resp. 49% higher in labor.
Additionally, the average TIMP-4 concentration was 33% higher
in labor. MMP-9:TIMP-1 ratios tended to be higher (632%) in
labor, although the adjusted p-value was not significant. Regression
results show no significant association between labor and MMP-3
or any of the MMP-3:TIMP ratios.
Rupture of the Membranes vs. Intact Membranes
The regression results show no significant association between
rupture of the membranes and MMP, TIMP concentrations or any of
their ratios.
Other Covariates
Other important covariates withheld in the regression models
are history of PTB, storage time (i.e. window between storage and
analysis) and BMI.
Our regression results showed that MMP-9 concentrations and
all MMP-9:TIMP ratios tended to be lower for women with
a history of PTB, but not significantly. For example, the average
MMP-9 concentration was 39% lower in women with a history of
PTB. Furthermore, regression results demonstrated that storage time
was significantly associated with MMP-9 concentrations and all
MMP-9:TIMPs ratios (all P,0.05). With other variables held
constant, MMP-9 concentrations multiplied with a factor 1.010
(i.e. increased with 1%) for every additional week of storage.
Finally, MMP-3 concentrations and MMP-3:TIMP-1 and MMP-
3:TIMP-4 ratios decreased with increasing body mass index (all
P,0.10).
Discussion
The role of MMPs and to a lesser extent of TIMPs has been
widely investigated in human term and preterm parturition over
the past decades. The novelty of our study is the determination of
MMP-3, MMP-9 and all four TIMPs in maternal serum. A
number of studies have explored MMP-9 in amniotic fluid[11,19–
24,26,35,36]. This requires invasive procedures, while blood
samples can be easily obtained during pregnancy.
In line with previous observations in maternal plasma [37] and
amniotic fluid [22,24], we found that MMP-9 concentrations were
elevated in maternal serum during preterm labor. In contrast, we
observed no significant increase in MMP-9 levels during term
parturition. Furthermore, our results showed that labor was not
associated with a change in serum MMP-3 concentration. To our
knowledge, no previous study measured serum MMP-3 during
labor, although Park et al [29] reported that MMP-3 levels were
elevated in amniotic fluid from women with spontaneous labor at
term and preterm.
TIMPs are endogenous specific inhibitors that have been shown
to regulate the proteolytic activity of MMPs in normal and
pathological processes. A fully functional TIMP network has been
demonstrated in human fetal membranes [32,33], in placenta and
decidua [33], in the extra-embryonic coelomic fluid [38] and in
amniotic fluid during the second trimester [38]. The four
inhibitors were present in maternal serum, but TIMP-3 levels
could not be quantified in the majority of the samples.
Table 2. Comparison of MMP-3, MMP-9, TIMPs levels and MMP:TIMPs ratios in maternal serum among groups.
Group 1
PTB (n =47)
Group 2
GA matched controls
(n =47)
Group 3
AT in labor
(n =40)
Group 4
AT not in labor
(n =32)
Group 1 vs.
2 P-value $
Group 3 vs.
4 P-value$
Group 1 vs.
3 P-value$
MMP-9 1125.1 [694.1–1977.4] 639.5 [513.8–924.5] 828.7 [420.7–1259.8] 554.6 [377.5–711.3] ,0.001 (0.001) 0.06 (NS) 0.006 (0.07)
TIMP-1 132.04 [118.25–152.27] 125.65 [111.07–139.21] 149.49 [133.01–
185.46]
137.98 [125.18–
149.44]
0.08 (NS) 0.02 (NS) 0.008 (0.09)
TIMP-2 121.76 [107.62–132.19] 121.26 [109.35–135.82] 156.12 [139.67–
190.19]
137.71 [124.57–
164.27]
0.68 (NS) 0.03 (NS) ,0.001
(,0.001)
TIMP-4 1.46 [1.09–1.96] 1.04 [0.83–1.26] 1.24 [1.12–1.46] 1.08 [0.81–1.35] ,0.001
(,0.001)
0.01 (NS) 0.08 (NS)
MMP-9:TIMP-1 ratio 8.21 [4.82–13.88] 5.26 [3.89–7.09] 4.85 [2.86–8.98] 3.94 [3.07–5.33] 0.002 (0.02) 0.35 (NS) ,0.001 (0.006)
MMP-9:TIMP-2 ratio 9.68 [6.06–14.34] 5.23 [3.95–7.35] 4.61 [2.80–6.75] 3.69 [2.92–5.45] ,0.001
(,0.001)
0.26 (NS) ,0.001
(,0.001)
MMP-9:TIMP-4 ratio 847.3 [386.8–1463.3] 657.4 [434.0–995.9] 578.0 [342.7–980.3] 567.7 [337.6–765.7] 0.29 (NS) 0.57 (NS) 0.13 (NS)
PTB (n = 34) GA matched controls
(n = 34)
AT in labor (n = 27) AT not in labor
(n = 21)
P-value$ P-value$ P-value$
MMP-3 9.10 [5.83–15.53] 8.78 [4.68–14.97] 9.55 [3.96–15.83] 7.14 [4.76–13.46] 0.55 (NS) 0.76 (NS) 0.52 (NS)
MMP-3:TIMP-1 ratio 0.065 [0.046–0.111] 0.065 [0.032–0.136] 0.062 [0.033–0.108] 0.057 [0.035–0.093] 0.60 (NS) 0.88 (NS) 0.25 (NS)
MMP-3:TIMP-2 ratio 0.073 [0.058–0.118] 0.074 [0.041–0.111] 0.048 [0.031–0.103] 0.045 [0.030–0.102] 0.47 (NS) 0.99 (NS) 0.03 (NS)
MMP-3:TIMP-4 ratio 6.13 [3.86–12.40] 7.95 [4.84–13.37] 8.45 [3.94–11.37] 7.36 [4.06–11.37] 0.44 (NS) 0.96 (NS) 0.74 (NS)
Results are expressed as median (interquartile range) (ng/ml), group differences were evaluated with the Mann-Whitney U-test.
PTB, preterm birth; PT, preterm; AT, at term; NS, not significant.
$Unadjusted P values and Bonferroni-adjusted P values (adjusted for 11 tests) between brackets.
doi:10.1371/journal.pone.0049042.t002
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dilutions were required to obtain fluorescence signals within the
linear range of detection (an 80-fold dilution for MMP-9 and a 2-
fold dilution for MMP-3). TIMP levels (TIMP-1, -2, -3 and -4)
were assessed using a Human TIMP Multiplex Kit according to
the manufacturers’ instructions (R&D systems, Minneapolis, MN).
MMP and TIMP levels were measured using Luminex technology
(Luminex 200, Luminex Corporation, Austin, TX).
Statistical Analysis
Univariate group differences were tested with Fisher’s Exact test
for categorical and Mann-Whitney U-test for continuous variables.
As multiple markers were considered as outcome variables, we
accounted for multiple testing by applying the Bonferroni
correction: where appropriate, adjusted p-values were obtained
by multiplying with the total number of markers and ratios and
used to evaluate significance.
The normality of continuous data was evaluated using the
Kolmogorov-Smirnov test and visual inspection of QQ-plots.
Since the distributions of MMPs and TIMPs were positively
skewed, their natural log transformed values were used so as to
have normally distributed outcome variables for multiple re-
gression analysis, which was performed on the full dataset. The
subgroups were translated into three variables: preterm (vs. at
term), labor (vs. not in labor) and rupture of membranes (ROM)
(vs. intact membranes).
Because these key covariates were the focus of our investigation,
they remained in the models regardless of their significance. To
adjust for possible confounding effects, the following covariates
were considered in the model selection procedure: maternal age,
education level, marital status, smoking, body mass index (BMI),
history of PTB, storage time and time delay between sampling and
processing (referred to as sample age). This set of covariates was
included in the initial model of the selection procedure for each
outcome. Model selection was carried out for each outcome
independently and occurred in two steps. First, a backward
selection of main terms was applied in which covariates were
sequentially removed in order of increasing significance until only
terms with p-value below 0.10 remained. In the second step, first
order interactions were considered between the covariates
remaining in the model. The forward selection of interaction
terms was performed with an inclusion criterion of p = 0.05. When
no further interactions met this criterion, the final model was
obtained for that outcome.
Unless noted otherwise, all statistical analyses and tests were
performed two-sided at the 5% significance level using SPSS
statistics 19 software (IBM, Chicago, Illinois).
Results
Demographic and Clinical Characteristics of the Study
Population
Maternal and clinical characteristics of the study population
(n = 166) are summarized in Table 1. No significant differences
were found regarding pre-pregnancy BMI, marital status, ethnic-
ity, conception, parity and history of PTB. Women with PTB had
a significantly lower education level than GA matched controls
(P = 0.003). There were significantly more smokers among women
with PTB as compared to women AT in labor (P = 0.007).
Significant differences were also found in maternal age (P= 0.03)
and the proportion of smokers (P = 0.04) between women AT not in
labor and women AT in labor. As these comparisons evaluated
different aspects of the study population and were not part of
a family of tests, no correction for multiple testing was applied.
Demographic and clinical characteristics were similar for the 116
singleton pregnancies included in the MMP-3 analysis (data not
shown).
Serum MMPs and TIMPs Concentrations and MMP:TIMP
Ratios
MMP-3, TIMP-1, TIMP-2 and TIMP-4 were detectable in all
serum samples, MMP-9 in 97.2% and TIMP-3 in only 26.7% of
samples. Serum MMP-9 concentrations of 4 samples (all patients
from the PTB group) were outside the linear range and omitted
from further analysis. TIMP-3 levels were below detection limits of
the assay in most samples (75.3%) and this parameter was
therefore omitted from further analyses. As mentioned previously,
MMP-13 could not be assessed in serum. Because we investigated
2 MMPs, 3 TIMPs and 6 MMP:TIMP ratios, we obtained
Bonferroni-adjusted p-values by multiplying p-values with a factor
11. In the text, we report the adjusted p-values. Serum MMP-3,
and -9, TIMP-1, -2 and -4 concentrations and their ratios are
summarized in Table 2.
Women with preterm birth vs. GA matched
controls. Median levels of MMP-9 and TIMP-4 were signifi-
cantly higher in women with PTB compared to GA matched
controls (respectively P= 0.001 and P,0.001). The same was true
for median MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios (re-
spectively P,0.02 and P,0.001).
Women at term in labor vs. at term not in labor. No
significant differences in MMP-9, MMP-3, all TIMP concentra-
tions or any of the MMP:TIMP ratios were observed between
women AT in labor vs. AT not in labor.
Women with preterm birth vs. at term in labor. Median
TIMP-2 levels were significantly lower in women with PTB
compared to those AT in labor (P,0.001). A significant higher
MMP-9:TIMP-1 and MMP-9:TIMP-2 ratio was observed in
women with PTB (respectively P = 0.006 and P,0.001). Higher
MMP-9 and lower TIMP-1 concentrations were observed in
women with PTB, but these differences were marginally not
significant (respectively P= 0.07 and P= 0.09).
Women with PPROM vs. PTL and intact membranes. In
the PTB group, no significant differences were observed in MMP-
9, MMP-3 or any of the MMP:TIMP ratios between women with
PPROM compared to those with PTL and intact membranes (data not
shown).
Determinants of MMP-3, MMP-9, TIMPs and MMP:TIMP
Ratios
Multiple regression analysis was performed on the full dataset.
After model selection, no significant interaction effects between the
covariates were found for any outcome. Results of the final models
are shown in Table S1. Since the models used the natural log of
marker concentration as outcome variable, model coefficients
reflect differences on the ln(concentration) scale. To allow
interpretation on the original concentration scale, we also provide
exponentiated coefficients that reflect relative (percent wise)
instead of absolute changes. The R2 of our regression models
varied from 7 to 33%, indicating a large amount of variation in log
marker concentration (ratio) not explained by the covariates
included.
Preterm vs. at Term
Our regression results showed that, after adjusting for other
covariates, MMP-9 and all MMP-9:TIMP ratios were significantly
higher for preterm (vs. at term, P,0.001), whereas TIMP-1 and
TIMP-2 were significantly lower for preterm (P = 0.002 resp.
P,0.001). In particular, the average MMP-9 concentration as
MMP:TIMP Imbalance in Serum during Preterm Labor
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Multiple regression analysis showed that TIMP-1 and TIMP-2
levels were lower in preterm gestations compared to those at term,
irrespective of labor status. This is in agreement with Clark et al
[39], who demonstrated that TIMP-1 is suppressed during
pregnancy with increasing serum levels from 37 weeks onwards,
back to pre-pregnant levels. The similar observation was made in
amniotic fluid for TIMP-2 showing an increase in concentration
with advancing gestational age [34]. By contrast, amniotic fluid
levels of TIMP-1 have been shown to decrease with advancing
gestation [24,26].
TIMP-4 is the most recently identified member of the TIMP
family and differs from the other TIMPs in its restricted expression
pattern and its structure [40]. Recent reports showed that TIMP-4
is also disregulated during cancer invasion and progression of
several organs (for instance in reproductive organs) which
highlights its potential role as a biomarker or therapeutic target
of disease [40]. Previous research focused on TIMP-4 expression
in intrauterine compartments during early and term pregnancy
and term parturition. Fortunato et al [32] showed a sparse and
inconsistent TIMP-4 expression and low mRNA levels of TIMP-4
in the fetal membranes from laboring and non-laboring women.
Furthermore, TIMP-4 was present predominantly in the extra-
embryonic coelomic fluid, with low amounts in the amniotic fluid
of the first trimester, but significantly increasing with gestation
[38]. To the best of our knowledge, there is no information on
TIMP-4 in women with preterm labor. Our results showed
a significant increase in serum TIMP-4 concentrations during
labor (either term or preterm).
Imbalances in the MMP:TIMP ratios may underlie the
pathogenesis of various diseases [41,42] and have been associated
with progression [43], remission [44] and severity [45] of disease.
Importantly, case-control group comparison showed higher
MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios in women with
preterm labor. These ratio shifts agreed with the higher MMP-9
and lower TIMP-1 and TIMP-2 concentrations in preterm labor.
Multiple regression analyses showed a strong association with
preterm status, as MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios
were markedly significant higher for the key covariate preterm,
while for the key covariate labor only the MMP-9:TIMP-2 ratio
was significantly higher. Only few studies have investigated
MMP:TIMP ratios during preterm labor. One previous study of
Fortunato et al [11] found that the molar ratio between MMP-2
and TIMP-2, but not TIMP-1 was increased in amniotic fluid
during PPROM.
None of the MMPs or TIMPs concentrations and MMP:TIMP
ratios differed significantly between women with PPROM and
those with PTL and intact membranes. This finding is consistent
with Romero et al [25] who found higher MMP-9 concentrations
in the fetal compartments, but not in maternal plasma [25]. These
observations suggest that cytokine changes during pregnancy are
not always reflected in the maternal circulation which is in line
with data from animal models indicating that that alterations in
cytokine profiles are strictly compartmentalized and independently
regulated [46]. Recently, Brou et al [47] evaluated thirty-six
biomarkers in maternal, fetal and intra-amniotic compartment of
women with preterm labor and demonstrated that the biomarkers
of the PTB pathway differ between different compartments.
It has been shown that pre-analytical variability arising from
sampling and storage procedures affect assayed concentration of
biological markers [48,49]. The impact of storage time and sample
age on MMP and TIMP concentrations was considered in the
multiple regression analysis. Our regression results showed that
storage time was positively correlated with serum MMP-9
concentration after adjusting for other covariates. Studies in-
vestigating MMP-9 stability during long-term storage at 280uC
show conflicting results [50,51]. The reason for these discrepant
results is not clear. In our study, we found no interactions between
storage time and other covariates in the model, indicating no
differences in storage time between groups.
Some limitations of this study deserve consideration. First, the
relatively small sample size of this study. More women with
PPROM and PTL and intact membranes might be necessary to
determine differences in MMPs and TIMPs concentrations.
Therefore, large studies are required to confirm our results. Since
we conducted a case control study and MMP and TIMP
concentrations were measured only once upon admission, we
were unable to demonstrate the exact timing of the ratio shift
between MMP and TIMP. It has been shown that MMPs are
temporally regulated to perform specific functions during preg-
nancy [8]. For example, MMP-9 is selectively expressed in the
decidua and fetal membranes with the onset of labor, but barely
detectable before labor [4]. Furthermore, it would be interesting to
evaluate whether MMP:TIMP ratios differ between patients with
preterm labor who delivered preterm and those delivering at term.
A preliminary evaluation showed no significant differences, but the
number of patients with preterm labor and term delivery was
rather low (n= 10). Finally, we only evaluated immunoreactive
forms of MMP-3 and -9 with a MMP 3–plex detecting all
circulating MMPs (including pro, active and TIMP bound forms).
An alternative would be to evaluate the enzymatic activity of
MMPs, because the mere presence of MMP does not necessarily
establish their catalytic capacity [8]. Fortunato et al [11]
demonstrated that only a small amount of total amniotic fluid
MMP-9 and -2 were active. However, it has been shown that the
immunoreactivity of MMP-9 in amniotic fluid correlates well with
its enzymatic activity [23].
In conclusion, this study showed that MMP-9:TIMP-1 and
MMP-9:TIMP-2 balances in maternal serum are tilting in favor of
gelatinolysis in women with preterm labor. All four TIMPs were
expressed in maternal serum. While TIMP-1 and -2 concentra-
tions were lower during gestation, irrespective of labor, TIMP-4
levels were elevated during labor (either at term or preterm). The
observations in the present study indicate that circulating MMPs
and TIMPs may also play a role in the pathogenesis of preterm
labor at systemic level or at least reflect pregnancy and labor
status. Our findings provide the possibility to develop a far less
invasive approach (compared to amniocentesis) for measurement
of enzymes essential for ECM remodeling during pregnancy and
parturition. However, a great deal still remains to be learned about
MMPs and in particular TIMPs during various stages of normal
pregnancy and labor as well as in pathological conditions such as
preterm labor.
Supporting Information
Table S1 Multiple regression model for ln(MMP-9,
MMP-3, TIMPs levels and MMP:TIMP ratios. This is
a table in PDF format. The file can be viewed with Adobe Acrobat
reader
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Table S1: Multiple regression model for ln(MMP-9, MMP-3, TIMPs levels and MMP:TIMP ratios) 
Outcome 
variable 
n Parameter Model coefficient 
[95%CI] 
Exponentiated coefficient [95%CI] Unadjusted 
P-value 
Adjusted 
P-value$ 
R² 
MMP-9 162 Intercept 5.575 [5.138, 6.012] 263.7 [170.4, 408.3] <0.001 <0.001 0.23 
  Preterm [vs. at term] 0.794 [0.466, 1.122] 2.212 [1.594, 3.071] <0.001 <0.001  
  Labor [vs. not in labor] 0.411 [0.147, 0.675] 1.508 [1.158, 1.964] 0.002 0.03  
  ROM [vs. intact membranes] -0.188 [-0.453, 0.078] 0.829 [0.636, 1.081] 0.17 NS  
  History of PTB [vs. no history] -0.489 [-0.898, -0.080] 0.613 [0.407, 0.923] 0.02 NS  
  Storage time (in weeks) 0.010 [0.004, 0.017] 1.010 [1.004, 1.017] 0.001 0.01  
TIMP-1 166 Intercept 4.761 [4.563, 4.959] 116.9 [95.9, 142.5] <0.001 <0.001 0.15 
  Preterm [vs. at term] -0.113 [-0.174, -0.053] 0.893 [0.840, 0.948] <0.001 0.003  
  Labor [vs. not in labor] 0.078 [-0.001, 0.156] 1.081 [0.999, 1.169] 0.05 NS  
  ROM [vs. intact membranes] 0.028 [-0.056, 0.112] 1.028 [0.946, 1.119] 0.51 NS  
  BMI (kg/m²) 0.008 [-0.001, 0.016] 1.008 [0.999, 1.016] 0.08 NS  
TIMP-2 166 Intercept 5.275 [5.064, 5.486] 195.4 [158.2, 241.3] <0.001 <0.001 0.33 
  Preterm [vs. at term] -0.244 [-0.309, -0.179] 0.783 [0.734, 0.836] <0.001 <0.001  
  Labor [vs. not in labor] 0.006 [-0.077, 0.089] 1.006 [0.926, 1.093] 0.89 NS  
  ROM [vs. intact membranes] 0.053 [-0.036, 0.142] 1.054 [0.965, 1.153] 0.24 NS  
  Smoker [vs. no smoker] -0.140 [-0.245, -0.035] 0.869 [0.783, 0.966] 0.009 0.10  
  BMI (kg/m²) -0.011 [-0.020, -0.002] 0.989 [0.980, 0.998] 0.02 NS  
TIMP-4 166 Intercept -0.007 [-0.101, 0.088] 0.993 [0.904, 1.092] 0.89 NS 0.16 
  Preterm [vs. at term] 0.072 [-0.030, 0.174] 1.075 [0.970, 1.190] 0.17 NS  
  Labor [vs. not in labor] 0.287 [0.155, 0.420] 1.332 [1.168, 1.522] <0.001 <0.001  
  ROM [vs. intact membranes] -0.010 [-0.153, 0.132] 0.990 [0.858, 1.141] 0.89 NS  
MMP-9:TIMP-1 162 Intercept 0.645 [0.176, 1.114] 1.906 [1.192, 3.047] 0.007 0.08 0.21 
  Preterm [vs. at term] 0.911 [0.559, 1.264] 2.487 [1.749, 3.540] <0.001 <0.001  
  Labor [vs. not in labor] 0.322 [0.039, 0.606] 1.380 [1.040, 1.062] 0.03 NS  
  ROM [vs. intact membranes] -0.205 [-0.491, 0.080] 0.815 [0.612, 1.083] 0.16 NS  
  History of PTB [vs. no history] -0.484 [-0.923, -0.044] 0.616 [0.397, 0.957] 0.03 NS  
  Storage time (in weeks) 0.010 [0.004, 0.017] 1.010 [1.004, 1.017] 0.003 0.03  
MMP-9:TIMP-2 162 Intercept 0.571 [0.129, 1.012] 1.770 [1.138, 2.751] 0.01 NS 0.29 
  Preterm [vs. at term] 1.036 [0.704, 1.368] 2.818 [2.022, 3.927] <0.001 <0.001  
  Labor [vs. not in labor] 0.397 [0.130, 0.664] 1.487 [1.139, 1.943] 0.004 0.04  
  ROM [vs. intact membranes] -0.231 [-0.500, 0.037] 0.794 [0.607, 1.038] 0.09 NS  
  History of PTB [vs. no history] -0.413 [-0.827, 0.001] 0.662 [0.424, 1.001] 0.05 NS  
  Storage time (in weeks) 0.010 [0.004, 0.016] 1.010 [1.004, 1.016] 0.002 0.02  
  
Outcome 
variable 
n Parameter Model coefficient 
[95%CI] 
Exponentiated coefficient [95%CI] Unadjusted 
P-value 
Adjusted 
P-value$ 
R² 
MMP-9:TIMP-4 162 Intercept 5.543 [5.061, 6.024] 255.4 [157.7, 413.2] <0.001 <0.001 0.13 
  Preterm [vs. at term] 0.760 [0.398, 1.122] 2.138 [1.489, 3.071] <0.001 <0.001  
  Labor [vs. not in labor] 0.120[-0.170, 0.411] 1.127 [0.844, 1.508] 0.42 NS  
  ROM [vs. intact membranes] -0.192 [-0.485, 0.101] 0.825 [0.616, 1.106] 0.20 NS  
  History of PTB [vs. no history] -0.634 [-1.084, -0.183] 0.530 [0.338, 0.833] 0.006 0.08  
  Storage time (in weeks) 0.011 [0.004, 0.018] 1.011 [1.004, 1.018] 0.002 0.02  
MMP-3 116 Intercept 3.103 [2.254, 3.951] 22.27 [9.526, 51.99] <0.001 <0.001 0.09 
  Preterm [vs. at term] 0.023 [-0.255, 0.300] 1.023 [0.775, 1.350] 0.87 NS  
  Labor [vs. not in labor] -0.036 [-0.395, 0.323] 0.965 [0.674, 1.381] 0.84 NS  
  ROM [vs. intact membranes] 0.087 [-0.286, 0.460] 1.091 [0.751, 1.584] 0.64 NS  
  Sample age (in hours) 0.010 [-0.002, 0.021] 1.010 [0.998, 1.021] 0.09 NS  
  BMI (kg/m²) -0.049 [-0.085, -0.013] 0.952 [0.919, 0.987] 0.008 0.08  
MMP-3:TIMP-1 116 Intercept -1.762 [-2.677, -0.847] 0.172 [0.069, 0.429] <0.001 0.002 0.08 
  Preterm [vs. at term] 0.184 [-0.112, 0.479] 1.202 [0.894, 1.614] 0.22 NS  
  Labor [vs. not in labor] -0.004 [-0.377, 0.368] 0.996 [0.686, 1.445] 0.98 NS  
  ROM [vs. intact membranes] 0.084 [-0.320, 0.487] 1.088 [0.726, 1.627] 0.68 NS  
  BMI (kg/m²) -0.053 [-0.092, -0.015] 0.948 [0.912, 0.985] 0.007 0.08  
MMP-3:TIMP-2 116 Intercept -2.301 [-3.181, -1.421] 0.100 [0.042, 0.241] <0.001 <0.001 0.09 
  Preterm [vs. at term] 0.354 [0.070, 0.638] 1.424 [1.073, 1.893] 0.02 NS  
  Labor [vs. not in labor] 0.071 [-0.287, 0.429] 1.073 [0.751, 1.536] 0.70 NS  
  ROM [vs. intact membranes] 0.020 [-0.368, 0.408] 1.020 [0.692, 1.503] 0.92 NS  
  BMI (kg/m²) -0.034 [-0.071, 0.004] 0.967 [0.931, 1.004] 0.08 NS  
MMP-3:TIMP-4 116 Intercept 3.120 [2.213, 4.026] 22.65 [9.143, 56.04] <0.001 <0.001 0.07 
  Preterm [vs. at term] -0.007 [-0.300, 0.286] 0.993 [0.741, 1.331] 0.96 NS  
  Labor [vs. not in labor] -0.156 [-0.525, 0.214] 0.856 [0.592, 1.239] 0.41 NS  
  ROM [vs. intact membranes] 0.107 [-0.293, 0.507] 1.113 [0.746, 1.660] 0.60 NS  
  BMI (kg/m²) -0.053 [-0.091, -0.014] 0.948 [0.913, 0.986] 0.008 0.08  
Results of the model fitted on the full dataset , obtained from the  model selection procedure outlined in the text. Coefficients of the model (additive on 
the log scale) were exponentiated to multiplicative factors, allowing interpretation on the concentration scale. 
CI, confidence interval; R², R square; ROM, rupture of the membranes; PTB, preterm birth; BMI, body mass index; NS, not significant 
$ Bonferroni-adjusted P values (adjusted for 11 tests) 
48. Kisand K, Kerna I, Kumm J, Jonsson H, Tamm A (2011) Impact of
cryopreservation on serum concentration of matrix metalloproteinases (MMP)-7,
TIMP-1, vascular growth factors (VEGF) and VEGF-R2 in Biobank samples.
Clin Chem Lab Med 49: 229–235.
49. Tworoger SS, Hankinson SE (2006) Collection, processing, and storage of
biological samples in epidemiologic studies: sex hormones, carotenoids,
inflammatory markers, and proteomics as examples. Cancer epidemiology,
biomarkers & prevention : a publication of the American Association for Cancer
Research, cosponsored by the American Society of Preventive Oncology 15:
1578–1581.
50. Rouy D, Ernens I, Jeanty C, Wagner DR (2005) Plasma storage at 280 degrees
C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem
338: 294–298.
51. Tarr GP, Williams MJ, Phillips LV, van Rij AM, Jones GT (2011) Seasonal
variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor
of matrix metalloproteinase-1 with storage at -80 degrees C. Clin Biochem 44:
1346–1348.
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MaTernal InFlaMMaTOry reSPOnSe In 
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 aBstract
BacKGrounD:
human term and preterm parturition are inflammatory processes in which cytokines play a pivotal role. dys-
regulated cytokine networks may lead to adverse pregnancy outcomes such as preterm labour. a number of 
studies have explored amniotic fluid cytokine profiles in women with preterm birth (PTB), but few studies have 
evaluated circulating cytokines during term and preterm labour (PTl). We hypothesized that inflammatory 
serum markers are differently expressed in labour, especially in women with PTl. Therefore, we sought to 
evaluate the maternal inflammatory response in labouring vs. non labouring women either term or preterm.
stuDy DesiGn:
This case control study included 144 singleton pregnancies, divided into four groups: (1) women with PTl, 
delivering before 34 weeks (PTB) (n=39); (2) gestational age (Ga) matched controls, not in preterm labour 
(n=39); (3) women at term (aT) in labour (n=34) and (4) aT not in labour (n=32). a panel of 30 inflammatory 
markers was measured in serum using luminex technology.
results:
Median hepatocyte growth factor (hGf) levels were significantly higher in women with PTB compared to Ga 
matched controls. In women aT in labour, interleukin (Il)-12 concentrations were significantly lower than in 
women aT not in labour, but significantly higher than in women with PTB. eotaxin and Ifn-γ inducible protein 
(IP)-10 levels were significantly lower in women with PTB compared to aT in labour. Multiple regression results 
with groups recoded as three key covariates showed significantly higher IP-10 concentrations in term gesta-
tion, irrespective of labour status and lower Il-12 levels in labour, irrespective of gestational age. 
conclusIons: There is a weak maternal inflammatory response in women during term and preterm labour. 
among the 30 inflammatory serum markers, only hGf was increased in women with PTB, while Il-12 levels 
were lower in labouring women and IP-10 levels were higher in term gestation. 
Keywords: maternal serum, biomarkers, cytokines, preterm labour, human parturition, inducible protein (IP)-
10, interleukin (Il)-12, hepatocyte growth factor (hGf)
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It has been shown that measurement of a single biomarker lacks effectiveness to predict PTB, which can partly 
be explained by the complex nature of PTB and the redundancy between pathways leading to PTB and bio-
markers (Menon et al., 2011). Therefore multiplex technology has been increasingly applied for simultaneous 
measurement of multiple proteins, thereby requiring only small sample volumes (chow et al., 2008; cobo, 
Kacerovsky, holst et al., 2012; cobo, Kacerovsky, Palacio et al., 2012; cobo, Tsiartas et al., 2012; curry et al., 
2008; denney et al., 2011; Gargano et al., 2008; holst et al., 2009, 2011; Keeler et al., 2009; Kramer et al., 
2010; Matoba et al., 2009; Mestan et al., 2009; skogstrand et al., 2005; Tsiartas et al., 2012). several studies 
investigated whether inflammatory biomarker profiles in amniotic fluid (Keeler et al., 2009) or maternal blood 
(Gargano et al., 2008; Kramer et al., 2010; Yang et al., 2010) could predict PTB in pregnant women in the 
midtrimester or microbial invasion of the amniotic cavity (MIac) in amniotic fluid of patients with PTl (cobo, 
Kacerovsky, holst et al., 2012; cobo, Kacerovsky, Palacio et al., 2012; cobo, Tsiartas et al., 2012; holst et al., 
2011). few studies have assayed maternal inflammatory biomarkers in women with active PTl (cobo, Tsiartas 
et al., 2012; holst et al., 2009; Tsiartas et al., 2012). They evaluated the predictive power of multiple proteins in 
maternal serum to predict MIac or delivering within 7 days of sampling. however, an inflammatory response 
is also involved in the onset of term labour. Because term and preterm parturition are both inflammatory pro-
cesses, we hypothesized that inflammatory markers are differently expressed in serum of women in labour and 
more likely to be increased in PTl, because infection is the most important causative trigger of PTB. Therefore, 
the objective of this study was to determine a panel of 30 cytokines, chemokines and growth factors in mater-
nal serum from pregnant women in labour (either term or preterm) vs. non labouring controls. 
 introDuction 
cytokines comprise a diverse family of small soluble glycoproteins that regulate various biological processes 
(Murphy, Travers & Walport, 2008; oppenheim et al., 2001; orsi, 2008). They are produced by a number of 
immune and non-immune cells engaged in inflammatory host defense (oppenheim et al., 2001). cytokines 
also play pivotal roles in several reproductive processes such as menstrual cycle, implantation, placentation, 
embryogenesis, foetal development, uterine expansion, labour and parturition (Keelan et al., 2003; orsi, 2008; 
orsi & Tribe, 2008). 
Pregnancy is a unique immunological state in which changes in the maternal immune system promote foetal 
allograft tolerance (chen, liu & sytwu, 2012; MacIntyre, sykes, Teoh & Bennett, 2012; orsi, 2008; sykes, Mac-
intyre, Yap, Teoh & Bennett, 2012). The balance between immune tolerance and suppression is tightly regulat-
ed by a plethora of cytokines, in concert with hormones including progesterone (orsi, 2008; orsi & Tribe, 2008; 
sykes et al., 2012). successful pregnancy has been characterized by a switch in the Th1:Th2 cytokine balance 
towards Th2 predominance (MacIntyre et al., 2012; orsi, 2008; sykes et al., 2012). The Th2 bias is reversed 
towards term gestation, especially with the onset of labour (sykes et al., 2012). There is evidence that an 
aberrant Th1:Th2 profile is associated with adverse pregnancy outcomes such as miscarriage, pre-eclampsia, 
preterm labour and foetal brain injury (orsi & Tribe, 2008; sykes et al., 2012). In particular, activation of the Th1 
profile, rather than suppression of the Th2 profile, seems to be more apparent in preterm labour (PTl) (sykes 
et al., 2012).
human parturition is increasingly recognized as an inflammatory process (norman, Bollapragada, Yuan & nel-
son, 2007; orsi & Tribe, 2008; romero, espinoza, Goncalves et al., 2006), characterized by a massive influx of 
inflammatory cells in gestational tissues (Bowen, chamley, Keelan & Mitchell, 2002; MacIntyre et al., 2012; 
orsi, 2008; sykes et al., 2012; Yuan, Jordan, McInnes, harnett & norman, 2009) and an increased production of 
inflammatory cytokines and chemokines (Bowen et al., 2002; MacIntyre et al., 2012; orsi, 2008; sykes et al., 
2012). This in turn drives the synthesis of prostaglandins, stimulating myometrial contractions and increases 
matrix metalloproteinases (MMP) expression leading to membrane remodeling and rupture as well as cervical 
ripening (Bowen et al., 2002; MacIntyre et al., 2012; orsi, 2008). although term and preterm labour result from 
the activation of a common pathway, PTl is characterized by an untimely and asynchronous inflammatory 
activation, caused by multifactorial triggers including infection (orsi, 2008; romero, espinoza, Kusanovic et al., 
2006). Intra-uterine infection (IuI) is the only pathological process for which both a causal link with preterm 
birth (PTB) and a molecular pathophysiology has been demonstrated (Goldenberg, culhane, Iams & romero, 
2008; Goldenberg, hauth & andrews, 2000; Goncalves, chaiworapongsa & romero, 2002; romero, espinoza, 
Kusanovic et al., 2006). evidence suggests that most IuI are chronic and subclinical in nature and consequently 
hard to diagnose before labour or rupture of the membranes (Goldenberg et al., 2008; Goldenberg et al., 2000; 
Goncalves et al., 2002). Therefore a diagnostic marker of subclinical infection or inflammation would be most 
useful to identify women at risk for PTB.
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formed if PProM was suspected on the basis of fluid leakage or oligohydramnion. In case of a positive test, the 
diagnosis of PProM was considered. PTB was defined as PTl and/or PProM, followed by a delivery before 34 
weeks. Gestational age was determined based on last menstrual period corrected by early ultrasound before 
20 weeks gestation.
sample collection and processing 
Blood samples of labouring women (either term or preterm) were collected by the attending midwife upon ad-
mission to the labour and delivery ward using serum separating tubes (gel + clot-activator, Venosafe® Plastic 
tube serum Gel, Terumo europe leuven, Belgium). Women at term not in labour were sampled prior to their 
caesarean section. Ga matched controls were enrolled from the prenatal clinic. These pregnant women were 
screened at 20-22 weeks (structural ultrasound) to verify whether they fulfilled the inclusion criteria. When 
they were eligible for participation and agreed with the study procedure, these women were matched for 
week of gestation with a PTB case. sampling was performed during a subsequent prenatal consultation at the 
appropriate gestational age.
samples were stored at 4°c until centrifugation. Blood samples were centrifuged at 1000 g for 10 minutes 
at room temperature to harvest serum. all samples were stored at -80 °c until analysis. samples used for 
this analysis were never thawed previously. Protein analysis was achieved by using a multiplex bead immu-
noassay (human cytokine 30-plex Panel, Invitrogen, carlsbad, ca) run on a luminex 200 platform (luminex 
corporation, austin, TX), equipped with Bio-Plex software (Bio-Plex Manager 4.1.1, Bio-rad, hercules, ca). 
The assay was performed in accordance to the manufacturer’s instructions. The panel consisted of epidermal 
growth factor (eGf), eotaxin, basic fibroblast growth factor (fGf-basic), granulocyte colony-stimulating fac-
tor (G-csf), granulocyte macrophage colony-stimulating factor (GM-csf), hepatocyte growth factor (hGf), 
interferon alpha (Ifn-α), interferon gamma (Ifn-γ), interleukin (Il) receptor antagonist (Il-1ra), Il-1β, Il-2, 
soluble Il-2 receptor (sIl2r), Il-4, Il-5, Il-6, Il-7, Il-8, Il-10, Il-12 (p40/p70), Il-13, Il-15, Il-17, inducible pro-
tein-10 (IP-10), monocyte chemoattractant protein (McP)-1, monokine induced by gamma interferon (MIG), 
macrophage inflammatory protein (MIP)-1α, MIP-1β, regulated on activation, normal T-cell expressed and 
secreted (ranTes)), tumor necrosis factor alpha (Tnf-α), and vascular endothelial growth factor (VeGf). Pro-
tein levels were expressed as pg/ml. The mean intra-assay and interassay coefficients of variation were 6.0 and 
4.4 %, respectively. 
statistical analysis
univariate group differences were tested with fisher’s exact test for categorical and Mann-Whitney u-test for 
continuous variables. as multiple markers were considered as outcome variables, we accounted for multiple 
 materials anD methoDs
ethics statement
The study was approved by the ethical committee of Ghent university hospital (ec/2009/010). all participants 
provided oral and written informed consent.
study design and population
all subjects for this study, except patients from group 2, were selected from a prospective cohort study at the 
department of obstetrics and Gynecology of Ghent university hospital; this study has been described previ-
ously(Tency et al., 2012). Group 2 was recruited at the prenatal clinic (see below). a convenience sample of 144 
singleton pregnancies was selected and divided into four groups according to gestational age (Ga) and labour 
status: Group 1 consisted of women with preterm labour (PTl), allocated to the PTB group when delivered 
before 34 weeks gestation (=PTB) (n=39). This group included 26 patients with preterm premature rupture of 
the membranes (PProM) and 13 with PTl and intact membranes. Group 2 consisted of women not in labour, 
attending the prenatal clinic of Ghent university hospital and matched for week of gestation with the PTB 
group. all these women had an uncomplicated pregnancy that proceeded to term delivery (Ga matched con-
trols) (n=39). Group 3 consisted of healthy pregnant women at term in labour (aT in labour) (n=34). This group 
included patients in labour with intact membranes (n=15) and women with premature rupture of the mem-
branes (ProM) (n=19). Group 4 consisted of healthy pregnant women at term not in labour, undergoing a pri-
mary caesarean section (=aT not in labour) (n=32). eligibility criteria included age ≥18 years, gestational age 
≥24 weeks, absence of foetal (congenital) malformations, absence of infectious disease (hIV, syphilis, hepatitis 
B and c, cMV, toxoplasmosis) or acute infection and dutch speaking. data on maternal demographics, medical 
and obstetrical history and pregnancy outcome were recorded. Written informed consent was obtained from 
every patient. The study was approved by the ethical committee of Ghent university hospital (ec/2009/010).
Definitions
PTl was defined as having regular uterine contractions (six to twelve contractions in one hour) and document-
ed cervical changes before 37 completed weeks of gestation. cervical changes include cervical effacement 
or dilatation, cervical shortening (<25 mm) and/or funneling and were measured by vaginal examination or 
transvaginal sonography. PProM was defined as amniorrhexis before the onset of PTl. a confirmatory test 
(crystallization test on slide or rapid rupture of membranes (roM) - test (amnisure, Boston, us)) was per-
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 results
Demographic and clinical characteristics of the study population
Maternal and clinical characteristics of the study population (n=144) are presented in Table 1. no significant 
differences were found regarding maternal age, pre-pregnancy BMI, marital status, ethnicity, conception, par-
ity and history of PTB. Women with PTB had significantly lower education levels than Ga matched controls and 
than women aT in labour (respectively p=0.002 and p=0.02). There were significantly more smokers among 
women with PTB as compared to women aT in labour (p=0.006). 
serum levels of the inflammatory markers
detection and concentration levels of each measured inflammatory marker are summarized in Table 2. of the 
30 inflammatory markers analyzed, only 8 were detectable in more than 50% of the maternal serum samples: 
eGf, hGf, Il-12, eotaxin, MIP-1β, McP-1, IP-10 and sIl-2r (Table 2, shaded lines). concentrations of ranTes were 
all outside the linear range. levels of the other 21 inflammatory markers were below the detection limits of 
the assay in more than 50% of samples in all groups; therefore these markers were omitted from further anal-
ysis. of the 8 markers considered, 5 had undetectable levels in 1 to 20% of samples. To avoid biased results in 
subsequent statistical analyses, these censored values were imputed at half the detection limit. all reported 
analyses and results of serum concentrations of the 8 inflammatory markers provided in Table 3 were based 
on the imputed dataset. as we investigated 8 inflammatory markers, Bonferroni-adjusted p-values were ob-
tained by multiplying with a factor 8.
Women with preterm birth vs. Ga matched controls 
Median levels of eGf and hGf were significantly higher in women with PTB compared to Ga matched controls 
(respectively p<0.01 and p<0.05). 
Women at term in labour and not in labour 
a significantly lower median Il-12 concentration was observed in women aT in labour compared to aT not in 
labour (p<0.05). 
testing by applying the Bonferroni correction: where appropriate, adjusted p-values were obtained by multi-
plying with the number of markers and used to evaluated significance.
The normality of continuous data was evaluated using the Kolmogorov-smirnov test and visual inspection 
of q-q-plots. since the distributions of protein levels were positively skewed, their natural log transformed 
values were used to obtain normally distributed outcome variables for multiple regression analysis, which was 
performed on the full dataset (n=144). The subgroups were translated into three variables: preterm (vs. at 
term), labour (vs. not in labour) and rupture of membranes (roM) (vs. intact membranes). 
Because these three key covariates were the focus of our investigation, they remained in the model regardless 
of their significance. To adjust for possible confounding effects, the following covariates were considered in 
the model selection procedure: maternal age, education level, marital status, smoking, body mass index (BMI), 
history of PTB, storage time and time delay between sampling and centrifugation (referred to as sample age). 
This set of covariates was included in the initial model of the selection procedure for each outcome. Model se-
lection was carried out for each outcome independently and occurred in two steps. first, a backward selection 
of main terms was applied in which covariates were sequentially removed in order of increasing significance 
until only terms with p-value below 0.10 remained. In the second step, first order interactions were considered 
between covariates remaining in the model. The forward selection of interaction terms was performed with 
an inclusion criterion of p=0.05. When no further interactions met this criterion, the final model was obtained 
for that outcome. unless noted otherwise, all statistical analyses and tests were performed two-sided at the 
5% significance level using sPss statistics 19 software (IBM, chicago, Il).
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branes. among women with roM, McP-1 levels multiplied with a factor 1.014 (= e(0.003 + 0.011), increase 
with 1.4%) for every additional week of storage, while among women with intact membranes the increase was 
negligible (an increase of 0.3% per week).
other covarIates
In addition to the three key covariates, other covariates were withheld in our regression models including 
sample age (i.e. window between sample collection and processing with subsequent storage), storage time 
(i.e. window between sample storage and analysis), educational level, smoking, history of PTB and maternal 
age. While the model selection procedure considered the first order interaction terms between the withheld 
covariates, none of these terms met the inclusion criterion of p=0.05.
regression results demonstrated that sample age was significantly associated with eGf concentrations 
(p<0.001), whereas storage time was weakly associated with Il-12 and eotaxin (p<0.10). With other variables 
held constant, eGf concentrations multiplied with a factor 1.032 (i.e. increased with 3.2%) for every additional 
hour in sample age. Il-12 and McP-1 levels were higher in women with secondary (or less) education (resp. 
p<0.05 and p<0.10). furthermore, regression results showed that Il-12 and McP-1 concentrations were lower 
in smokers (resp. p<0.05 and p<0.001). finally, hGf levels were on average 49% lower in women with a history 
of PTB (p<0.05) and sIl2-r decreased with 5% for every year of maternal age (p<0.01). 
Women with preterm birth vs. at term labour
Median Il-12, eotaxin and IP-10 were significantly lower in women with PTB compared to aT in labour (respec-
tively p<0.01, p<0.05 and p<0.01). lower median McP-1 levels were observed in women with PTB, although 
this difference was marginally not significant (p=0.05). 
Women with pprom vs. ptl and intact membranes
In the PTB group, no significant differences were observed in any of the inflammatory markers between wom-
en with PProM compared to those with PTl and intact membranes (data not shown). 
Determinants of the inflammatory markers
Multiple regression analysis was performed on the full dataset. results of the final models are shown in Table 
4. since the models used the natural log of marker concentration as the outcome variable, model coefficients 
reflect differences on the ln(concentration) scale. To allow interpretation on the original concentration scale, 
we also provide exponentiated coefficients that reflect relative (percent-wise) instead of absolute changes. 
The r2 of our regression models varied from 10 to 39%, indicating a large amount of variation in log marker 
concentration not explained by the covariates included.
preterm vs. at term
our regression results showed that, after adjusting for other covariates (including the key covariate labour 
status), average IP-10 concentrations were 47% lower preterm (vs. at term, p<0.001). We observed no similar 
significant association of term status with any of the other 7 markers.
laBour vs. no laBour
The regression results showed that, after adjusting for other covariates (including the key covariate preterm vs. 
term), average Il-12 concentrations were 23% lower in labour (vs. no labour, p<0.01). We observed no similar 
significant association of labour status with any of the other 7 markers.
rupture of the memBranes vs. Intact memBranes
The regression results showed that McP-1 concentrations were significantly associated with roM (vs. intact 
membranes, p<0.01). The significant interaction between roM and storage time (p<0.05) indicates that the 
effect of storage time on McP-1 levels was not consistent across women with roM and those with intact mem-
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predominance and Th1 suppression appears to exist during pregnancy (MacIntyre et al., 2012; orsi, 2008). as 
widely demonstrated, Il-12 is a potent inducer of the Th1 response, bridging innate and adaptive immunity 
and being critical in controlling microbial infections (langrish et al., 2004). since preterm labour likely rep-
resents an activation of the Th1 response (sykes et al., 2012), several studies evaluated the potential of Il-12 as 
a short- and long-term predictor of preterm birth (cobo, Tsiartas et al., 2012; ekelund et al., 2008; Gargano et 
al., 2008; holst et al., 2009; Keeler et al., 2009; Tsiartas et al., 2012; Vogel et al., 2007). however, few studies 
investigated circulating Il-12 levels during labour. In the present study, group comparison showed lower Il-12 
concentrations in women aT in labour vs. those not in labour. We found lower Il-12 levels in preterm vs. term 
labour. Multiple regression showed a strong association with labour status since Il-12 levels were lower in 
labouring women, irrespective of gestational age (term or preterm). our observations are in agreement with 
those of dubicke et al. (dubicke et al., 2010) who demonstrated that mrna Il-12 was downregulated in cervical 
tissues of labouring women and expression was lower in preterm than in term labour. These data are contrary 
to the classical Th1:Th2 paradigm, which assumes that a Th1 response is associated with adverse pregnancy 
outcomes. however, decreased percentage of Il-12 producing monocytes has been observed in preeclampsia 
(van nieuwenhoven, Moes, heineman, santema & faas, 2008) as well as in spontaneous abortions (Zenclussen 
et al., 2002). as such, the Th1:Th2 paradigm may be insufficient in explaining complex and dynamic immuno-
logical processes such as pregnancy (chaouat, 2007; saito, nakashima, shima & Ito, 2010; sykes et al., 2012). 
Therefore, it has been recently suggested to expand the Th1:Th2 dichotomy into the Th1:Th2:Th17 and regulato-
ry T (Treg) cells paradigm (saito et al., 2010). additionally, the Th1:Th2 ratio may be of greater importance than 
the absolute concentrations of the Th1 or Th2 cytokines. ekelund et al. (ekelund et al., 2008) found no direct 
correlation between Il-12 levels and PTB, but a high Il-12:Il-18 ratio was associated with a twofold increased 
risk for delivery before 34 weeks. unfortunately, we were not able to calculate Th1:Th2 cytokine ratios since the 
majority of cytokines were undetectable in maternal serum. Il-12 alterations may also be compartmentalized 
and independently regulated. It has been shown that Il-12 levels were elevated in placentas from women with 
preterm vs. term delivery (el-shazly, Makhseed, azizieh & raghupathy, 2004) whereas in women with preterm 
labour, Il-12 serum levels did not differ in the presence of microbial invasion of the amniotic cavity (cobo, 
Tsiartas et al., 2012) and did not predict delivery within 7 days of sampling (Tsiartas et al., 2012). 
chemokines mediate the early inflammatory response by local recruitment and activation of leukocytes (Go-
mez-lopez, estrada-Gutierrez, Jimenez-Zamudio, Vega-sanchez & Vadillo-ortega, 2009; liu et al., 2011; Mur-
phy et al., 2008; romagnani & crescioli, 2012). They are important regulatory molecules with the ability to 
initiate labour-associated events such as cervical ripening and rupture of the foetal membranes in normal and 
pathological conditions (Gomez-lopez, laresgoiti-servitje, olson, estrada-Gutierrez & Vadillo-ortega, 2010). 
In particular, cXcl10 (also named Ifn-γ induced peptide or IP-10) acts as a powerful chemotactic factor for Th1 
cell recruitment into inflamed tissues and has potent anti-angiogenic and pro-inflammatory properties (liu 
et al., 2011; romagnani & crescioli, 2012). IP-10 has been proven to be an important biomarker for allograft 
rejection after transplantation in circulating fluids (romagnani & crescioli, 2012). There is growing evidence 
that IP-10 is involved in the pathophysiology of preeclampsia and preterm labour. Increased IP-10 levels were 
 Discussion
among the 30 inflammatory markers we studied, only eGf and hGf serum levels were significantly associated 
with preterm labour. eGf plays a major role in placental (anteby et al., 2004; Maruo, Matsuo, otani & Mochizu-
ki, 1995) and foetal (shigeta, hiramatsu, eguchi & sekiba, 1992) growth by degradation of the extra cellular 
matrix (qiu, Yang, Tsang & Gruslin, 2004; staun-ram, Goldman, Gabarin & shalev, 2004). little is known about 
serum eGf levels during term and preterm labour. Group comparison showed significantly higher eGf concen-
trations in women with preterm labour compared to Ga matched controls. It has been shown that eGf is also 
involved in the mechanism of term parturition (romero, Wu, oyarzun, hobbins & Mitchell, 1989). In line with 
the observations in amniotic fluid, we found higher eGf levels in labouring vs. non labouring women at term 
(but not significant). however, such direct group comparisons must be interpreted with caution, since the 
multiple regression model for eGf showed that sample age (i.e. the time lapse between blood collection and 
centrifugation) may act as a confounding factor and that none of the key covariates were significant in this 
model. Yucel et al. (Yucel, Karakus & cemalettin, 2007) demonstrated that blood eGf levels are susceptible to 
changes in blood clotting and test tube type. serum eGf values were higher than those measured in plasma 
which yielded values below detection limit (Biancotto, feng, langweiler, Young & Philip Mccoy, 2012; Yucel 
et al., 2007). This can be attributed to the platelet derived eGf. eGf levels in platelet-lysate started to increase 
after 40 min, with the peak at 49 min, and decreased to nearly baseline level after 60 min (Yucel et al., 2007). 
Because median sample age differed significantly between groups (Table 1) and eGf levels were associated 
with sample age as evidenced by the multiple regression model, we cannot exclude that group differences in 
eGf were the results of variation in sample handling procedures. The best way to limit the impact of pre-ana-
lytical factors (such as sample age) is to start sample processing immediately and to standardize it as much as 
possible. however, it should be recognized that this is not always feasible in practice; therefore these factors 
should be considered in subsequent statistical analyses. 
hGf has also a significant role in placental (choy, siu, leung & lau, 2004; dokras, Gardner, seftor & hendrix, 
2001; Kauma, hayes & Weatherford, 1997) and foetal (aoki, hata, Manabe & Miyazaki, 1998) growth. de-
creased hGf levels have been associated with pregnancy complications such as preeclampsia (furugori et al., 
1997; somerset et al., 1998) and intrauterine growth restriction (IuGr) (aoki et al., 1998). It has been shown 
that maternal hGf is mainly released from the placenta into the maternal circulation (horibe et al., 1995). 
Plasma levels of hGf are increasing with advancing gestational age in normal, healthy pregnancy (Watanabe 
et al., 2006). To the best of our knowledge, only one previous study determined hGf levels in maternal serum 
in pregnancies with small for gestational age infants (aoki et al., 1998). no information is available on blood 
levels of hGf in labour. our group comparison showed that hGf levels were significantly higher in the preterm 
labour group compared to Ga matched controls. our regression results for hGf showed that while none of the 
key covariates were significant, hGf levels were significantly lower in women with a history of preterm birth. 
downregulation of the maternal immune system is essential for successful pregnancy. a switch toward Th2 
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els for eGf en hGf. Moreover, the value of eGf as non-invasive marker for preterm labour seems to be limited, 
since levels are undetectable in plasma and elevated serum levels may be attributed to platelet derived eGf. 
serum Il-12 levels were lower in labouring women, irrespective of gestational age (term or preterm) and IP10 
levels were higher in term gestation, irrespective of labour. These observations suggest that the aberrant Th1 
profile that clearly exists at the maternal interface during preterm labour is not reflected in the maternal 
circulation. further research is needed to establish the contribution of the maternal compartment in the final 
common pathway of spontaneous term and preterm parturition. 
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reported in maternal blood of patients with preeclampsia (Gotsch et al., 2007; szarka, rigo, lazar, Beko & 
Molvarec, 2010) and in amniotic fluid during chronic chorioamnionitis, a common lesion of the placenta in 
patients with preterm labour and PProM (Kim et al., 2010; ogge et al., 2011). few studies have reported the 
relation between IP-10 in term and preterm labour. In the present study, group comparison showed that IP-10 
levels were higher in women at term in labour compared to those with preterm labour that is in contrast with 
previous studies that found no differences in circulating IP-10 concentrations (Brou et al., 2012; laudanski, 
lemancewicz, Pierzynski, akerlund & laudanski, 2006). however, aminzadeh et al. (aminzadeh et al., 2012) 
observed increased IP-10 levels in women with preterm vs. term delivery, but women in this study were sam-
pled postnatal (within 1 hour after delivery). These conflicting results may be related to differences in study 
design, sample size, characteristics of the study population, type of blood sample, timing of blood collection, 
sample processing and applied technology and assay. Multiple regression results also showed that IP-10 levels 
were higher in term gestation, irrespective of labour status. This is in line with Kraus et al. (Kraus et al., 2010) 
who observed increasing IP-10 levels in maternal blood with advancing gestational age. IP-10 seems to be 
a main mediator of T cell chemotaxis during labour. chemotactic activity in foetal membranes extracts was 
higher in term labour and associated with the presence of IP-10 (Gomez-lopez et al., 2009). This suggests that 
local rather than peripheral production may be important in the initiation of term labour (sykes et al., 2012), 
since we did not find higher IP-10 levels in serum during term labour. 
one of the strengths of this study is that we performed a comprehensive evaluation of the maternal inflamma-
tory response during term and preterm labour by using multiplex technology. The advantage of this approach 
is that a panel of relevant biomarkers can be identified simultaneously in a minimal amount of biological sam-
ple. We performed multiple regression analysis to determine the effect of three key covariates (preterm vs. at 
term, labour vs. no labour, roM vs. intact membranes) and to adjust for possible confounding effects by other 
covariates including sample age and storage time. as multiple biomarkers were considered, we also accounted 
for the number of tests by applying Bonferroni correction. however, some limitations of this study deserve 
consideration. The study was conducted in a single institution which prevented the use of a larger sample size; 
hence the number of women was inadequate for extensive subgroup analyses. We were not able to measure 
cytokines in the local uterine environment, because amniocentesis for assessing microbial invasion of the cav-
ity as well as foetal lung maturity at term is not routinely performed in our institution. hence, we could not 
evaluate whether the maternal cytokine profiles in maternal serum reflected the presence of intra amniotic 
infection. We did not study placental pathology of patients with preterm birth. It has been demonstrated 
that amniotic fluid levels of IP-10 were elevated in preterm labour cases with chronic chorioamnionitis. This 
lesion has been characterized by infiltration of maternal T-cells into foetal tissues and has been considered as 
a common histological manifestation of maternal anti-foetal allograft rejection and graft-versus-host disease 
in the placenta in late preterm birth (Kim et al., 2010; ogge et al., 2011). It would be interesting to investigate 
whether chronic chorioamnionitis also reflects in changes in chemokine profile in the maternal blood.
In conclusion, we found higher eGf and hGf levels in women with preterm labour. however, these observations 
deserve further consideration since none of the key covariates were significant in the multiple regression mod-
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Table 2: Detectable levels of the inflammatory markers in maternal serum 
(pg/ml)(n=144) 
Inflammatory marker Detection 
Limit  
Range Detectable in serum  
(n,%) 
Me [IQR] 
 
EGF 20 [ud - 397.0 116 (80.6) 82.6 [62.2-143.9] 
Eotaxin 5 [16.2 - 273.3] 144 (100.0) 53.2 [39.4-70.1] 
FGF-basic 22 [ud - 3280] 3 (2.1) n/a 
G-CSF 20 [ud - 448.5] 8 (5.6) 279.7 [170.9-340.9] 
GM-CSF 5 [ud - 853.8] 17 (11.8) 105.7 [61.7-265.3] 
HGF 30 [ud - 3139.8] 142 (98.6) 644.9 [456.7-854.4] 
IFN-α 10 [ud - 265.6] 14 (9.7) 97.2 [79.2-161.6] 
IFN-γ 5 [ud - 33.1] 1 (0.7) n/a 
IL-1β 15 [ud - 261.4] 9 (6.3) 77.4 [38.1-172.2] 
IL1-RA 30 [ud - 3529.4] 40 (27.8) 326.2 [259.0-495.9] 
IL-2 6 [ud - 45.5] 3 (2.1) n/a 
IL-4 5 [ud - 122.1] 3 (2.1) n/a 
IL-5 3 [ud - 244.0] 2 (1.4) n/a 
IL-6 3 [ud - 315.7] 28 (19.4) 16.3 [11.7-48.6] 
IL-7 10 [ud - 658.8] 2 (1.4) n/a 
IL-8 3 [ud - 2369.3] 39 (27.1) 34.2 [26.2-73.8] 
IL-10 5 [ud - 340.6] 12 (8.3) 58.4 [42.3-193.1] 
IL-12 5 [44.6 - 280.4] 144 (100.0) 108.8 [91.0-133.1] 
IL-13 5 [ud - 667.6] 6 (4.3) 71.9 [62.8-244.1] 
IL-15 10 [ud - 269.5] 9 (6.3) 95.2 [62.0-151.1] 
IL-17 16 [ud - 313.3] 4 (2.8) 127.6 [71.9-268.2] 
IP-10 5 [ud - 189.9] 143 (99.3) 38.2 [29.2-52.7] 
MCP-1 10 [73.6 - 1626.4] 144 (100.0) 357.5 [272.9-454.5] 
MIG 6 [ud - 263.6] 19 (13.2) 93.3 [51.6-165.5] 
MIP-1α 10 [ud - 208.2] 14 (9.7) 83.0 [62.2-97.3] 
MIP-1β 10 [ud - 235.1] 142 (98.6) 62.3 [47.6-84.8] 
sIL-2R 24 [ud - 1417.1] 136 (94.4) 321.8 [246.0-452.9] 
TNF-α 5 [ud - 104.7] 5 (3.5) 30.7 [22.0-68.3] 
VEGF 5 [ud - 10.7] 3 (2.1) n/a 
Shading indicates those inflammatory markers with more than 50% of the samples above the detection 
limit. Concentrations of RANTES were outside the linear range. 
Legend: IQR, interquartile range; Me, Median; n/a, not applicable; ud, undetectable 
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in the second trimester were associated with an increased risk of PTB in high risk (Vogel et al., 2007), but not in 
low risk women (Kramer et al., 2010). additional research is recommended to assess the usefulness of sTreM-1 
as diagnostic and prognostic biomarker in maternal blood of both symptomatic and asymptomatic patients 
compared with standard of care.
Beside sTreM-1, other potentially clinical relevant markers are MMPs which are involved in remodelling of the 
extracellular matrix (ecM) during pregnancy and parturition. Therefore, the role of MMPs in human term and 
preterm parturition, and to a lesser extent that of TIMPs, have been widely investigated over the past decades. 
The novelty of our study regards the determination of MMP-3 (stromelysin-1), MMP-9 (gelatinase-B) and all 
four TIMPs in maternal serum as well as the MMP:TIMP ratios. We found elevated MMP-9 concentrations in 
maternal serum during preterm labour, whereas no changes in serum MMP-3 concentration could be observed. 
To the best of our knowledge, we demonstrated for the first time that all four TIMPs were expressed in mater-
nal serum. however, TIMP-3 levels could not be quantified in the majority of the samples and TIMP-3 analysis 
was therefore omitted from further analysis. levels TIMP-1 and TIMP-2 were lower during gestation compared 
to term gestation, irrespective of labour status, while TIMP-4 levels were elevated during labour (either term 
or preterm). Importantly, this study showed that MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios were significantly 
higher in women with preterm labour, indicating a ratio shift towards matrix degradation (gelatinolysis) . In 
contrast, changes in MMP-9:TIMP-4 ratio were not significant. no significant changes were observed in MMP-
3:TIMP balances, but this observation was based on a limited number of cases (chapter 4, Table 3, p. 81). our 
observations indicate that circulating MMPs and TIMPs may also play a role in the pathogenesis of preterm 
labour at systemic level and suggest that a far less invasive approach (compared with amniocentesis) could be 
developed for the measurement of enzymes essential for ecM remodelling during pregnancy and parturition. 
The human MMP family currently consists of 23 members (Brew & nagase, 2010; nagase et al., 2006). not all 
of them have been studied in relation to pregnancy and (preterm) labour. Most research focuses on MMPs in 
amniotic fluid or foetal membranes and to a lesser extent in maternal serum. Previous studies in amniotic 
fluid (fortunato & Menon, 2001; fortunato et al., 1999a; Maymon et al., 2001; Vadillo-ortega et al., 1996) and 
in vitro studies on foetal membranes (fortunato & Menon, 2001; fortunato et al., 1997; fortunato, Menon, & 
lombardi, 2000) demonstrated imbalances between MMPs and TIMPs during preterm prelabour rupture of the 
membranes (PProM). fortunato et al (fortunato et al., 1999a) addressed MMP:TIMP ratios in amniotic fluid 
and found that the molar ratio between MMP-2 and TIMP-2 (but not TIMP-1) was increased during PProM. our 
finding of MMP-9:TIMP imbalances in maternal serum, tilting the balance toward matrix degradation, deserves 
further consideration. It has been shown that MMP-9 is detectable in serum approximately 24 hours before 
the initiation of labour or PProM (Goldenberg, Goepfert, & ramsey, 2005), so probably also the MMP-9:TIMP 
ratio will do, thereby limiting the time to initiate an intervention. further research is needed to determine the 
temporal relationship between MMP:TIMP ratio shift and PTB. future research should also evaluate immuno-
reactivity as well as enzymatic activity of MMPs and TIMPs in order to determine whether immunoreactive and 
enzymatic forms correlate well. 
Preterm birth (PTB), accounting worldwide for more than 15 million preterm babies each year, is a major 
perinatal health problem, not only in terms of associated mortality, but also with regard to morbidity and 
its financial implications for the health care and social welfare system (Beck et al., 2010). Preterm birth has 
lifelong effects on neurodevelopmental functioning such as increased risk of cerebral palsy, impaired learning 
and visual disorders, and an increased risk of chronic disease in adulthood (Blencowe et al., 2012). apart from 
the overall neonatal and economic burden, PTB has a profound personal impact on the infant and its family 
(emotionally, financially and socially). 
despite significant advances in perinatal care and advancing knowledge of risk factors and mechanisms associ-
ated with PTB, there has been little progress in reducing the PTB rate (Goldenberg et al., 2008). Infection and/
or inflammation is the only pathological process for which both a firm causal link with PTB has been estab-
lished and a molecular pathophysiology defined (Goldenberg et al., 2008; Goldenberg et al., 2000; Goncalves et 
al., 2002; romero, espinoza, Kusanovic et al., 2006). Because of the complex nature of PTB and the involvement 
of several pathways in its pathogenesis, prediction and prevention remains difficult and poses a continuing 
and significant challenge to modern obstetrics. a tremendous amount of efforts has been expended to iden-
tify inflammatory markers to predict PTB in both asymptomatic and symptomatic women and to improve our 
understanding of the mechanisms and pathways leading to PTB. 
In the present study, multiple inflammatory markers have been evaluated in maternal serum of women with 
term and preterm labour vs. non labouring controls. (chapter 4, p. 81). Briefly, we assessed levels of soluble 
triggering receptor expressed on myeloid cells-1 (sTreM-1), matrix metalloproteinase (MMP)-9, MMP-3, tissue 
inhibitor of metalloproteinase (TIMP)-1, TIMP-2, TIMP-3, TIMP-4, MMP:TIMP ratios and a panel of 30 cytokines, 
chemokines and growth factors. The overall objective of the study was to determine the association between 
several inflammatory serum markers and (term and preterm) labour. 
In the following paragraphs the main findings of the analysed biomarkers are briefly discussed. for a more 
detailed discussion, we refer to the discussion section of each publication. We observed elevated sTreM-1 
concentrations during spontaneous parturition (either term or preterm) vs. non labouring controls. We also 
found higher sTreM-1 levels in women with preterm labour compared to term labour. This finding has not been 
described previously and needs further confirmation. our observations support the involvement of an inflam-
matory process in human parturition. The increased circulating sTreM-1 levels during preterm labour may indi-
cate a contributory role of sTreM-1 in infectious-associated PTB. There is evidence that sTreM-1 may play a role 
during preterm parturition and IuI (cobo, Kacerovsky, Palacio et al., 2012; holst et al., 2011; Kusanovic et al., 
2010; Menon & fortunato, 2008). Previous studies have assessed the accuracy of sTreM-1 as a predictor of PTB 
within 7 days (cobo, Kacerovsky, holst et al., 2012; Tsiartas et al., 2012) or as a marker of IuI (cobo, Kacerovsky, 
Palacio et al., 2012; cobo, Tsiartas et al., 2012; holst et al., 2011; Kusanovic et al., 2010), but yielded conflicting 
results in amniotic fluid (cobo, Kacerovsky, holst et al., 2012; cobo, Kacerovsky, Palacio et al., 2012; holst et 
al., 2011; Kusanovic et al., 2010). The predictive value of sTreM-1 in maternal serum could not be confirmed 
(Tsiartas et al., 2012). The former studies showed a wide variation in type of assays, timing of sampling and 
reported values. In asymptomatic women, it has been shown that elevated serum concentrations of sTreM-1 
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in tissues such as foetal membranes, decidua or trophoblast that are available only after birth. although these 
studies provide valuable information regarding the role of biomarkers in the mechanisms and pathophysio-
logic pathways leading to PTB, a non-invasive approach for predicting PTB is more relevant to clinical practice.
secondly, we determined serum biomarkers in women with either term or preterm labour vs. non-labouring 
controls. The mechanisms of preterm labour are largely unknown, at least in part because the process of la-
bour at term is poorly understood. The majority of studies assessed biomarkers in women with spontaneous 
preterm labour without considering women with term labour. however, further understanding of the inflam-
matory processes during term and preterm labour is essential for the development of novel and effective 
therapies to block preterm labour (hamilton et al., 2012; norman et al., 2007). 
another strength of our study is that we performed multiple regression analysis to determine the effect of 
three key covariates (preterm vs. at term, labour vs. no labour, roM vs. intact membranes) and to adjust for 
possible confounding effects by other covariates including important risk factors of PTB, sample age and 
storage time. These regression models reflect the multiple etiology of PTB, but are a rather exploratory than 
explanatory. r square (r²) varied from 7 to 39%, indicating that a large amount of variation in log marker con-
centration was not explained by the covariates included. Therefore, these models should be further validated 
and extended with other risk factors such as ethnicity (which was not included in our models because our 
population was mainly white and caucasian). When multiple biomarkers were considered, we also accounted 
for the number of tests by applying Bonferroni correction.
finally, our analyses were performed by using multiplex technology, when commercially available. This novel 
technological approach makes it possible to measure multiple proteins simultaneously in a minimal amount 
of biological sample. This is important, because it has been shown that single biomarkers lack effectiveness 
to predict PTB prediction (conde-agudelo, Papageorghiou, Kennedy, & Villar, 2011; Menon et al., 2011; Taylor 
et al., 2013). Moreover, since PTB is a complex syndrome, initiated by multiple mechanisms, it is doubtful that 
a single biomarker will be able to identify all the pathophysiological pathways activated in this condition 
(Menon et al., 2011).
despite these strengths, some limitations of our study deserve consideration. first, we only evaluated ma-
ternal biomarkers in serum, mainly because of the non-invasive approach, but also because amniocentesis 
(for assessing microbial invasion of the amniotic cavity (MIac) as well as foetal lung maturity) and placental 
and foetal membranes histology are not standard of care in our institution. hence, our PTB group represents 
a quite heterogeneous group of patients, because information on foetal or placental conditions such as MIac 
or histological chorioamnionitis was lacking. secondly, the study was conducted in a single institution which 
prevented the use of a larger sample size; hence the number of women was inadequate for extensive subgroup 
analysis. This may explain why no differences were observed in biomarker concentrations between women 
with PProM vs. those with  preterm labour and intact membranes. another explanation for this observation 
could be that biomarker profiles are strictly compartmentalized and independently regulated, since it has 
been shown that their expression differ between maternal, foetal and intra-amniotic compartment in women 
with  preterm labour (Brou et al., 2012). It has been shown that expression of biomarkers might be different 
little is known about the role of TIMP-4 during pregnancy and parturition. It has been shown that TIMP-4 
is involved in reproductive processes such as the menstrual cycle (chegini, rhoton-Vlasak, & Williams, 2003; 
Pilka, domanski, hansson, eriksson, & casslen, 2004) and implantation (Pilka et al., 2006). Tissue inhibitor of 
metalloproteinases-4 also participates in the carcinogenesis of reproductive tissues.elevated TIMP-4 levels 
have been found in breast, ovary, cervical and endometrium tumours (Melendez-Zajgla, del Pozo, ceballos, 
& Maldonado, 2008). We found that TIMP-4 levels were elevated during labour (either term or preterm), but 
changes in MMP-9:TIMP-4 ratio were not significant. This may be related to the relatively low sample size of 
the study (chapter 4, Table 3, p. 81), but may also be explained by the different potency of TIMP-4 against 
different MMPs. It has been shown that, although TIMP-4 effectively inhibits MMP-9, it has the highest affinity 
for MMP-26 (liu et al., 1997; Zhang, cao, Zhao, sang, & duan, 2002). Pilka et al. (2004) observed correspon-
dence in the cyclic patterns of TIMP-4 mrna and MMP-26 mrna. It would be interesting to investigate wheth-
er higher MMP-26:TIMP-4 ratios are associated with preterm labour. 
finally, we evaluated a biomarker panel in maternal serum during term and preterm labour by using the lu-
minex technology. This novel technological approach makes it possible to simultaneously assess a broad panel 
of proteins in a single sample. among the 30 inflammatory markers we studied, only eGf and hGf levels were 
associated with preterm labour. however, the multiple regression model for eGf showed that sample age (i.e. 
the time lapse between blood collection and centrifugation) may act as a confounding factor. It has been 
demonstrated that eGf levels are higher in serum than those measured in plasma, which may be attributed to 
platelet derived eGf (Yucel, Karakus, & cemalettin, 2007). Therefore, the value of eGf as non-invasive marker 
for preterm labour seems to be limited. To our knowledge, no other studies investigated hGf serum levels 
during labour. although group comparison showed higher hGf levels in preterm labour, none of the key co-
variates (preterm vs. term, labour vs. no labour, rupture of the membranes (roM) vs. no roM) were significant 
in the multiple regression models. large studies are needed to confirm the possible role of hGf in the onset 
of preterm labour. 
We observed lower Il-12 levels in labouring women, irrespective of gestational age (term or preterm) and 
higher IP-10 levels in term gestation, irrespective of labour. It has been shown that Il-12 can interact synergis-
tically with Il-18 to provoke a Th1 response. Therefore, the cytokine balance may be of greater importance than 
the absolute concentrations. ekelund et al. (2008) found that a high Il-12:Il-18 ratio in women with  preterm 
labour was associated with a twofold increased risk for delivery before 34 weeks. studies investigating the 
association between IP-10 and labour (either term or preterm) revealed conflicting results (aminzadeh et al., 
2012; Brou et al., 2012; laudanski, lemancewicz, Pierzynski, akerlund, & laudanski, 2006). It has been demon-
strated that amniotic fluid levels of IP-10 were elevated in preterm labour cases with chronic chorioamnionitis 
(Kim et al., 2010; ogge et al., 2011). It would be interesting to investigate whether chronic chorioamnionitis is 
associated with an altered chemokine profile in maternal blood.
our study has several strengths. first, we evaluated several biomarkers in maternal serum which can be easily 
obtained during pregnancy. The primary limitation of studies utilizing biomarkers identified in amniotic fluid 
is that they require invasive procedures (e.g. amniocentesis). other studies investigated biomarker expression 
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ffn and cervical ultrasound constitute undeniable progress in the identification of patients at risk of PTB. large 
prospective multicentre trials are however necessary to confirm the efficacy, impact (in terms of reduction of 
PTB and perinatal outcome) and the cost-effectiveness of both tests either alone or combined. There is grow-
ing evidence that a combined approach of universal cervical length assessment in the midtrimester, followed 
by progesterone administration in women with a short cervix is beneficial to prevent PTB and neonatal mor-
bidity and mortality (campbell, 2011; hassan et al., 2011; romero et al., 2012). 
another established predictor of PTB is interleukin 6 (Il-6) which is one of the most studied biomarkers in 
spontaneous PTB so far. higher Il-6 concentrations were observed in amniotic fluid of asymptomatic women 
delivering preterm vs. those with term delivery (Menon et al., 2011), but a temporal relationship between Il-6 
and time until delivery has yet not been established (Krupa et al., 2006). The test accuracy of Il-6 in amniotic 
fluid seems to be especially good (lr+ > 5, lr- < 0.2) for both asymptomatic and symptomatic women, but 
is generally poor in other biological fluids (e.g. blood, cervicovaginal fluid) (conde-agudelo, Papageorghiou 
et al., 2011; honest et al., 2009). however, elevated Il-6 in midtrimester vaginal fluid might be an accurate 
predictor in two subtypes of PTB (PTB < 35 weeks and PTB with histological chorioamnionitis) (Taylor et al., 
2013). elevated Il-6 concentration in foetal plasma is strongly associated with a foetal inflammatory response 
syndrome (fIrs), which is the most advanced and serious stage of ascending IuI (romero, espinoza, Kusanovic 
et al., 2006). Wu et al. (2011) performed a meta-analysis to evaluate the association between genetic poly-
morphisms and cerebral palsy (cP). among the 17 polymorphisms they studied, only  genetic polymorphism 
Il-6 was significantly associated with cP. The Il-6 gene encodes the proinflammatory cytokine Il-6 which is 
a major modulator of the host response to inflammation and tissue damage. Infection and inflammation are 
known risk factors for brain damage. Therefore, the Il-6 gene may play an important role in the pathogenesis 
of cP (Wu et al., 2011). 
any progress in our understanding and prevention of PTB requires acknowledgement that it is not one disease 
with a single solution or cure, but rather the product of overlapping risk factors and pathophysiological path-
ways (Villar et al., 2012). Therefore, it is increasingly accepted that a single biomarker cannot accurately predict 
PTB (conde-agudelo, Papageorghiou et al., 2011; Menon et al., 2011; Taylor et al., 2013). There is evidence that 
predictive biomarkers perform differently across ethnic populations and/or geographical locations. Brou et al. 
(2012) demonstrated racial disparity in biomarker profile between african americans and european americans 
with spontaneous PTB (Brou et al., 2012). Therefore, it seems highly unlikely that universal biomarkers will 
be capable of predicting the risk of PTB in all women across the globe (conde-agudelo, Papageorghiou et al., 
2011; Menon et al., 2011). In addition, biomarkers, predominantly cytokines, interact with one another for the 
overall balance of inflammatory responses (Taylor et al., 2013). cytokine imbalance is a key feature in women at 
high risk of preterm labour (orsi & Tribe, 2008). for example, ekelund et al. (2008) found no direct correlation 
between Il-12 levels and PTB, but a high Il-12:Il-18 ratio was associated with a twofold increased risk for deliv-
ery before 34 weeks (ekelund et al., 2008). This indicates that the balance of certain inflammation biomarkers 
may be of greater importance than the actual concentration produced and that detecting disruption in this bal-
ance may be most informative for understanding and/or predicting PTB (sykes et al., 2012; Taylor et al., 2013). 
depending on the presence or absence of MIac and histological chorioamnionitis. as mentioned above, this 
information was not available in our PTB cases. another interesting subgroup analysis would be to evaluate 
whether biomarker levels differ between women with  preterm labour and intact membranes who delivered 
preterm vs. those with term delivery. We carried out preliminary evaluations for sTreM-1, MMP-9 and -3, TIMPs 
and MMP:TIMP balances, but found no differences in inflammatory markers levels between both groups. These 
results must be interpreted with caution since the number of patients with  preterm labour who delivered at 
term was rather low (n=10). 
Pre-analytical variability arising from sampling and storage procedures has been shown to affect assayed bio-
marker concentrations. cytokine levels are most critically affected by sample age, i.e. the time lapse between 
blood collection and processing (friebe & Volk, 2008; Jackman et al., 2011; Kisand, Kerna, Kumm, Jonsson, & 
Tamm, 2011; Knudsen et al., 2008; Tworoger & hankinson, 2006). The impact of sample age and storage time 
on levels of inflammatory markers is often poorly addressed in studies. The best way to limit the effect of 
pre-analytical factors is to start sample processing immediately and to standardize it as much as possible. This 
approach was not always feasible in our study due to logistic reasons and median sample age and storage time 
differed significantly between groups. Therefore, we considered these factors in subsequent statistical anal-
ysis. sample age can affect sTreM-1 and eGf measurements in serum as evidenced by the multiple regression 
model. none of the key covariates were significant in the model for eGf and, therefore, we cannot exclude 
that group differences in eGf were the results of variation in sample handling procedures. This indicates that 
pre-analytical factors such as sample age have to be considered when developing a predictive test for PTB. 
finally, the nested case control design does not allow us to evaluate the accuracy of the analysed inflammatory 
markers to predict PTB. a large multicentre prospective cohort study is needed to investigate the relationship 
between these biomarkers in maternal blood and PTB in asymptomatic women (before preterm labour) and 
to develop good combined multivariable prediction models. a study protocol for such a study is annexed (ad-
dendum 1). 
The diagnosis of preterm labour and accurate prediction of PTB is notoriously difficult.. Based on known risk 
factors and pathways of PTB, several biomarkers have been tested for their usefulness and accuracy as pre-
dictors for PTB. however, few biomarkers have been shown clinical usefulness, because they are either non-
specific or become positive too late (Goldenberg et al., 2008; Menon et al., 2011). It remains to be determined 
whether diagnostic and predictive methods could be improved to identify patients at risk before preterm la-
bour becomes clinically apparent, by which time it is in general too late for existing treatments to be effective 
(agrawal & hirsch, 2012). 
among the biomarkers evaluated to date, the presence of foetal fibronectin (ffn) in the cervicovaginal se-
cretions together with a short cervical length on transvaginal ultrasound, has been found to be the most 
powerful and consistent predictors of PTB (Berghella et al., 2009; Berghella et al., 2008). The clinical usefulness 
of both tests primarily lies in their negative predictive value (when ffn test is negative and cervical length by 
ultrasound is > 25 mm) thereby avoiding unnecessary interventions and guiding clinicians in decision-making 
regarding in utero transfer, administration of antenatal corticosteroids and/or tocolysis. new markers such as 
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should identify women who present with all PTB subtypes and would be detectable during early pregnancy 
(Goldenberg et al., 2005; hanna & Kiefer, 2012). Moreover, the usefulness of any biomarker as predictor of PTB 
should be considered relative to the Ga at which the sample is collected. for example, ffn is a powerful marker 
for subsequent PTB when measured at ≥ 24 weeks of gestation, but has less predictive accuracy when mea-
sured at earlier Ga (conde-agudelo, Papageorghiou et al., 2011; Goldenberg et al., 2005). an understanding of 
when a marker turns positive in relation to PTB (e.g. time-to-delivery interval) is also important. for example, 
it has been shown that MMP-9 turns positive approximately 24 hours before the initiation of labour or PProM, 
thereby limiting the time to initiate an intervention (Goldenberg et al., 2005). an important consideration for 
evaluation of biomarkers is the time of day of the sample collection and whether the biomarker predicts an 
early or late PTB. for example, salivary estriol levels demonstrate diurnal variation and predict late PTB quite 
well (conde-agudelo, Papageorghiou et al., 2011; Goldenberg et al., 2005). finally, cost-effectiveness and re-
producibility in a low-risk population would allow incorporation into routine practice (Goldenberg et al., 2005; 
hanna & Kiefer, 2012; Krupa et al., 2006).
although a non-invasive approach is preferable for predicting PTB, it is currently not clear which non-invasive 
body fluid can predict intrauterine environment and whether biomarkers in non-invasive samples reflect dif-
ferent intrauterine compartments equally (hanna & Kiefer, 2012). It has been shown that the accuracy of serum 
or plasma biomarkers to predict PTB in asymptomatic women is very low (conde-agudelo, Papageorghiou et 
al., 2011). There is evidence that the inflammatory status of the amniotic cavity is not accurately reflected in 
maternal serum. cobo et al. (2012) evaluated the maternal serum inflammatory response according to the 
presence of MIac in women with preterm labour. They observed a weak maternal inflammatory response in 
women with MIac and found that differences in biomarkers concentrations were only evident at early Gas (< 
32 weeks) (cobo, Tsiartas et al., 2012). however, studies have demonstrated that combination of biomarkers 
in minimally invasive samples (cervical fluid, serum) and cervical length measurement can help to predict im-
minent PTB in women with PProM (Park et al., 2012), preterm labour (holst et al., 2009) or MIac (holst et al., 
2011). Moreover, the predictive power of non-invasive models were as good as those of invasive models (holst 
et al., 2009, 2011; Park et al., 2012). further research is needed to determine the predictive value of non-inva-
sive methods for imminent PTB as well as to establish the potential contribution of non-invasive (maternal) 
inflammatory biomarkers (in combination with those already identified in amniotic fluid or combined with 
other risk factors) for the prediction of PTB. 
over the last decade, it has become increasingly apparent that the cause of PTB is multifactorial, involving both 
genetic and environmental factors. data suggest that the risk of PTB is inherited across generations and differs 
between ethnicities, indicating a genetic predisposition to PTB (esplin, 2006; Gracie et al., 2011; Pennell et 
al., 2007; romero, friel et al., 2010; romero, Velez edwards et al., 2010). data provide evidence for gene-gene 
and gene-environment interactions in PTB (crider, Whitehead, & Buus, 2005; esplin, 2006; Goldenberg et al., 
2008; romero, espinoza, Gotsch et al., 2006). for example, women who carry both the Tnf(-308a) allele, which 
increases inflammation, and the Il6(-174c) allele, which reduces inflammation, may not be at increased risk of 
PTB. conversely, women who have both the Tnf(-308a) allele and the Il1ra*2 allele might have an increased 
It is clear that research focused on the actions of individual cytokines is no longer sufficient for identifying all 
pathways leading to PTB (honest et al., 2009; Menon et al., 2011; orsi & Tribe, 2008; Wei, fraser, & luo, 2010). 
The Preterm Prediction study was one of the first studies demonstrating that overlap among the strongest 
biologic predictors for spontaneous PTB was small (Goldenberg et al., 2001). Given the redundancy between 
pathways and biomarkers, using multiple biomarkers from different and distinct biologic pathways may better 
predict the risk of preterm labour (hanna & Kiefer, 2012). Therefore, multiplex analyses allowing simultane-
ous measurement of a panel of inflammatory markers constitute the future direction of biomarker research 
(Menon et al., 2011). In the Preterm Prediction study, Goldenberg et al. (2001)  demonstrated that with the 
use of a triple serum test at 24 weeks, any positive test among them identified 78.1% of the women delivering 
within 8 weeks, with an odds ratio of 14.7 [5.0-42.7] and a sensitivity of 80.5% (Goldenberg et al., 2001). More 
recently, Greco, Gupta, syngelaki, Poon & nicolaides  demonstrated that an algorithm combining maternal 
characteristics and cervical length at 11-13 weeks gestation can identify about 54.8% of the pregnancies re-
sulting in early preterm delivery, with a false-positive rate of 10% (Greco, Gupta, syngelaki, Poon, & nicolaides, 
2012). These findings suggest that the development of a predictive multiple marker test is feasible and that 
early identification of women at risk might allow time for intervention (such as prophylactic progesterone use) 
before the onset of labour. large multicentre trials are necessary to confirm these findings and to investigate 
how pregnancy outcome (in terms of perinatal outcome and reduction of PTB) may be influenced by early 
intervention in those identified at risk. 
The development of a multiple markers test might also be useful for predicting PTB in symptomatic women. as 
mentioned previously, cervicovaginal ffn and cervical length are established predictors of PTB. several studies 
have investigated whether combined ffn and cervical length assessment may predict PTB more accurately 
in women with threatened preterm labour. a recent systematic review showed that a combined screening 
approach of ffn and cervix length in symptomatic women results in a higher sensitivity and positive predictive 
value for PTB risk, particularly within 7 days and at earlier Ga (< 28 weeks), while maintaining high negative 
predictive value. This combined screening approach yields useful information regarding short time risk and 
identification of a low risk population in whom interventions could be avoided. In addition, preliminary results 
of the aPosTel 1 trial demonstrate that ffn testing in case of a cervix length between 15 and 30 mm reduces 
unnecessary referrals and treatment in women with signs of preterm labour and may be a safe and cost-effec-
tive strategy in the triage of patients with threatened preterm labour (van Baaren et al., 2013). 
When developing a multiple marker test, several issues should be carefully considered. a perfect predictor 
for PTB needs to have good specificity, sensitivity and high accuracy (lr+ > 5, lr- < 0.2) to increase the 
probability of PTB in women with a positive test result and to exclude the disorder with a negative test result 
(Goldenberg et al., 2005; hanna & Kiefer, 2012; honest et al., 2009; Krupa et al., 2006). also feasibility, acces-
sibility and patient convenience are important. sampling has to be relatively easy and minimally invasive for 
the pregnant woman and her foetus. Vaginal ultrasound, collection of vaginal fluid samples and blood testing 
appear acceptable to most women. If the test is to be of widespread value, the handling of the sample must be 
relatively convenient and the technological platform should be widely available. The ideal clinical biomarker 
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since implementation of the new law, especially in women > 36 years (cammu et al., 2011). This indicates that 
the implementation of such a law should at least be accompanied with public education strategies to inform 
women about their limited reproductive youth and risk associated with delayed motherhood. another effort 
of the Belgian government was the introduction of a national smoking cessation campaign , initially focused 
on pregnant women and subsequently expanded to the total smoking population. This smoking cessation 
program was accompanied with the implementation of different smoke-free legislation bans. recently, cox, 
Martens, nemery, Vangronsveld, & nawrot (2013) observed a consistent pattern of reduction in the risk of PTB 
after each of the first three smoking bans, suggesting that these bans have public health benefit from early 
life. smoking is an important risk factor for PTB. In our study, we observed more smoking women in the PTB 
group compared to other groups. regression results demonstrated that biomarker concentrations tended to be 
lower in smoking women (e.g. TIMP-2, McP-1, Il-12) which reflects the immunosuppressive effects of smoking 
and may explain the enhanced susceptibility of smokers to infections and consequently PTB. Therefore, much 
efforts should be put to increase the public knowledge about potentially avoidable risk factors of PTB and to 
promote smoking cessation (prior to) during pregnancy..
secondly, a national evidence-based guideline on PTB has to be developed. currently, no national guidelines 
for screening and prevention of PTB are available. however, in the near future, the Belgian health care Knowl-
edge centre will develop a good clinical practice guideline on secondary and tertiary prevention of sponta-
neous PTB in singleton pregnancies. national guidelines should provide clear recommendations regarding the 
routinely use of biomarkers for predicting PTB, in particular for the established predictors such as ffn and 
cervical length. Issues on primary prevention and increasing awareness will be considered in the revision of the 
national guideline on prenatal care in low risk women, which was developed in 2004. currently, the flemish 
tertiary referral hospitals, together with secondary  hospitals, try to reach a consensus regarding foetus viabil-
ity, Ga at in utero transfer and active treatment of preterm neonates. These initiatives may lead to the develop-
ment of a standardized evidence-based protocol for the management of preterm labour. The implementation 
of such a protocol has been shown to reduce the rate of unnecessary hospital admissions for observation with 
consequent significant reduction in expenses (rose, McWeeney, Brost, davies, & Watson, 2010). This approach 
may also promote early identification and appropriate referral of high risk pregnancies to tertiary care centres. 
Thirdly, there is universal agreement that a comprehensive, consistent and uniform classification for PTB 
should be developed. standard definitions, consistent measurement procedures and consistency in reporting 
pregnancy outcomes are essential to improve quality and quantity of data and to facilitate meaningful inter-
national comparisons across populations or over time (Beck et al., 2010; Blencowe et al., 2012; Goldenberg et 
al., 2012; Kramer et al., 2012). The Ga boundaries and measurements need to be defined consistently. as dis-
cussed in chapter 1 (p. 24-25), a prototype phenotypic classification for PTB has been recently proposed, rather 
than focussing on suspected causes (Goldenberg et al., 2012; Villar et al., 2012). This classification captures 
information about the clinical presentation on admission, but also about conditions and observations during 
pregnancy, including infection. determination of inflammatory biomarkers may enhance accurate diagnosis 
of infection. 
risk for PTB (crider et al., 2005). a gene-environment interaction has been described between Tnf(-308a) 
allele and bacterial vaginosis (BV). The combination of the Tnf(-308a) allele and BV increased the risk of PTB, 
but each characteristic alone did not (crider et al., 2005; esplin, 2006; Goldenberg et al., 2008). several studies 
have identified maternal or foetal gene polymorphisms that are associated with spontaneous PTB (crider et 
al., 2005; esplin, 2006; romero, espinoza, Gotsch et al., 2006). recently, a large candidate gene association 
study has been performed to determine maternal or foetal single-nucleotide polymorphisms (snPs) in can-
didate genes that may predispose to either PProM (romero, friel et al., 2010) or preterm labour with intact 
membranes (romero, Velez edwards et al., 2010). They found that certain alleles of maternal genes (TIMP-2 
and alpha 3 type IV collagen) involved in ecM metabolism, doubled the risk of preterm delivery, regardless 
of the membrane status. a snP involved in controlling foetal inflammation (Il-6 receptor 1) was significantly 
associated with preterm labour/delivery. Multilocus analysis indicated that three maternal genes (collagen 
type I alpha 2, defensin alpha 5 and endothelin 1) may interact to modify the risk for PProM. These observa-
tions highlight the importance of investigating both maternal and foetal genotypes as well as the necessity of 
evaluating multiple candidate genes to identify associations with PTB rather than focussing on a single gene 
mutation. functional studies are needed to assess the precise physiological implications of the dna variants 
identified in this study. opportunities now exist to address high throughput technology that can achieve in a 
matter of hours what previously took several years (Gracie et al., 2011). This high throughput approach, re-
ferred to as “omics” technology, allows simultaneous examination of changes in the genome (dna, genomics), 
transcriptome (messenger rna, transriptomics), proteome (proteins, proteomics) and metabolome (metabo-
lites, metabolomics) in a single biological sample (Gracie et al., 2011; romero, espinoza, Gotsch et al., 2006). 
until now, few studies have assessed proteomic or metabolomics markers during preterm labour. changes 
in amniotic fluid proteomic profiling have been associated with intra-amniotic infection (Buhimschi et al., 
2007; Buhimschi, christner, & Buhimschi, 2005; romero, espinoza et al., 2008; ruetschi et al., 2005) and cho-
rioamnionitis (Buhimschi et al., 2007; Buhimschi et al., 2008; ogge et al., 2011). among patients with preterm 
labour, amniotic fluid metabolomic profiling has been shown useful for assessing the risk for PTB (romero, 
Mazaki-Tovi et al., 2010). These studies indicate that the “omic” approach presents exciting possibilities for 
PTB research in advancing our understanding, treatment and prevention of PTB (Gracie et al., 2011; Pennell et 
al., 2007). 
In addition to the importance of biomarker research, some other issues concerning PTB should be considered. 
despite the considerable and growing number of PTBs across the european region, neonatal and preterm in-
fant health rank low on the policy agendas of european member states (Keller et al., 2010). as outlined in 
chapter 1, PTB represents a major perinatal health issue, accounting for 7% of all births in flanders. although 
the number of PTBs remained relatively stable the last 10 years, its incidence has not decreased. Therefore, PTB 
must have the highest priority in national healthcare policy. Policies specifically intended to reduce the risk of 
higher-order multiple gestation have been successful in europe. The Belgian law on IVf reimbursement (2003) 
resulted in a dramatic decrease in the number of twin pregnancies (from 1.91% in 2003 to 1.61% in 2004). un-
fortunately, the number of twins gradually increased(reaching 1.81% in 2011) because IVf treatments doubled 
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however, the application of such a classification system may have several implications for both research and 
clinical practice. first, the information on each of the components should be carefully and completely docu-
mented in the clinical record to allow classification of the PTB case. It is vital that PTB is distinguished by its 
different phenotypes preferably some time after delivery, but at least prior to all analyses, including those uti-
lizing “-omics” technologies (Goldenberg et al., 2012; Gracie et al., 2011). data collection should be standard-
ized and accompanied with clear definitions for each of the compartments (Goldenberg et al., 2012; Villar et 
al., 2012). Moreover, the proposed classification system needs empiric validation in order to evaluate whether 
the defined PTB phenotypes are sufficient and whether several phenotypes predominate, but also to compare 
the approximate frequency of different phenotypes. The system has major implications for sample size and 
statistical power, because the incidence of a given phenotype is expected to be considerably lower than the 
total PTB rate (Villar et al., 2012). although this may decrease numbers in any given study, it may increase 
biological homogeneity, thereby potentially replacing the lost statistical power. This also highlights the need 
for international consortia to bring large and comprehensive clinical resources, experts and data together and 
to build biobanks of consistent samples linked to a minimal dataset available (Gracie et al., 2011). Probably one 
of the greatest challenges of the phenotypic classification is that placentas of all PTB cases should be studied 
macro- and microscopically, which is not routinely performed in many hospitals, at least in Belgium. This also 
requires trained (reproductive) pathologists, is accompanied with additional costs and may be initially feasible 
only in the context of research projects. 
In conclusion, accurate prediction of PTB remains a continue challenge in modern obstetrics. until present, 
few biomarkers have shown clinical usefulness, because they are nonspecific or become positive too late. 
among the biomarkers evaluated to date, the most powerful and consistent predictors of PTB are the presence 
of foetal fibronectin in cervicovaginal fluid and a short cervix on transvaginal ultrasound examination. The 
clinical value of both tests primarily lies in their negative predictive value thereby guiding clinicians in deci-
sion-making and avoiding unnecessary interventions. during the last decades, it has become clear that single 
or universal biomarkers will not be capable to predict PTB accurately in all populations. future research should 
focus on multiple biomarkers in different PTB subtypes to allow differentiation depending on the underlying 
causes. The future development of an accurate, minimally invasive multiple marker test is necessary to permit 
incorporation into clinical practice. The availability of new technologies capable of probing the genome offers 
exciting possibilities to gain new insights into the mechanisms leading to PTB and to develop targeted thera-
pies. Beside advancing the research agenda, efforts should be made to raise public and professional awareness 
of the impact of PTB, to prioritize PTB on national health care policy including commitment of more funds for 
research, to develop national guidelines on PTB and to standardize definitions of PTB and classification (e.g. 
the recently developed phenotypic classification) in order to allow international comparison across studies. 
optimal communication and intensive collaboration among health care professionals, researchers, policy mak-
ers, society and parents are essential to tackle the global burden of preterm birth. 
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2 oBjective of the stuDy
To assess the accuracy of several inflammatory biomarkers in maternal plasma to predict PTB in asymptomatic 
women, individually and/or combined with two established predictors of PTB: ffn and cervical length mea-
surement, thereby accounting for maternal characteristics e.g. maternal age, educational level, racial origin, 
parity, smoking status, body mass index, history of PTB, conception, etc.
To evaluate whether a multiple marker test could be used to predict PTB more effectively than a single bio-
marker. 
3 stuDy DesiGn anD stuDy population
a large multicentre prospective cohort study will be conducted in which pregnant women, receiving routine 
prenatal care, will be enrolled at 20-24 weeks gestation. The study will be conducted in four hospitals in Ghent 
(three secondary and one tertiary hospital), accounting for circa 6,500 deliveries/year . 
an extensive questionnaire will be obtained from every women at recruitment including baseline demograph-
ics, medical and obstetrical history, gestational age at study entry and data on current pregnancy and preg-
nancy outcome (intrapartum, neonatal). 
3.1 selection criteria
3.1.1 Inclusion criteria
-    singleton pregnancies between 20-24 weeks
-    asymptomatic (no signs of latent labour, intact membranes)
-    no clinical evidence of chorio-amnionitis
-    no vaginal bleeding
-    age ≥ 18 years
-    absence of foetal (congenital) malformations
1 introDuction
Preterm birth (PTB), defined as a delivery at less than 37 weeks of gestation, is a major perinatal health prob-
lem because it is the leading cause of perinatal morbidity and mortality worldwide (Beck, 2010; Goldenberg, 
2008; Gotsch, 2007). accurate prediction of PTB is notoriously difficult, but important to identify women at 
risk for initiating treatment and studying specific interventions (conde-agudelo, 2011; Goldenberg & culhane, 
2003). among the biomarkers evaluated to date, the presence of foetal fibrinectin (ffn) in cervicovaginal se-
cretions together with a short cervical length on transvaginal ultrasound (us), have been found to be the most 
powerful and consistent predictors of PTB (Berghella, Baxter & hendrix, 2013; Berghella, hayes, Visintine & 
Baxter, 2008). several inflammatory biomarkers have been tested for their diagnostic accuracy or their po-
tential usefulness as predictive marker. The best studied site is amniotic fluid. however, an non-invasive ap-
proach seems to be more relevant to clinical practice because of the feasibility and accessibility. The majority of 
studies have analysed biomarkers in women with preterm labour, fewer studies have examined the maternal 
inflammatory response prior to labour onset. Therefore, the aim of this study is to examine the potential value 
of inflammatory biomarkers in midtrimester maternal plasma as predictors of PTB, individually or combined.
references:
Beck, s., Wojdyla, d., say, l., Betran, a. P., Merialdi, M., requejo, J. h., . . . Van look, P. f. (2010). The worldwide incidence 
of preterm birth: a systematic review of maternal mortality and morbidity. Bulletin of the World health organization, 
88(1), 31-38. doi: 10.2471/BlT.08.062554
Berghella, V., Baxter, J. K., & hendrix, n. W. (2013). cervical assessment by ultrasound for preventing preterm delivery. 
cochrane database syst rev, 1, cd007235. doi: 10.1002/14651858.cd007235.pub3
Berghella, V., hayes, e., Visintine, J., & Baxter, J. K. (2008). fetal fibronectin testing for reducing the risk of preterm birth. 
cochrane database syst rev(4), cd006843. doi: 10.1002/14651858.cd006843.pub2
conde-agudelo, a., Papageorghiou, a. T., Kennedy, s. h., & Villar, J. (2011). novel biomarkers for the prediction of 
the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJoG, 118(9), 1042-1054. doi: 
10.1111/j.1471-0528.2011.02923.x
Goldenberg, r. l., & culhane, J. f. (2003). Infection as a cause of preterm birth. clinics in Perinatology, 30(4), 677-700. 
Goldenberg, r. l., culhane, J. f., Iams, J. d., & romero, r. (2008). Preterm birth 1 - epidemiology and causes of preterm 
birth. lancet, 371(9606), 75-84. 
Gotsch, f., romero, r., Kusanovic, J. P., Mazaki-Tovi, s., Pineles, B. l., erez, o., . . . hassan, s. s. (2007). The fetal inflamma-
tory response syndrome. clin obstet Gynecol, 50(3), 652-683. doi: 10.1097/Grf.0b013e31811ebef6
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3.3 ethics statement and ich -Gcp guidelines
The study can only be undertaken after full approval of the protocol by an Independent ethical committee 
(Iec). The study protocol must be dated and clearly identify the protocol, amendments (if any), the informed 
consent form (Icf) and any applicable recruiting materials and subject compensation. during the trial all pro-
tocol amendments and revised informed consent form (if any) will be sent to the Iec for review. 
The study will be conducted in accordance with the protocol, current Ich-GcP guidelines and applicable law(s). 
Good clinical Practice (GcP) is an international ethical and scientific quality standard for designing, conducting, 
recording and reporting trials that involve the participation of human subjects. compliance with this standard 
provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with 
the principles that have their origin in the declaration of helsinki, and that the clinical trial data are credible.
3.4 subject information and informed consent
Written, dated and signed informed consent will be obtained from every pregnant women prior to sampling. 
The study and the implication of participation must be explained to potential participants prior to study entry. 
The Icf will include the following information: voluntary participation, withdrawal to participate, access to 
medical records, confidentiality, possible advantages and risks. Participants will be given sufficient time to 
read the Icf and to ask additional questions. The Icf should be provided in a language sufficiently understood 
by the participants. after having obtained the consent, a copy of the Icf must be given to the participant.
4 proceDures
4.1 procedures
recruitment of the participants and specimen sampling will be coupled with the structural us which is rou-
tinely carried out in the midtrimester. The midtrimester us will be extended with a transvaginal scan to mea-
sure the cervical length. Procedures involve obtaining one blood sample through venepuncture and one cervi-
covaginal specimen, followed by transvaginal us for measurement of the cervical length. delivered placentas 
will be sent to the pathology department. 
-    no evidence of acute or chronic infectious diseases
-    able to understand, read and speak dutch and hence to provide written and oral informed consent
3.1.2 Exclusion criteria
-    Multiple and high order pregnancies
-    signs of latent labour and rupture of the membranes
-    evidence of clinical chorio-amnionitis
-    Vaginal bleeding
-    age < 18 years
-    Presence of foetal (congenital) malformations
-    evidence of acute or chronic infectious diseases
-    unable to provide written and oral informed consent
3.2 outcome parameters
3.2.1 Primary outcome
-    Preterm birth before 37 weeks gestation 
3.2.2 Secondary outcomes
-    subtypes of PTB: extremely preterm (<28 weeks), very preterm (28-31 weeks), moderate (32-33 weeks) and 
late preterm (34-36 weeks)
-    Gestational age at delivery
-    subtypes of birth weight: extremely low birth weight (<1000g), very low birth weight (1000-1499g) and 
low birth weight (1500-2499g)
-    composite perinatal morbidity (sepsis, respiratory distress syndrome, intraventricular haemorrhage, necro-
tising enterocolitis, seizures)
-    Perinatal mortality
-    admission to neonatal intensive care unit (nIcu)
-    Placental pathologic conditions
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5.2 sample collection and processing
5.2.1 BIOMARKERS
after collection, plasma samples will be centrifuged and frozen at -80°c until analysis. 
samples will be analysed in a blinded fashion. Both standards and samples will be measured in duplicate. 
sensitivity, specificity, interassay and intra-assay coefficients of variation will be determined. 
We initially plan to measure 10 plasma analytes that have been previously addressed with PTB in order to 
investigate their usefulness as risk predictor in asymptomatic women in the midtrimester. The following se-
lection of biomarkers will be quantified in maternal plasma: 
-    soluble triggering receptor expressed on myeloid cells (TreM)-1
-    Pentraxins: high sensitivity c-reactive protein (hscrP) and pentraxin 3 (PTX3)
-    Procalcitonin (PcT)
-    Matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs) and MMP:TIMP balances: 
MMP-9, MMP-2, TIMP-1 through-4, MMP-9:TIMPs, MMP-2:TIMPs
-    α-foetoprotein (afP)
-    alkaline phosphatase
-    Granulocyte colony-stimulating factor (G-csf)
-    hepatocyte growth factor (hGf)
-    Inducible protein (IP)-10
-    Interleukin (Il)-6
references
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in 3 in maternal circulation: an association with preterm labor and preterm ProM, but not with intra-amniotic infection/
inflammation. J Matern fetal neonatal Med, 23(10), 1097-1105.
fortunato, s.J, Menon, r., & lombardi, s.J. (1999). MMP/TIMP imbalance in amniotic fluid during ProM: an indicrect 
support for endogeneous pathway to membrane rupture. J Perinat Med, 27, 362-368.
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Prediction study: toward a multiple-marker test for spontaneous preterm birth. am J obstet Gynecol, 185, 643-651.
Gulati, a., agrawal, s., raghunandan, c., Bhattacharya, J., saili, a., agarwal, s. & sharma, d. (2012). Maternal serum 
interleukin-6 and its association with clinicopathological infectious morbidity in preterm premature rupture of mem-
branes: a prospective cohort study. J Matern fetal neonatal Med, 25(8), 1428-1432. 
Kouchy, M., Germanova, a., Kalousova, M., hill, M., cindrova-davies, T., Parizek, a.,… hajek, Z. (2010). low maternal 
serum matrix metalloproteinases (MMP)-2 concentrations are associated with preterm labor and fetal inflammatory 
4.2 flowchart
Identifying eligible women for participation
|
Informed consent at 20-24 weeks gestation (structural us)
|
Interview + blood sampling (plasma)
|
sterile speculum examination + cervicovaginal sampling (ffn)
|
Transvaginal us (cervical length) (coupled with structural us)
|
storage at -80°c (for blood samples: after centrifugation)
|
histopathological examination of the placentas
5 stuDy analysis
5.1 sample size calculation
a convenience sample of singleton pregnancies will be recruited. 
Multiple pregnancies account for 1.8% deliveries in flanders. about 6.3% of the deliveries in singleton preg-
nancies occur preterm. It can be estimated that approximately 6380 out of the 6500 expected deliveries, will 
occur in singleton pregnancies. With an expected participation rate of 85%, a total of 5425 women can be 
included annually. about 341 of these women will deliver preterm (<37 weeks). It is expected that a total of 
circa 1000 preterm deliveries will be included over a 3-year study period .
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5.2.3 MEASUREMENT OF THE CERVICAL LENGTH
cervical length will be measured by transvaginal us and carried out by appropriately trained doctors. each 
measurement will be performed with the woman in dorsolithotomy position and an empty bladder. 
5.2.4 PLACENTAL HISTOPATHOLOGY
delivered placentas will be placed in a sterile examination basin and placental tissues will be taken after de-
livery for macro- and microscopic investigation by a pathologist. Gross parameters will be recorded including 
weight, disc dimensions, presence of an accessory lobe and membrane insertion. The cord will be described 
with respect to insertion, twist, knot and number of vessels. representative sections of the placental disc, cord 
and chorioamniotic membranes will be taken to evaluate the presence of inflammation.
5.3 statistical analysis
descriptive statistics will be performed on demographic and clinical characteristics of the study population. 
univariate group differences will be tested with chi-square (χ²) test or fisher’s exact test for categorical vari-
ables and Mann-Whitney u-test or student’s t-test for continuous variables, when appropriate. 
sensitivity, specificity, negative predictive value (nPV), positive predictive value (PPV), positive and negative 
likelihood ratio (lr) will be calculated to determine the accuracy of each biomarker/test. receiver-operator 
characteristic (roc) curves will be generated to define the best cut-off levels of the biomarker that best predict 
PTB. 
The distribution of the biomarkers will be assessed prior to statistical assessment by visual inspection of the 
histograms and probability plots and logarithmically transformed to obtain normal distribution. Multiple lo-
gistic and linear regression analysis will be applied for adjusting for possible confounders. The Bonferroni 
correction will be used to account for multiple testing. 
all statistical analyses and tests will be performed two-sided at the 5% significant level.
5.4 abbreviations
PTB = preterm birth
Cl =  cervical length
fFN =  foetal fibronectin
GCP =  good clinical practice
ICF =  informed consent form
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inflammatory chemokine-3beta/ccl19 in preterm labor and delivery. eur J obstet Gynecol reprod Biol, 124(1), 23-26.
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and subsequent risk of preterm delivery. clin Biochem, 40(5-6), 330-335.
Maymon, e., romero, r., Pacora, P., Gomez, r., Mazor, M., edwin, s.,… fortunato, s.J. (2001). a role for the 72 kda gelati-
nase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of the membranes and intraamniotic 
infection. J Perinat Med, 29, 208-216.
Park, K.h., lee, s.Y., Kim, s.n., Jeong, e.h., oh, K.J. & ryu, a. (2011). Prediction of imminent preterm delivery in women 
with preterm premature rupture of membranes. J Perinat Med, 40(2), 151-157.
Pitiphat, W., Gillman, M.W., Joshipura, K.J., Williams, P.l., douglass, c.W., & rich-edwards, J.W. (2005). Plasma c-reactive 
protein in early pregnancy and preterm delivery. am J epidemiol, 162(11), 1108-1113.
sorokin, Y., romero, r., Mele, l., Wapner, r.J., Iams, J.d., dudley, d.J.,… sibai, B. (2010). Maternal interleukin-6, c-re-
active protein, and matrix metalloproteinase-9 concentrations as risk factors for preterm birth < 32 weeks and adverse 
neonatal outcomes. am J Perinatol, 27(8), 631-640.
Tency, I., Verstraelen, h., Kroes, I., holtappels, G., Verhasselt, B., Vaneechoutte, M., … Temmerman, M. (2013). Imbal-
ances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum 
during preterm labour. Plos one, 7(11), doi:10.1371/journal.pone.0049042
Tency, I., Verstraelen, h., saerens, B., Verhasselt, B., Vaneechoutte, M., degomme, o., … Temmerman, M. (2013). elevat-
ed soluble triggering receptor expressed on myeloid cells (sTreM-1) levels in maternal serum during term and preterm 
labour. Plos one, 8(2), doi:10.1371/journal.pone.0056050
Torbé, a, & czajka, r. Maternal plasma procalcitonin concentrations in patients with preterm labor and intact mem-
branes: prediction of preterm delivery and admission-to-delivery interval. (2004). J Perinat Med, 32(4), 332-336.
Vogel, I., Thorsen, P., curry, a., sandager, P., & uldbjerg, n. (2005). Biomarkers for the prediction of preterm delivery. acta 
obstet Gynecol scand, 84(6), 516-525.
5.2.2 FOETAL FIBRONECTIN (FFN)
a sterile speculum examination will be performed to collect a cervicovaginal sample. a dacron swab will be 
gently applied to the posterior fornix. after collection, the swab will be transferred to an extraction buffer. The 
specimen will be analysed by using a rapid bed-side test (rapid ffn, TliIq® system hologic, Marlborough, Ma). 
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ICH =  International conference on harmonisation of Technical requirements for registration of Parmaceuti-
cals for human use
IEC =  Independent ethical committee
lR =  likelihood ratio
NICu =  neonatal intensive care unit
NPV =  negative predictive value
PPV =  positive predictive value
ROC =  receiver-operator characteristic
uS =  ultrasound
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Preterm birth (PTB), defined as a delivery at less than 37 weeks of gestation, is the leading cause of perinatal 
morbidity and mortality worldwide. The serious effects of PTB on parents, infant and society make PTB an im-
portant issue to public health. despite significant advances in perinatal care and advancing knowledge of risk 
factors and mechanisms associated with PTB, there has been little progress in reducing the PTB rate. diagnosis 
of preterm labour as well as accurate prediction of PTB is notoriously difficult, because of the heterogeneity of 
the condition. PTB is a syndrome initiated by multiple mechanisms including infection or inflammation which 
is the only pathological process for which both a firm causal link with PTB has been established and a molec-
ular pathophysiology defined. Intrauterine infection evokes an immune response that involves the release of 
cytokines and chemokines, prostaglandins and matrix-degrading enzymes. These substances trigger uterine 
contractions, membrane rupture and cervical ripening. Most intra-uterine infections are chronic and subclin-
ical in nature and consequently hard to diagnose before labour or rupture of the membranes. a tremendous 
amount of efforts has been expended to identify markers to predict PTB and to improve our understanding of 
the mechanisms and pathways leading to PTB. The best studied site of infection is amniotic fluid, but obtaining 
this sample requires an invasive and sometimes risky procedure (e.g. amniocentesis). a non-invasive approach 
seems to be more relevant to clinical practice because of the feasibility and accessibility. however, few studies 
have investigated the maternal inflammatory response during preterm labour. Therefore, the overall objective 
of this study was to determine several inflammatory markers in maternal serum from pregnant women in 
labour (either term or preterm) vs. non-labouring controls. 
We completed a nested case control study in which singleton pregnancies were recruited at the obstetric de-
partment of Ghent university hospital and divided into groups according to gestational age and labour status. 
Multiple proteins were evaluated in maternal serum using enzyme-linked or multiplex bead immunoassays in-
cluding soluble triggering receptor expressed on myeloid cells-1 (sTreM-1), matrix metalloproteinases (MMP)-
9 and MMP-3, tissue inhibitor of metalloproteinases (TIMP)-1, TIMP-2, TIMP-3 and TIMP-4 and a panel of 30 
cytokines, chemokines and growth factors.
our study showed that serum levels of sTreM-1 were elevated during spontaneous term and preterm labour 
vs. non-labouring women. sTreM-1 concentrations were significantly higher in preterm vs. term labour. In line 
with previous studies, MMP-9 concentrations were elevated during preterm labour. TIMP-1 and TIMP-2 were 
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lower in preterm gestation, irrespective of labour, while TIMP-4 concentrations were raised in labour. one of 
the most intriguing findings of our study is that MMP-9:TIMP-1 and MMP-9:TIMP-2 balances in maternal serum 
were tilting in favour of matrix degradation (gelatinolysis) in women with preterm labour. This observation 
suggests that aberrant serum expression of MMP:TIMP ratios may provide a far less invasive method to deter-
mine enzymes essential in the degradation of extracellular matrix (ecM) during pregnancy and parturition. 
among the 30 inflammatory serum markers, only hepatocyte growth factor (hGf) was increased in women 
with PTB, while interleukin (Il)-12 serum levels were lower in labouring women and interferon gamma in-
duced protein (IP)-10 serum levels were higher in women at term gestation. This may indicate that the inflam-
matory response in serum of women with term and preterm labour is rather weak. 
until present, few biomarkers have shown clinical usefulness, because they are nonspecific or become pos-
itive too late. among the biomarkers evaluated to date, the most powerful and consistent predictors of PTB 
are the presence of foetal fibronectin in cervicovaginal fluid and a short cervix on transvaginal ultrasound 
examination. The clinical value of both tests primarily lies in their negative predictive value thereby guiding 
clinicians in decision-making and avoiding unnecessary interventions. during the last decades, it has become 
clear that single or universal biomarkers will not be capable to predict PTB accurately in all populations. future 
research should focus on multiple biomarkers in different PTB subtypes to allow differentiation depending 
on the underlying causes. The future development of an accurate, minimally invasive multiple marker test is 
necessary to permit incorporation into clinical practice. The availability of new technologies capable of prob-
ing the genome offers exciting possibilities to gain new insights into the mechanisms leading to PTB and to 
develop targeted therapies. 
SaMenVaTTInG
Vroeggeboorte (een bevalling vóór 37 weken) is wereldwijd de belangrijkste oorzaak van perinatale morbi-
diteit en mortaliteit. ondanks de belangrijke vooruitgang in perinatale zorg en de toegenomen kennis over 
risicofactoren en inzicht in mechanismen van vroeggeboorte, daalt het aantal vroeggeboortes niet. diagnose 
van preterme arbeid en accurate voorspelling van vroeggeboorte is niet evident. hoewel vroeggeboorte een 
syndroom is dat uitgelokt wordt door verschillende mechanismen, is infectie/inflammatie de enige risico-
factor waarvoor een oorzakelijk verband met vroeggeboorte werd aangetoond en waarvoor een duidelijk 
moleculair pathofysiologisch proces werd gedefinieerd. Intra-uteriene infectie lokt een immuunresponse uit 
waarbij cytokines, chemokines en matrix proteasen vrijkomen. deze factoren geven aanleiding tot uteriene 
contracties, breken van de vliezen en rijping/ontsluiting van de cervix. de meeste intra-uteriene infecties zijn 
chronisch en kennen een subklinisch verloop, waardoor de vroegtijdige diagnose van infectie wordt bemoei-
lijkt. er is zeer veel onderzoek gevoerd naar de identificatie van inflammatoire voorspellers van vroeggeboorte 
alsook om ons inzicht in de verschillende pathofysiologische processen te verbeteren. het amniotisch com-
partiment is het best bestudeerd, maar dit vereist een invasieve en risicovolle procedure (m.n. amniocentese). 
een non-invasieve aanpak is echter relevanter voor de klinische praktijk, omdat deze procedures gemakkelijk 
uitvoerbaar zijn tijdens de zwangerschap. de maternale inflammatoire response tijdens preterme arbeid is 
echter beperkt bestudeerd. de doelstelling van deze studie was dan ook om verschillende inflammatoire mer-
kers te bepalen in maternaal serum van zwangere vrouwen in arbeid (zowel a term als preterm) ten opzichte 
van zwangeren niet in arbeid. 
er werd een nested case control studie uitgevoerd waarbij  eenlingzwangerschappen werden gerekruteerd op 
de afdeling verloskunde van het universitair Ziekenhuis Gent. de zwangeren werden onderverdeeld in ver-
schillende groepen naargelang de zwangerschapsduur en arbeidsstatus. Verschillende inflammatoire merkers 
werden bestudeerd in maternaal serum door middel van elIsa en multiplex analyse: soluble triggering recep-
tor expressed on myeloid cells-1 (sTreM-1), matrix metalloproteinasen (MMP)-9 en MMP-3, weefselinhibitors 
van metalloproteinasen (tissue inhibitor of metalloproteinases) TIMP-1, TIMP-2, TIMP-3 and TIMP-4 en een 
panel van 30 cytokines, chemokines en groeifactoren.
onze resultaten toonden hogere sTreM-1 concentraties in vrouwen met spontane arbeid (zowel a term als 
preterm) t.o.v. vrouwen niet in arbeid. sTreM was significant hoger in preterme t.o.v. a terme arbeid. MMP-9 
160 161
saM
enVaTTInG sa
M
en
Va
TT
In
G
concentraties waren verhoogd tijdens preterme arbeid. TIMP-1 en TIMP-2 waren lager preterm, onafhankelijk 
van arbeidsstatus, terwijl TIMP-4 concentraties hoger waren in arbeid, ongeacht zwangerschapsduur. eén van 
de belangrijkste bevindingen uit onze studie is dat de MMP-9:TMP-1 en MMP-9:TMP-2 ratio’s in maternaal 
serum neigen naar degradatie van de extracellulaire matrix in vrouwen met preterme arbeid. dit betekent dat 
het bepalen van afwijkende serum MMP:TIMP ratio’s mogelijks een minder invasieve aanpak kan vormen voor 
de bepaling van enzymen die essentieel zijn in de degradatie van de extracellulaire matrix tijdens de zwanger-
schap en baring. Van het panel van 30 inflammatoire merkers, bleek enkel “hepatocyte growth factor” (hGf) 
significant geassocieerd te zijn met preterme arbeid, terwijl interleukine (Il)-12 concentraties lager waren in 
vrouwen in arbeid en “interferon gamma induced protein” (IP)-10 levels hoger a term. dit wijst mogelijks op 
een relatieve zwakke inflammatoire response in maternaal serum tijdens a terme en preterme arbeid. 
Tot op heden zijn er weinig biomerkers klinisch bruikbaar gebleken voor predictie van vroeggeboorte, omdat 
ze vaak niet specifiek genoeg zijn en te laat positief worden. foetaal fibronectine in cervicovaginaal vocht en 
een verkorte cervix op transvaginale echografie zijn tot nu toe de meest effectieve en consistente voorspellers 
van vroeggeboorte. Vooral hun negatieve predictieve waarde is klinisch van belang omdat dit kan helpen bij 
vermijden van onnodige interventies. Tijdens de laatste 10 jaar is het duidelijk geworden dat één enkele of een 
universele biomerker niet zal volstaan om vroeggeboorte te voorspellen in alle populaties. Verder onderzoek 
moet zich richten tot een combinatie van merkers in verschillende subtypes van vroeggeboorte om differen-
tiatie met betrekking tot de onderliggende oorzaak toe te laten. In de toekomst is ook de ontwikkeling van 
een accurate, minimaal invasieve combinatie test noodzakelijk om implementatie in de klinische praktijk toe 
te laten. de opkomst van nieuwe technologieën die in staat zijn het hele genoom te onderzoeken, zijn van 
fundamenteel belang om nieuwe inzichten te verkrijgen in de mechanismen van vroeggeboorte en specifieke, 
individugerichte therapieën te ontwikkelen. 
163
re
fe
re
nc
es
reFerenCeS
abdel-aleem, h., shaaban, o. M., & abdel-aleem, M. a. (2010). cervical pessary for preventing preterm birth. 
cochrane database syst rev(9), cd007873. doi: 10.1002/14651858.cd007873.pub2
abramovici, a., cantu, J., & Jenkins, s. M. (2012). Tocolytic therapy for acute preterm labor. obstet Gynecol clin 
north am, 39(1), 77-87. doi: 10.1016/j.ogc.2011.12.003
agrawal, V., & hirsch, e. (2012). Intrauterine infection and preterm labor. semin fetal neonatal Med, 17(1), 
12-19. doi: 10.1016/j.siny.2011.09.001
albayrak, M., ozdemir, I., Koc, o., ankarali, h., & ozen, o. (2011). comparison of the diagnostic efficacy of the 
two rapid bedside immunoassays and combined clinical conventional diagnosis in prelabour rupture of mem-
branes. eur J obstet Gynecol reprod Biol, 158(2), 179-182. doi: 10.1016/j.ejogrb.2011.04.041
alfirevic, Z., stampalija, T., roberts, d., & Jorgensen, a. l. (2012). cervical stitch (cerclage) for preventing 
preterm birth in singleton pregnancy. cochrane database syst rev, 4, cd008991. doi: 10.1002/14651858.
cd008991.pub2
allen, M. c., cristofalo, e. a., & Kim, c. (2011). outcomes of preterm infants: morbidity replaces mortality. clin 
Perinatol, 38(3), 441-454. doi: 10.1016/j.clp.2011.06.011
altinkaya, o., Gungor, T., ozat, M., danisman, n., & Mollamahmutoglu, l. (2009). cervical phosphorylated insu-
lin-like growth factor binding protein-1 in prediction of preterm delivery. archives of gynecology and obstet-
rics, 279(3), 279-283. doi: 10.1007/s00404-008-0703-7
amalinei, c., caruntu, I. d., & Balan, r. a. (2007). Biology of metalloproteinases. romanian journal of morphol-
ogy and embryology = revue roumaine de morphologie et embryologie, 48(4), 323-334. doi: 480407323334 
[pii]
aminzadeh, f., Ghorashi, Z., nabati, s., Ghasemshirazi, M., arababadi, M. K., shamsizadeh, a., . . . hassanshahi, 
G. (2012). differential expression of cXc chemokines cXcl10 and cXcl12 in Term and Pre-term neonates and 
Their Mothers. am J reprod Immunol. doi: 10.1111/j.1600-0897.2012.01167.x
andersen, h. f. (2000). use of fetal fibronectin in women at risk for preterm delivery. clin obstet Gynecol, 43(4), 
746-758. 
anotayanonth, s., subhedar, n. V., Garner, P., neilson, J. P., & harigopal, s. (2004). Betamimetics for inhibiting 
preterm labour. cochrane database syst rev(4), cd004352. doi: 10.1002/14651858.cd004352.pub2
164 165
re
fe
re
nc
es
references
Brew, K., & nagase, h. (2010). The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with 
structural and functional diversity. Biochimica et biophysica acta, 1803(1), 55-71. doi: s0167-4889(10)00004-2 
[pii]10.1016/j.bbamcr.2010.01.003
Brik, M., hernandez, a. I., Pedraz, c. c., & Perales, a. (2010). Phosphorylated insulin-like growth factor binding 
protein-1 and cervical measurement in women with threatening preterm birth. acta obstet Gynecol scand, 
89(2), 268-274. doi: 10.3109/00016340903443668
Brou, l., almli, l. M., Pearce, B. d., Bhat, G., drobek, c. o., fortunato, s., & Menon, r. (2012). dysregulat-
ed biomarkers induce distinct pathways in preterm birth. BJoG, 119(4), 458-473. doi: 10.1111/j.1471-
0528.2011.03266.x
Brownfoot, f. c., crowther, c. a., & Middleton, P. (2008). different corticosteroids and regimens for accelerat-
ing fetal lung maturation for women at risk of preterm birth. cochrane database syst rev(4), cd006764. doi: 
10.1002/14651858.cd006764.pub2
Bryant-Greenwood, G. d., & Yamamoto, s. Y. (1995). control of peripartal collagenolysis in the human chori-
on-decidua. am J obstet Gynecol, 172(1 Pt 1), 63-70. 
Buhimschi, c. s., Bhandari, V., hamar, B. d., Bahtiyar, M. o., Zhao, G., sfakianaki, a. K., . . . Buhimschi, I. a. 
(2007). Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. Plos 
medicine, 4(1), e18. doi: 10.1371/journal.pmed.0040018
Buhimschi, I. a., christner, r., & Buhimschi, c. s. (2005). Proteomic biomarker analysis of amniotic fluid for 
identification of intra-amniotic inflammation. BJoG, 112(2), 173-181. doi: 10.1111/j.1471-0528.2004.00340.x
Buhimschi, I. a., Zambrano, e., Pettker, c. M., Bahtiyar, M. o., Paidas, M., rosenberg, V. a., . . . Buhimschi, c. s. 
(2008). using proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis. obstet 
Gynecol, 111(2 Pt 1), 403-412. doi: 10.1097/aoG.0b013e31816102aa
cammu, h., Martens, e., Martens, G., Van Mol, c., & Jacquemyn, Y. (2011). Perinatale activiteiten in Vlaanderen 
2011 (pp. 110). Brussel: studiecentrum voor Perinatale epidemiologie (sPe).
campbell, s. (2011). universal cervical-length screening and vaginal progesterone prevents early preterm 
births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. ultrasound in 
obstetrics & gynecology : the official journal of the International society of ultrasound in obstetrics and Gyne-
cology, 38(1), 1-9. doi: 10.1002/uog.9073
chandiramani, M., di renzo, G. c., Gottschalk, e., helmer, h., henrich, W., hoesli, I., . . . shennan, a. (2011). fetal 
fibronectin as a predictor of spontaneous preterm birth: a european perspective. J Matern fetal neonatal Med, 
24(2), 330-336. doi: 10.3109/14767058.2010.496879
chegini, n., rhoton-Vlasak, a., & Williams, r. s. (2003). expression of matrix metalloproteinase-26 and tissue 
inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and 
alteration in users of levonorgestrel implants who experience irregular uterine bleeding. fertil steril, 80(3), 
564-570. 
chelladurai, P., seeger, W., & Pullamsetti, s. s. (2012). Matrix metalloproteinases and their inhibitors in pulmo-
nary hypertension. european respiratory Journal, 40(3), 766-782. doi: 10.1183/09031936.00209911
chen, f. c., & dudenhausen, J. W. (2008). comparison of two rapid strip tests based on IGfBP-1 and PaMG-1 for 
the detection of amniotic fluid. am J Perinatol, 25(4), 243-246. doi: 10.1055/s-2008-1066876
ascarelli, M. h., & Morrison, J. c. (1997). use of fetal fibronectin in clinical practice. obstet Gynecol surv, 52(4 
suppl), s1-12. 
athayde, n., edwin, s. s., romero, r., Gomez, r., Maymon, e., Pacora, P., & Menon, r. (1998). a role for matrix 
metalloproteinase-9 in spontaneous rupture of the fetal membranes. am J obstet Gynecol, 179(5), 1248-1253. 
athayde, n., romero, r., Gomez, r., Maymon, e., Pacora, P., Mazor, M., . . . edwin, s. s. (1999). Matrix metallo-
proteinases-9 in preterm and term human parturition. The Journal of maternal-fetal medicine, 8(5), 213-219. 
doi: 10.1002/(sIcI)1520-6661(199909/10)8:5<213::aId-MfM3>3.0.co;2-r
Beck, s., Wojdyla, d., say, l., Betran, a. P., Merialdi, M., requejo, J. h., . . . Van look, P. f. (2010). The worldwide 
incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bulletin of the World 
health organization, 88(1), 31-38. doi: 10.2471/BlT.08.062554
Berghella, V. (2009). novel developments on cervical length screening and progesterone for preventing 
preterm birth. BJoG, 116(2), 182-187. doi: 10.1111/j.1471-0528.2008.02008.x
Berghella, V., Baxter, J. K., & hendrix, n. W. (2009). cervical assessment by ultrasound for preventing preterm 
delivery. cochrane database syst rev(3), cd007235. doi: 10.1002/14651858.cd007235.pub2
Berghella, V., Baxter, J. K., & hendrix, n. W. (2013). cervical assessment by ultrasound for preventing preterm 
delivery. cochrane database syst rev, 1, cd007235. doi: 10.1002/14651858.cd007235.pub3
Berghella, V., hayes, e., Visintine, J., & Baxter, J. K. (2008). fetal fibronectin testing for reducing the risk of 
preterm birth. cochrane database syst rev(4), cd006843. doi: 10.1002/14651858.cd006843.pub2
Berghella, V., & Mackeen, a. d. (2011). cervical length screening with ultrasound-indicated cerclage compared 
with history-indicated cerclage for prevention of preterm birth: a meta-analysis. obstet Gynecol, 118(1), 148-
155. doi: 10.1097/aoG.0b013e31821fd5b0
Berghella, V., rafael, T. J., szychowski, J. M., rust, o. a., & owen, J. (2011). cerclage for short cervix on ultra-
sonography in women with singleton gestations and previous preterm birth: a meta-analysis. obstet Gynecol, 
117(3), 663-671. 
Blank, V., hirsch, e., challis, J. r., romero, r., & lye, s. J. (2008). cytokine signaling, inflammation, innate 
immunity and preterm labour - a workshop report. Placenta, 29 suppl a, s102-104. doi: 10.1016/j.placen-
ta.2007.10.011
Blencowe, h., cousens, s., oestergaard, M. Z., chou, d., Moller, a. B., narwal, r., . . . lawn, J. e. (2012). national, 
regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for 
selected countries: a systematic analysis and implications. lancet, 379(9832), 2162-2172. doi: 10.1016/s0140-
6736(12)60820-4
Bouchon, a., facchetti, f., Weigand, M. a., & colonna, M. (2001). TreM-1 amplifies inflammation and is a crucial 
mediator of septic shock. nature, 410(6832), 1103-1107. 
Bowen, J. M., chamley, l., Keelan, J. a., & Mitchell, M. d. (2002). cytokines of the placenta and extra-placen-
tal membranes: roles and regulation during human pregnancy and parturition. Placenta, 23(4), 257-273. doi: 
10.1053/plac.2001.0782
166 167
re
fe
re
nc
es
references
crowther, c. a., McKinlay, c. J., Middleton, P., & harding, J. e. (2011). repeat doses of prenatal corticosteroids 
for women at risk of preterm birth for improving neonatal health outcomes. cochrane database syst rev(6), 
cd003935. doi: 10.1002/14651858.cd003935.pub3
da fonseca, e. B., damiao, r., & nicholaides, K. (2009). Prevention of preterm birth based on short cervix: 
progesterone. semin Perinatol, 33(5), 334-337. doi: 10.1053/j.semperi.2009.06.006
davey, M. a., Watson, l., rayner, J. a., & rowlands, s. (2011). risk scoring systems for predicting preterm 
birth with the aim of reducing associated adverse outcomes. cochrane database syst rev(11), cd004902. doi: 
10.1002/14651858.cd004902.pub4
defranco, e. a., lewis, d. f., & odibo, a. o. (2012). Improving the screening accuracy for preterm labor: is the 
combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm 
birth? a systematic review. am J obstet Gynecol. doi: 10.1016/j.ajog.2012.12.015
delaey, e. (2009). Kostenanalyse van vroeggeboorte (<34wk) tot op de leeftijd van 2 jaar. (licentiaat medisch 
sociale wetenschappen, optie beheer en beleid van verzorgingsinstellingen), universiteit Gent, Gent.   
dharan, V. B., & ludmir, J. (2009). alternative treatment for a short cervix: the cervical pessary. semin Perina-
tol, 33(5), 338-342. doi: 10.1053/j.semperi.2009.06.008
di renzo, G. c., roura, l. c., facchinetti, f., antsaklis, a., Breborowicz, G., Gratacos, e., . . . Ville, Y. (2011). 
Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, 
diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern fetal 
neonatal Med, 24(5), 659-667. doi: 10.3109/14767058.2011.553694
dodd, J. M., flenady, V., cincotta, r., & crowther, c. a. (2006). Prenatal administration of progesterone for 
preventing preterm birth. cochrane database syst rev(1), cd004947. doi: 10.1002/14651858.cd004947.pub2
domin, c. M., smith, e. J., & Terplan, M. (2010). Transvaginal ultrasonographic measurement of cervical length 
as a predictor of preterm birth: a systematic review with meta-analysis. ultrasound q, 26(4), 241-248. doi: 
10.1097/ruq.0b013e3181fe0e05
doyle, n. M., & Monga, M. (2004). role of ultrasound in screening patients at risk for preterm delivery. obstet 
Gynecol clin north am, 31(1), 125-139. doi: 10.1016/s0889-8545(03)00120-7
edwards, r. K., clark, P., locksmith Gregory, J., & duff, P. (2001). Performance characteristics of putative tests 
for subclinical chorioamnionitis. Infect dis obstet Gynecol, 9(4), 209-214. doi: 10.1155/s1064744901000345
ekelund, c. K., Vogel, I., skogstrand, K., Thorsen, P., hougaard, d. M., langhoff-roos, J., & Jacobsson, B. (2008). 
Interleukin-18 and interleukin-12 in maternal serum and spontaneous preterm delivery. Journal of reproduc-
tive Immunology, 77(2), 179-185. doi: 10.1016/j.jri.2007.07.002
elizur, s. e., Yinon, Y., epstein, G. s., seidman, d. s., schiff, e., & sivan, e. (2005). Insulin-like growth factor 
binding protein-1 detection in preterm labor: evaluation of a bedside test. am J Perinatol, 22(6), 305-309. doi: 
10.1055/s-2005-870895
espinoza, J., Goncalves, l. f., romero, r., nien, J. K., stites, s., Kim, Y. M., . . . Mazor, M. (2005). The prevalence 
and clinical significance of amniotic fluid ‘sludge’ in patients with preterm labor and intact membranes. ultra-
sound in obstetrics & gynecology : the official journal of the International society of ultrasound in obstetrics 
and Gynecology, 25(4), 346-352. doi: 10.1002/uog.1871
chen, s. J., liu, Y. l., & sytwu, h. K. (2012). Immunologic regulation in pregnancy: from mechanism to thera-
peutic strategy for immunomodulation. clin dev Immunol, 2012, 258391. doi: 10.1155/2012/258391
cobo, T., Kacerovsky, M., holst, r. M., hougaard, d. M., skogstrand, K., Wennerholm, u. B., . . . Jacobsson, B. 
(2012). Intra-amniotic inflammation predicts microbial invasion of the amniotic cavity but not spontaneous 
preterm delivery in preterm prelabor membrane rupture. acta obstet Gynecol scand, 91(8), 930-935. doi: 
10.1111/j.1600-0412.2012.01427.x
cobo, T., Kacerovsky, M., Palacio, M., hornychova, h., hougaard, d. M., skogstrand, K., & Jacobsson, B. (2012). 
Intra-amniotic inflammatory response in subgroups of women with preterm prelabor rupture of the mem-
branes. Plos one, 7(8), e43677. doi: 10.1371/journal.pone.0043677
cobo, T., Tsiartas, P., Kacerovsky, M., holst, r. M., hougaard, d. M., skogstrand, K., . . . Jacobsson, B. (2012). 
Maternal inflammatory response to microbial invasion of the amniotic cavity: analyses of multiple proteins in 
the maternal serum. acta obstet Gynecol scand. doi: 10.1111/aogs.12028
cockle, J. V., Gopichandran, n., Walker, J. J., levene, M. I., & orsi, n. M. (2007). Matrix metalloproteinases and 
their tissue inhibitors in preterm perinatal complications. reproductive sciences, 14(7), 629-645. doi: 14/7/629 
[pii]10.1177/1933719107304563
collins, c. e., la, d. T., Yang, h. T., Massin, f., Gibot, s., faure, G., & stohl, W. (2009). elevated synovial expression 
of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. 
annals of the rheumatic diseases, 68(11), 1768-1774. doi: ard.2008.089557 [pii]10.1136/ard.2008.089557
colonna, M. (2003). Trems in the immune system and beyond. nature reviews Immunology, 3(6), 445-453. doi: 
doi 10.1038/nri1106
conde-agudelo, a., Papageorghiou, a. T., Kennedy, s. h., & Villar, J. (2011). novel biomarkers for the prediction 
of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJoG, 118(9), 1042-1054. 
doi: 10.1111/j.1471-0528.2011.02923.x
conde-agudelo, a., & romero, r. (2010). cervicovaginal fetal fibronectin for the prediction of spontaneous 
preterm birth in multiple pregnancies: a systematic review and meta-analysis. J Matern fetal neonatal Med, 
23(12), 1365-1376. doi: 10.3109/14767058.2010.499484
conde-agudelo, a., romero, r., hassan, s. s., & Yeo, l. (2010). Transvaginal sonographic cervical length for 
the prediction of spontaneous preterm birth in twin pregnancies: a systematic review and metaanalysis. am J 
obstet Gynecol, 203(2), 128 e121-112. doi: 10.1016/j.ajog.2010.02.064
conde-agudelo, a., romero, r., & Kusanovic, J. P. (2011). nifedipine in the management of preterm labor: a sys-
tematic review and metaanalysis. am J obstet Gynecol, 204(2), 134 e131-120. doi: 10.1016/j.ajog.2010.11.038
cox, B., Martens, e., nemery, B., Vangronsveld, J., & nawrot, T. s. (2013). Impact of a stepwise introduction of 
smoke-free legislation on the rate of preterm births: analysis of routinely collected birth data. BMJ, 346, f441. 
doi: 10.1136/bmj.f441
crider, K. s., Whitehead, n., & Buus, r. M. (2005). Genetic variation associated with preterm birth: a huGe 
review. Genet Med, 7(9), 593-604. doi: 10.109701.gim.0000187223.69947.db
crowther, c. a., hiller, J. e., & doyle, l. W. (2002). Magnesium sulphate for preventing preterm birth in threat-
ened preterm labour. cochrane database syst rev(4), cd001060. doi: 10.1002/14651858.cd001060
168 169
re
fe
re
nc
es
references
Glanc, P., andreotti, r. f., lee, s. I., dejesus allison, s. o., Bennett, G. l., Brown, d. l., . . . Zelop, c. M. (2011). 
acr appropriateness criteria(r) assessment of gravid cervix. ultrasound q, 27(4), 275-280. doi: 10.1097/
ruq.0b013e3182394123
Goffinet, f. (2005). Primary predictors of preterm labour. BJoG, 112 suppl 1, 38-47. doi: 10.1111/j.1471-
0528.2005.00583.x
Goldenberg, r. l., & culhane, J. f. (2003). Infection as a cause of preterm birth. clinics in Perinatology, 30(4), 
677-700. 
Goldenberg, r. l., culhane, J. f., Iams, J. d., & romero, r. (2008). Preterm birth 1 - epidemiology and causes of 
preterm birth. lancet, 371(9606), 75-84. 
Goldenberg, r. l., Goepfert, a. r., & ramsey, P. s. (2005). Biochemical markers for the prediction of preterm 
birth. american Journal of obstetrics and Gynecology, 192(5), s36-s46. doi: doI 10.1016/j.ajog.2005.02.015
Goldenberg, r. l., Gravett, M. G., Iams, J., Papageorghiou, a. T., Waller, s. a., Kramer, M., . . . Villar, J. (2012). 
The preterm birth syndrome: issues to consider in creating a classification system. am J obstet Gynecol, 206(2), 
113-118. doi: 10.1016/j.ajog.2011.10.865
Goldenberg, r. l., hauth, J. c., & andrews, W. W. (2000). Mechanisms of disease - Intrauterine infection and 
preterm delivery. new england Journal of Medicine, 342(20), 1500-1507. 
Goldenberg, r. l., Iams, J. d., Mercer, B. M., Meis, P. J., Moawad, a., das, a., . . . network, M.-f. M. u. (2001). The 
Preterm Prediction study: Toward a multiple-marker test for spontaneous preterm birth. american Journal of 
obstetrics and Gynecology, 185(3), 643-651. 
Goldman, s., Weiss, a., eyali, V., & shalev, e. (2003). differential activity of the gelatinases (matrix metallopro-
teinases 2 and 9) in the fetal membranes and decidua, associated with labour. Molecular human reproduction, 
9(6), 367-373. 
Gomez-lopez, n., estrada-Gutierrez, G., Jimenez-Zamudio, l., Vega-sanchez, r., & Vadillo-ortega, f. (2009). 
fetal membranes exhibit selective leukocyte chemotaxic activity during human labor. Journal of reproductive 
Immunology, 80(1-2), 122-131. doi: 10.1016/j.jri.2009.01.002
Goncalves, l. f., chaiworapongsa, T., & romero, r. (2002). Intrauterine infection and prematurity. Mental re-
tardation and developmental disabilities research reviews, 8(1), 3-13. doi: 10.1002/mrdd.10008 [pii]10.1002/
mrdd.10008
Gotsch, f., romero, r., erez, o., Vaisbuch, e., Kusanovic, J. P., Mazaki-Tovi, s., . . . Yeo, l. (2009). The preterm 
parturition syndrome and its implications for understanding the biology, risk assessment, diagnosis, treat-
ment and prevention of preterm birth. Journal of Maternal-fetal & neonatal Medicine, 22, 5-23. doi: doi 
10.1080/14767050902860690
Gotsch, f., romero, r., Kusanovic, J. P., Mazaki-Tovi, s., Pineles, B. l., erez, o., . . . hassan, s. s. (2007). The fetal 
inflammatory response syndrome. clin obstet Gynecol, 50(3), 652-683. doi: 10.1097/Grf.0b013e31811ebef6
Goya, M., Pratcorona, l., Merced, c., rodo, c., Valle, l., romero, a., . . . Pesario cervical para evitar Prematuri-
dad Trial, G. (2012). cervical pessary in pregnant women with a short cervix (PeceP): an open-label randomised 
controlled trial. lancet, 379(9828), 1800-1806. doi: 10.1016/s0140-6736(12)60030-0
esplin, M. s. (2006). Preterm birth: a review of genetic factors and future directions for genetic study. obstet 
Gynecol surv, 61(12), 800-806. doi: 10.1097/01.ogx.0000248747.52343.5f
flood, K., & Malone, f. d. (2012). Prevention of preterm birth. semin fetal neonatal Med, 17(1), 58-63. doi: 
10.1016/j.siny.2011.08.001
fonseca, e. B., celik, e., Parra, M., singh, M., nicolaides, K. h., & fetal Medicine foundation second Trimester 
screening, G. (2007). Progesterone and the risk of preterm birth among women with a short cervix. The new 
england journal of medicine, 357(5), 462-469. doi: 10.1056/neJMoa067815
ford, J. W., & McVicar, d. W. (2009). TreM and TreM-like receptors in inflammation and disease. current opin-
ion in Immunology, 21(1), 38-46. doi: doI 10.1016/j.coi.2009.01.009
fortunato, s. J., & Menon, r. (2001). distinct molecular events suggest different pathways for preterm labor 
and premature rupture of membranes. am J obstet Gynecol, 184(7), 1399-1405. 
fortunato, s. J., Menon, r., & lombardi, s. J. (1997). collagenolytic enzymes (gelatinases) and their inhibitors 
in human amniochorionic membrane. am J obstet Gynecol, 177(4), 731-741. 
fortunato, s. J., Menon, r., & lombardi, s. J. (1998). Presence of four tissue inhibitors of matrix metalloprotein-
ases (TIMP-1, -2, -3 and -4) in human fetal membranes. am J reprod Immunol, 40(6), 395-400. 
fortunato, s. J., Menon, r., & lombardi, s. J. (1999a). MMP/TIMP imbalance in amniotic fluid during ProM: an 
indirect support for endogenous pathway to membrane rupture. J Perinat Med, 27(5), 362-368. doi: 10.1515/
JPM.1999.049
fortunato, s. J., Menon, r., & lombardi, s. J. (1999b). stromelysins in placental membranes and amniotic fluid 
with premature rupture of membranes. obstet Gynecol, 94(3), 435-440. 
fortunato, s. J., Menon, r., & lombardi, s. J. (2000). amniochorion gelatinase-gelatinase inhibitor imbalance 
in vitro: a possible infectious pathway to rupture. obstet Gynecol, 95(2), 240-244. 
friebe, a., & Volk, h. d. (2008). stability of tumor necrosis factor alpha, interleukin 6, and interleukin 8 in blood 
samples of patients with systemic immune activation. archives of pathology & laboratory medicine, 132(11), 
1802-1806. doi: 2007-0745-oa [pii]10.1043/1543-2165-132.11.1802
Garcia-Verdugo, I., Tanfin, Z., & Breuiller-fouche, M. (2010). surfactant protein a: an immunoregulatory mol-
ecule involved in female reproductive biology. Int J Biochem cell Biol, 42(11), 1779-1783. doi: 10.1016/j.bio-
cel.2010.08.003
Gaunekar, n. n., & crowther, c. a. (2004). Maintenance therapy with calcium channel blockers for pre-
venting preterm birth after threatened preterm labour. cochrane database syst rev(3), cd004071. doi: 
10.1002/14651858.cd004071.pub2
Gibot, s. (2006). soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia and 
severe sepsis. seminars in respiratory and critical care Medicine, 27(1), 29-33. 
Gibot, s., cravoisy, a., Kolopp-sarda, M. n., Bene, M. c., faure, G., Bollaert, P. e., & levy, B. (2005). Time-course 
of sTreM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and c-reactive protein plas-
ma concentrations during sepsis. critical care Medicine, 33(4), 792-796. doi: 00003246-200504000-00016 [pii]
170 171
re
fe
re
nc
es
references
hodek, J. M., von der schulenburg, J. M., & Mittendorf, T. (2011). Measuring economic consequences of preterm 
birth - Methodological recommendations for the evaluation of personal burden on children and their caregiv-
ers. health econ rev, 1(1), 6. doi: 10.1186/2191-1991-1-6
holst, r. M., hagberg, h., Wennerholm, u. B., skogstrand, K., Thorsen, P., & Jacobsson, B. (2009). Prediction 
of spontaneous preterm delivery in women with preterm labor: analysis of multiple proteins in amniotic and 
cervical fluids. obstet Gynecol, 114(2 Pt 1), 268-277. doi: 10.1097/aoG.0b013e3181ae6a08
holst, r. M., hagberg, h., Wennerholm, u. B., skogstrand, K., Thorsen, P., & Jacobsson, B. (2011). Prediction 
of microbial invasion of the amniotic cavity in women with preterm labour: analysis of multiple proteins in 
amniotic and cervical fluids. BJoG, 118(2), 240-249. doi: 10.1111/j.1471-0528.2010.02765.x
honest, h., forbes, c. a., duree, K. h., norman, G., duffy, s. B., Tsourapas, a., . . . Khan, K. s. (2009). screening to 
prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic 
modelling. health Technol assess, 13(43), 1-627. doi: 10.3310/hta13430
Iams, J. d. (2003). Prediction and early detection of preterm labor. obstet Gynecol, 101(2), 402-412. 
Iams, J. d., cebrik, d., lynch, c., Behrendt, n., & das, a. (2011). The rate of cervical change and the phenotype of 
spontaneous preterm birth. am J obstet Gynecol, 205(2), 130 e131-136. doi: 10.1016/j.ajog.2011.05.021
Iams, J. d., Goldenberg, r. l., Meis, P. J., Mercer, B. M., Moawad, a., das, a., . . . roberts, J. M. (1996). The length 
of the cervix and the risk of spontaneous premature delivery. national Institute of child health and human 
development Maternal fetal Medicine unit network. The new england journal of medicine, 334(9), 567-572. 
doi: 10.1056/neJM199602293340904
Iams, J. d., romero, r., culhane, J. f., & Goldenberg, r. l. (2008). Primary, secondary, and tertiary interven-
tions to reduce the morbidity and mortality of preterm birth. lancet, 371(9607), 164-175. doi: 10.1016/s0140-
6736(08)60108-7
Iyer, r. P., Patterson, n. l., fields, G. B., & lindsey, M. l. (2012). The history of matrix metalloproteinases: mile-
stones, myths, and misperceptions. american journal of physiology. heart and circulatory physiology, 303(8), 
h919-930. doi: 10.1152/ajpheart.00577.2012
Jackman, r. P., utter, G. h., heitman, J. W., hirschkorn, d. f., law, J. P., Gefter, n., . . . norris, P. J. (2011). effects 
of blood sample age at time of separation on measured cytokine concentrations in human plasma. clinical and 
vaccine immunology : cVI, 18(2), 318-326. doi: cVI.00465-10 [pii]10.1128/cVI.00465-10
Jiyong, J., Tiancha, h., Wei, c., & huahao, s. (2009). diagnostic value of the soluble triggering receptor ex-
pressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive care medicine, 35(4), 587-595. doi: 
10.1007/s00134-008-1333-z
Kamel, r. M. (2010). The onset of human parturition. archives of gynecology and obstetrics, 281(6), 975-982. 
doi: 10.1007/s00404-010-1365-9
Keirse, M. J., hanssens, M., & devlieger, h. (2009). Trends in preterm births in flanders, Belgium, from 1991 to 
2002. Paediatr Perinat epidemiol, 23(6), 522-532. doi: 10.1111/j.1365-3016.2009.01067.x
Kekki, M., Kurki, T., Karkkainen, T., hiilesmaa, V., Paavonen, J., & rutanen, e. M. (2001). Insulin-like growth 
factor-binding protein-1 in cervical secretion as a predictor of preterm delivery. acta obstet Gynecol scand, 
80(6), 546-551. 
Gracie, s., Pennell, c., ekman-ordeberg, G., lye, s., McManaman, J., Williams, s., . . . Group, P. o. r. (2011). an 
integrated systems biology approach to the study of preterm birth using “-omic” technology--a guideline for 
research. BMc pregnancy and childbirth, 11, 71. doi: 10.1186/1471-2393-11-71
Greco, e., Gupta, r., syngelaki, a., Poon, l. c., & nicolaides, K. h. (2012). first-trimester screening for sponta-
neous preterm delivery with maternal characteristics and cervical length. fetal diagnosis and therapy, 31(3), 
154-161. doi: 10.1159/000335686
Guinto, V. T., de Guia, B., festin, M. r., & dowswell, T. (2010). different antibiotic regimens for treating asymp-
tomatic bacteriuria in pregnancy. cochrane database syst rev(9), cd007855. doi: 10.1002/14651858.cd007855.
pub2
haas, d. M., caldwell, d. M., Kirkpatrick, P., McIntosh, J. J., & Welton, n. J. (2012). Tocolytic therapy for preterm 
delivery: systematic review and network meta-analysis. BMJ, 345, e6226. doi: 10.1136/bmj.e6226
hamilton, s., oomomian, Y., stephen, G., shynlova, o., Tower, c. l., Garrod, a., . . . Jones, r. l. (2012). Macro-
phages infiltrate the human and rat decidua during term and preterm labor: evidence that decidual inflamma-
tion precedes labor. Biology of reproduction, 86(2), 39. doi: 10.1095/biolreprod.111.095505
han, s., crowther, c. a., & Moore, V. (2010). Magnesium maintenance therapy for preventing preterm birth af-
ter threatened preterm labour. cochrane database syst rev(7), cd000940. doi: 10.1002/14651858.cd000940.
pub2
han, Z., lutsiv, o., Mulla, s., rosen, a., Beyene, J., & Mcdonald, s. d. (2011). low gestational weight gain and the 
risk of preterm birth and low birthweight: a systematic review and meta-analyses. acta obstet Gynecol scand, 
90(9), 935-954. doi: 10.1111/j.1600-0412.2011.01185.x
han, Z., Mulla, s., Beyene, J., liao, G., & Mcdonald, s. d. (2011). Maternal underweight and the risk of preterm 
birth and low birth weight: a systematic review and meta-analyses. Int J epidemiol, 40(1), 65-101. doi: 10.1093/
ije/dyq195
hanna, n., & Kiefer, d. (2012). a translational view of biomarkers in preterm labor. am J reprod Immunol, 67(4), 
268-272. doi: 10.1111/j.1600-0897.2012.01112.x
harirah, h., donia, s. e., & hsu, c. d. (2002). amniotic fluid matrix metalloproteinase-9 and interleukin-6 in 
predicting intra-amniotic infection. obstet Gynecol, 99(1), 80-84. 
hassan, s. s., romero, r., Vidyadhari, d., fusey, s., Baxter, J. K., Khandelwal, M., . . . Trial, P. (2011). Vaginal 
progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, ran-
domized, double-blind, placebo-controlled trial. ultrasound in obstetrics & gynecology : the official journal 
of the International society of ultrasound in obstetrics and Gynecology, 38(1), 18-31. doi: 10.1002/uog.9017
hernandez-andrade, e., romero, r., ahn, h., hussein, Y., Yeo, l., Korzeniewski, s. J., . . . hassan, s. s. (2012). 
Transabdominal evaluation of uterine cervical length during pregnancy fails to identify a substantial number of 
women with a short cervix. J Matern fetal neonatal Med, 25(9), 1682-1689. doi: 10.3109/14767058.2012.657278
himaya, e., rhalmi, n., Girard, M., Tetu, a., desgagne, J., abdous, B., . . . Bujold, e. (2011). Midtrimester in-
tra-amniotic sludge and the risk of spontaneous preterm birth. am J Perinatol, 28(10), 815-820. doi: 10.1055/s-
0031-1295638
172 173
re
fe
re
nc
es
references
Kramer, M. s., Kahn, s. r., Platt, r. W., Genest, J., chen, M. f., Goulet, l., . . . Thorsen, P. (2010). Mid-trimester 
maternal plasma cytokines and crP as predictors of spontaneous preterm birth. cytokine, 49(1), 10-14. doi: doI 
10.1016/j.cyto.2009.08.014
Kramer, M. s., Papageorghiou, a., culhane, J., Bhutta, Z., Goldenberg, r. l., Gravett, M., . . . Villar, J. (2012). 
challenges in defining and classifying the preterm birth syndrome. am J obstet Gynecol, 206(2), 108-112. doi: 
10.1016/j.ajog.2011.10.864
Krupa, f. G., faltin, d., cecatti, J. G., surita, f. G., & souza, J. P. (2006). Predictors of preterm birth. International 
journal of gynaecology and obstetrics: the official organ of the International federation of Gynaecology and 
obstetrics, 94(1), 5-11. doi: 10.1016/j.ijgo.2006.03.022
Kusanovic, J. P., espinoza, J., romero, r., Goncalves, l. f., nien, J. K., soto, e., . . . hassan, s. s. (2007). clinical 
significance of the presence of amniotic fluid ‘sludge’ in asymptomatic patients at high risk for spontaneous 
preterm delivery. ultrasound in obstetrics & gynecology : the official journal of the International society of 
ultrasound in obstetrics and Gynecology, 30(5), 706-714. doi: 10.1002/uog.4081
Kusanovic, J. P., romero, r., chaiworapongsa, T., Mittal, P., Mazaki-Tovi, s., Vaisbuch, e., . . . hassani, s. s. 
(2010). amniotic fluid sTreM-1 in normal pregnancy, spontaneous parturition at term and preterm, and in-
tra-amniotic infection/inflammation. Journal of Maternal-fetal & neonatal Medicine, 23(1), 34-47. doi: doi 
10.3109/14767050903009248
lamont, r. f., nhan-chang, c. l., sobel, J. d., Workowski, K., conde-agudelo, a., & romero, r. (2011). Treatment 
of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: 
a systematic review and metaanalysis. am J obstet Gynecol, 205(3), 177-190. doi: 10.1016/j.ajog.2011.03.047
larma, J. d., & Iams, J. d. (2012). Is sonographic assessment of the cervix necessary and helpful? clin obstet 
Gynecol, 55(1), 324-335. doi: 10.1097/Grf.0b013e3182487e96
lasswell, s. M., Barfield, W. d., rochat, r. W., & Blackmon, l. (2010). Perinatal regionalization for very low-
birth-weight and very preterm infants: a meta-analysis. JaMa, 304(9), 992-1000. doi: 10.1001/jama.2010.1226
laudanski, P., lemancewicz, a., Pierzynski, P., akerlund, M., & laudanski, T. (2006). decreased serum level of 
macrophage inflammatory chemokine-3 beta/ccl19 in preterm labor and delivery. european Journal of ob-
stetrics Gynecology and reproductive Biology, 124(1), 23-26. doi: doI 10.1016/j.ejogrb.2005.05.006
leeman, M. f., curran, s., & Murray, G. I. (2002). The structure, regulation, and function of human ma-
trix metalloproteinase-13. critical reviews in biochemistry and molecular biology, 37(3), 149-166. doi: 
10.1080/10409230290771483
leitich, h. (2005). secondary predictors of preterm labour. BJoG, 112 suppl 1, 48-50. doi: 10.1111/j.1471-
0528.2005.00584.x
leitich, h., & Kaider, a. (2003). fetal fibronectin--how useful is it in the prediction of preterm birth? BJoG, 110 
suppl 20, 66-70. 
liu, Y. e., Wang, M., Greene, J., su, J., ullrich, s., li, h., . . . shi, Y. e. (1997). Preparation and characterization of 
recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol chem, 272(33), 20479-20483. 
locksmith, G. J., clark, P., duff, P., saade, G. r., & schultz, G. s. (2001). amniotic fluid concentrations of matrix 
metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during pregnancy and labor. am J obstet Gy-
necol, 184(2), 159-164. doi: 10.1067/mob.2001.108860
Keller, M., felderhoff-Mueser, u., lagercrantz, h., dammann, o., Marlow, n., huppi, P., . . . saugstad, o. d. 
(2010). Policy benchmarking report on neonatal health and social policies in 13 european countries. acta pae-
diatrica, 99(11), 1624-1629. doi: 10.1111/j.1651-2227.2010.01894.x
Keller, M., Mader, s., Thiele, n., saugstad, o.d/, & van steenbrugge, G. (2011). caring for tomorrow. efcnI White 
Paper on Maternal and newborn health and aftercare services (pp. 195). Germany: european foundation for 
the care of newborn Infants (efcnI).
Kenyon, s., Boulvain, M., & neilson, J. P. (2010). antibiotics for preterm rupture of membranes. cochrane data-
base syst rev(8), cd001058. doi: 10.1002/14651858.cd001058.pub2
Kenyon, s., Pike, K., Jones, d. r., Brocklehurst, P., Marlow, n., salt, a., & Taylor, d. J. (2008). childhood outcomes 
after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up 
of the oracle I trial. lancet, 372(9646), 1310-1318. doi: 10.1016/s0140-6736(08)61202-7
Kenyon, s. l., Taylor, d. J., & Tarnow-Mordi, W. (2001a). Broad-spectrum antibiotics for preterm, prelabour 
rupture of fetal membranes: the oracle I randomised trial. oracle collaborative Group. lancet, 357(9261), 
979-988. 
Kenyon, s. l., Taylor, d. J., & Tarnow-Mordi, W. (2001b). Broad-spectrum antibiotics for spontaneous preterm 
labour: the oracle II randomised trial. oracle collaborative Group. lancet, 357(9261), 989-994. 
Khan, K. s., & honest, h. (2007). risk screening for spontaneous preterm labour. Best practice & research. 
clinical obstetrics & gynaecology, 21(5), 821-830. doi: 10.1016/j.bpobgyn.2007.03.004
Kim, c. J., romero, r., Kusanovic, J. P., Yoo, W., dong, Z., Topping, V., . . . Kim, J. s. (2010). The frequency, clin-
ical significance, and pathological features of chronic chorioamnionitis: a lesion associated with spontaneous 
preterm birth. Mod Pathol, 23(7), 1000-1011. doi: 10.1038/modpathol.2010.73
King, J., & flenady, V. (2002). Prophylactic antibiotics for inhibiting preterm labour with intact membranes. 
cochrane database syst rev(4), cd000246. doi: 10.1002/14651858.cd000246
King, J., flenady, V., cole, s., & Thornton, s. (2005). cyclo-oxygenase (coX) inhibitors for treating preterm la-
bour. cochrane database syst rev(2), cd001992. doi: 10.1002/14651858.cd001992.pub2
King, J. f., flenady, V. J., Papatsonis, d. n., dekker, G. a., & carbonne, B. (2003). calcium channel blockers for 
inhibiting preterm labour. cochrane database syst rev(1), cd002255. doi: 10.1002/14651858.cd002255
Kisand, K., Kerna, I., Kumm, J., Jonsson, h., & Tamm, a. (2011). Impact of cryopreservation on serum concen-
tration of matrix metalloproteinases (MMP)-7, TIMP-1, vascular growth factors (VeGf) and VeGf-r2 in Biobank 
samples. clin chem lab Med, 49(2), 229-235. doi: 10.1515/cclM.2011.049
Klein, l. l., & Gibbs, r. s. (2005). Infection and preterm birth. obstet Gynecol clin north am, 32(3), 397-410. 
doi: 10.1016/j.ogc.2005.03.001
Klesney-Tait, J., Turnbull, I. r., & colonna, M. (2006). The TreM receptor family and signal integration. nature 
immunology, 7(12), 1266-1273. doi: ni1411 [pii]10.1038/ni1411
Knudsen, l. s., christensen, I. J., lottenburger, T., svendsen, M. n., nielsen, h. J., nielsen, l., . . . Johansen, J. 
s. (2008). Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients 
with rheumatoid arthritis. Biomarkers : biochemical indicators of exposure, response, and susceptibility to 
chemicals, 13(1), 59-78. doi: 781798073 [pii]10.1080/13547500701615017
174 175
re
fe
re
nc
es
references
Mercer, B. M., Miodovnik, M., Thurnau, G. r., Goldenberg, r. l., das, a. f., ramsey, r. d., . . . Mcnellis, d. (1997). 
antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. a ran-
domized controlled trial. national Institute of child health and human development Maternal-fetal Medicine 
units network. JaMa, 278(12), 989-995. 
Moutquin, J. M. (2003). classification and heterogeneity of preterm birth. BJoG, 110 suppl 20, 30-33. 
Murphy, K., Travers, P., & Walport, M. (2008). Janeway’s immunobiology (seventh edition ed.). united states: 
Garland science, Tayler & francis group.
Murray, G. I. (2001). Matrix metalloproteinases: a multifunctional group of molecules. Journal of Pathology, 
195(2), 135-137. doi: 10.1002/1096-9896(200109)195:2<135::aId-PaTh939>3.0.co;2-G
nagase, h., Visse, r., & Murphy, G. (2006). structure and function of matrix metalloproteinases and TIMPs. 
cardiovascular research, 69(3), 562-573. doi: s0008-6363(05)00565-1 [pii]10.1016/j.cardiores.2005.12.002
neil, P. r., & Wallace, e. M. (2010). Is amnisure(r) useful in the management of women with prelabour rupture 
of the membranes? aust n Z J obstet Gynaecol, 50(6), 534-538. doi: 10.1111/j.1479-828X.2010.01238.x
norman, J. e., Bollapragada, s., Yuan, M., & nelson, s. M. (2007). Inflammatory pathways in the mechanism of 
parturition. BMc pregnancy and childbirth, 7 suppl 1, s7. doi: 10.1186/1471-2393-7-s1-s7
ogge, G., romero, r., lee, d. c., Gotsch, f., Than, n. G., lee, J., . . . Kim, c. J. (2011). chronic chorioamnionitis dis-
plays distinct alterations of the amniotic fluid proteome. Journal of Pathology, 223(4), 553-565. doi: 10.1002/
path.2825
orsi, n. M. (2008). cytokine networks in the establishment and maintenance of pregnancy. human fertility, 
11(4), 222-230. doi: 10.1080/14647270802206879
orsi, n. M., & Tribe, r. M. (2008). cytokine networks and the regulation of uterine function in pregnancy and 
parturition. Journal of neuroendocrinology, 20(4), 462-469. doi: 10.1111/j.1365-2826.2008.01668.x
Papatsonis, d., flenady, V., cole, s., & liley, h. (2005). oxytocin receptor antagonists for inhibiting preterm 
labour. cochrane database syst rev(3), cd004452. doi: 10.1002/14651858.cd004452.pub2
Papatsonis, d., flenady, V., & liley, h. (2009). Maintenance therapy with oxytocin antagonists for in-
hibiting preterm birth after threatened preterm labour. cochrane database syst rev(1), cd005938. doi: 
10.1002/14651858.cd005938.pub2
Park, J. J., cheon, J. h., Kim, B. Y., Kim, d. h., Kim, e. s., Kim, T. I., . . . Kim, W. h. (2009). correlation of serum-sol-
uble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel dis-
ease. digestive diseases and sciences, 54(7), 1525-1531. doi: 10.1007/s10620-008-0514-5
Park, K. h., chaiworapongsa, T., Kim, Y. M., espinoza, J., Yoshimatsu, J., edwin, s., . . . romero, r. (2003). Matrix 
metalloproteinase 3 in parturition, premature rupture of the membranes, and microbial invasion of the amni-
otic cavity. J Perinat Med, 31(1), 12-22. doi: 10.1515/JPM.2003.002
Park, K. h., lee, s. Y., Kim, s. n., Jeong, e. h., oh, K. J., & ryu, a. (2012). Prediction of imminent preterm de-
livery in women with preterm premature rupture of membranes. J Perinat Med, 40(2), 151-157. doi: 10.1515/
JPM.2011.124
lumbiganon, P., laopaiboon, M., & Thinkhamrop, J. (2010). screening and treating asymptomatic bacteriuria in 
pregnancy. curr opin obstet Gynecol, 22(2), 95-99. doi: 10.1097/Gco.0b013e3283374adf
lumley, J., chamberlain, c., dowswell, T., oliver, s., oakley, l., & Watson, l. (2009). Interventions for promot-
ing smoking cessation during pregnancy. cochrane database syst rev(3), cd001055. doi: 10.1002/14651858.
cd001055.pub3
MacIntyre, d. a., sykes, l., Teoh, T. G., & Bennett, P. r. (2012). Prevention of preterm labour via the modulation of 
inflammatory pathways. J Matern fetal neonatal Med, 25 suppl 1, 17-20. doi: 10.3109/14767058.2012.666114
Maymon, e., romero, r., Pacora, P., Gervasi, M. T., Gomez, r., edwin, s. s., & Yoon, B. h. (2000). evidence of in 
vivo differential bioavailability of the active forms of matrix metalloproteinases 9 and 2 in parturition, sponta-
neous rupture of membranes, and intra-amniotic infection. am J obstet Gynecol, 183(4), 887-894. doi: 10.1067/
mob.2000.108878
Maymon, e., romero, r., Pacora, P., Gomez, r., Mazor, M., edwin, s., . . . Berry, s. M. (2001). a role for the 72 
kda gelatinase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of membranes and 
intraamniotic infection. J Perinat Med, 29(4), 308-316. doi: 10.1515/JPM.2001.044
Mazaki-Tovi, s., romero, r., Kusanovic, J. P., erez, o., Pineles, B. l., Gotsch, f., . . . hassan, s. s. (2007). recurrent 
preterm birth. semin Perinatol, 31(3), 142-158. doi: 10.1053/j.semperi.2007.04.001
Mcdonald, h. M., Brocklehurst, P., & Gordon, a. (2007). antibiotics for treating bacterial vaginosis in pregnan-
cy. cochrane database syst rev(1), cd000262. doi: 10.1002/14651858.cd000262.pub3
Mcdonald, s. d., han, Z., Mulla, s., & Beyene, J. (2010). overweight and obesity in mothers and risk of preterm 
birth and low birth weight infants: systematic review and meta-analyses. BMJ, 341, c3428. doi: 10.1136/bmj.
c3428
Melendez-Zajgla, J., del Pozo, l., ceballos, G., & Maldonado, V. (2008). Tissue inhibitor of metalloproteinases-4. 
The road less traveled. Mol cancer, 7, 85. doi: 10.1186/1476-4598-7-85
Menon, r., & fortunato, s. J. (2004). The role of matrix degrading enzymes and apoptosis in rupture of mem-
branes. Journal of the society for Gynecologic Investigation, 11(7), 427-437. doi: 10.1016/j.jsgi.2004.04.00
1s1071-5576(04)00180-7 [pii]
Menon, r., & fortunato, s. J. (2007). Infection and the role of inflammation in preterm premature rupture 
of the membranes. Best practice & research. clinical obstetrics & gynaecology, 21(3), 467-478. doi: s1521-
6934(07)00023-5 [pii]10.1016/j.bpobgyn.2007.01.008
Menon, r., & fortunato, s. J. (2008). Induction of Triggering receptors of Myeloid cell (TreM-1) expression in 
fetal Membranes and higher concentration of soluble TreM-1 in amniotic fluid With spontaneous Preterm 
Birth. reproductive sciences, 15(8), 825-830. doi: doi 10.1177/1933719108320090
Menon, r., Torloni, M. r., Voltolini, c., Torricelli, M., Merialdi, M., Betran, a. P., . . . arora, c. (2011). Biomarkers 
of spontaneous preterm birth: an overview of the literature in the last four decades. reprod sci, 18(11), 1046-
1070. doi: 10.1177/1933719111415548
Mercer, B. (2012). antibiotics in the management of ProM and preterm labor. obstet Gynecol clin north am, 
39(1), 65-76. doi: 10.1016/j.ogc.2011.12.007
176 177
re
fe
re
nc
es
references
romero, r., chaiworapongsa, T., espinoza, J., Gomez, r., Yoon, B. h., edwin, s., . . . Berry, s. (2002). fetal plasma 
MMP-9 concentrations are elevated in preterm premature rupture of the membranes. american Journal of 
obstetrics and Gynecology, 187(5), 1125-1130. doi: s0002937802003782 [pii]
romero, r., espinoza, J., Goncalves, l. f., Kusanovic, J. P., friel, l., & hassan, s. (2007). The role of inflammation 
and infection in preterm birth. seminars in reproductive Medicine, 25(1), 21-39. doi: doI 10.1055/s-2006-956773
romero, r., espinoza, J., Goncalves, l. f., Kusanovic, J. P., friel, l. a., & nien, J. K. (2006). Inflammation in preterm 
and term labour and delivery. semin fetal neonatal Med, 11(5), 317-326. doi: 10.1016/j.siny.2006.05.001
romero, r., espinoza, J., Gotsch, f., Kusanovic, J. P., friel, l. a., erez, o., . . . Tromp, G. (2006). The use of high-di-
mensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm 
parturition syndrome. BJoG, 113 suppl 3, 118-135. doi: 10.1111/j.1471-0528.2006.01150.x
romero, r., espinoza, J., Kusanovic, J. P., Gotsch, f., hassan, s., erez, o., . . . Mazor, M. (2006). The preterm 
parturition syndrome. Bjog-an International Journal of obstetrics and Gynaecology, 113, 17-42. doi: doI 
10.1111/j.1471-0528.2006.01120.x
romero, r., espinoza, J., rogers, W. T., Moser, a., nien, J. K., Kusanovic, J. P., . . . hassan, s. s. (2008). Proteomic 
analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: 
the use of a novel computational method to analyze mass spectrometric profiling. J Matern fetal neonatal 
Med, 21(6), 367-388. doi: 10.1080/14767050802045848
romero, r., friel, l. a., Velez edwards, d. r., Kusanovic, J. P., hassan, s. s., Mazaki-Tovi, s., . . . Menon, r. (2010). 
a genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture 
of membranes (ProM). am J obstet Gynecol, 203(4), 361 e361-361 e330. doi: 10.1016/j.ajog.2010.05.026
romero, r., Gotsch, f., Pineles, B., & Kusanovic, J. P. (2007). Inflammation in pregnancy: its roles in reproduc-
tive physiology, obstetrical complications, and fetal injury. nutrition reviews, 65(12 Pt 2), s194-202. 
romero, r., Kusanovic, J. P., espinoza, J., Gotsch, f., nhan-chang, c. l., erez, o., . . . costerton, J. W. (2007). 
What is amniotic fluid ‘sludge’? ultrasound in obstetrics & gynecology : the official journal of the International 
society of ultrasound in obstetrics and Gynecology, 30(5), 793-798. doi: 10.1002/uog.5173
romero, r., Mazaki-Tovi, s., Vaisbuch, e., Kusanovic, J. P., chaiworapongsa, T., Gomez, r., . . . Beecher, c. (2010). 
Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern 
fetal neonatal Med, 23(12), 1344-1359. doi: 10.3109/14767058.2010.482618
romero, r., nicolaides, K., conde-agudelo, a., Tabor, a., o’Brien, J. M., cetingoz, e., . . . hassan, s. s. (2012). 
Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases 
preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. am 
J obstet Gynecol, 206(2), 124 e121-119. doi: 10.1016/j.ajog.2011.12.003
romero, r., schaudinn, c., Kusanovic, J. P., Gorur, a., Gotsch, f., Webster, P., . . . costerton, J. W. (2008). detec-
tion of a microbial biofilm in intraamniotic infection. am J obstet Gynecol, 198(1), 135 e131-135. doi: 10.1016/j.
ajog.2007.11.026
romero, r., Velez edwards, d. r., Kusanovic, J. P., hassan, s. s., Mazaki-Tovi, s., Vaisbuch, e., . . . Menon, r. 
(2010). Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predis-
pose to spontaneous preterm labor with intact membranes. am J obstet Gynecol, 202(5), 431 e431-434. doi: 
10.1016/j.ajog.2010.03.026
Parry, s., simhan, h., elovitz, M., & Iams, J. (2012). universal maternal cervical length screening during the 
second trimester: pros and cons of a strategy to identify women at risk of spontaneous preterm delivery. am J 
obstet Gynecol, 207(2), 101-106. doi: 10.1016/j.ajog.2012.04.021
Paternoster, d. M., Muresan, d., Vitulo, a., serena, a., Battagliarin, G., dell’avanzo, M., & nicolini, u. (2007). 
cervical phIGfBP-1 in the evaluation of the risk of preterm delivery. acta obstet Gynecol scand, 86(2), 151-155. 
doi: 10.1080/00016340600935730
Peltier, M. r. (2003). Immunology of term and preterm labor. reproductive biology and endocrinology : rB&e, 
1, 122. doi: 10.1186/1477-7827-1-122
Pennell, c. e., Jacobsson, B., Williams, s. M., Buus, r. M., Muglia, l. J., dolan, s. M., . . . relton, c. (2007). Genetic 
epidemiologic studies of preterm birth: guidelines for research. am J obstet Gynecol, 196(2), 107-118. doi: 
10.1016/j.ajog.2006.03.109
Petrou, s., eddama, o., & Mangham, l. (2011). a structured review of the recent literature on the economic 
consequences of preterm birth. arch dis child fetal neonatal ed, 96(3), f225-232. doi: 10.1136/adc.2009.161117
Pilka, r., domanski, h., hansson, s., eriksson, P., & casslen, B. (2004). endometrial TIMP-4 mrna is high at 
midcycle and in hyperplasia, but down-regulated in malignant tumours. coordinated expression with MMP-
26. Molecular human reproduction, 10(9), 641-650. doi: 10.1093/molehr/gah092
Pilka, r., oborna, I., lichnovsky, V., havelka, P., fingerova, h., eriksson, P., . . . casslen, B. (2006). endometrial 
expression of the estrogen-sensitive genes MMP-26 and TIMP-4 is altered by a substitution protocol without 
down-regulation in IVf patients. human reproduction, 21(12), 3146-3156. doi: 10.1093/humrep/del180
raffetto, J. d., & Khalil, r. a. (2008). Matrix metalloproteinases and their inhibitors in vascular remodeling and 
vascular disease. Biochemical pharmacology, 75(2), 346-359. doi: 10.1016/j.bcp.2007.07.004
rahkonen, l., unkila-Kallio, l., nuutila, M., sainio, s., saisto, T., rutanen, e. M., & Paavonen, J. (2009). cervical 
length measurement and cervical phosphorylated insulin-like growth factor binding protein-1 testing in pre-
diction of preterm birth in patients reporting uterine contractions. acta obstet Gynecol scand, 88(8), 901-908. 
doi: 10.1080/00016340903104281
rahkonen, l., unkila-Kallio, l., rutanen, e. M., & Paavonen, J. (2009). factors affecting decidual IGfBP-1 
levels in the vagina and cervix in the first and mid-second trimester of pregnancy. BJoG, 116(1), 45-54. doi: 
10.1111/j.1471-0528.2008.01959.x
ramsey, P. s., & andrews, W. W. (2003). Biochemical predictors of preterm labor: fetal fibronectin and salivary 
estriol. clin Perinatol, 30(4), 701-733. 
rijkers, G. T., Kroese, f. G. M., Kallenberg, c. G. M., & derksen, r. h. W. M. (2009). Immunologie (eerste druk 
ed.). houten: Bohn stafleu van loghum.
riley, s. c., leask, r., denison, f. c., Wisely, K., calder, a. a., & howe, d. c. (1999). secretion of tissue inhibitors 
of matrix metalloproteinases by human fetal membranes, decidua and placenta at parturition. Journal of en-
docrinology, 162(3), 351-359. 
roberts, d., & dalziel, s. (2006). antenatal corticosteroids for accelerating fetal lung maturation for women at 
risk of preterm birth. cochrane database syst rev(3), cd004454. doi: 10.1002/14651858.cd004454.pub2
178 179
re
fe
re
nc
es
references
stoll, B. J., hansen, n. I., Bell, e. f., shankaran, s., laptook, a. r., Walsh, M. c., . . . human development neo-
natal research, n. (2010). neonatal outcomes of extremely preterm infants from the nIchd neonatal research 
network. Pediatrics, 126(3), 443-456. doi: 10.1542/peds.2009-2959
su, l., han, B., liu, c., liang, l., Jiang, Z., deng, J., . . . Xie, l. (2012). Value of soluble TreM-1, procalcitonin, 
and c-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new 
fever in intensive care units: a prospective cohort study. BMc Infect dis, 12, 157. doi: 10.1186/1471-2334-12-157
su, l. l., samuel, M., & chong, Y. s. (2010). Progestational agents for treating threatened or established 
preterm labour. cochrane database syst rev(1), cd006770. doi: 10.1002/14651858.cd006770.pub2
subramaniam, a., abramovici, a., andrews, W. W., & Tita, a. T. (2012). antimicrobials for preterm birth preven-
tion: an overview. Infect dis obstet Gynecol, 2012, 157159. doi: 10.1155/2012/157159
sykes, l., Macintyre, d. a., Yap, X. J., Teoh, T. G., & Bennett, P. r. (2012). The Th1:th2 dichotomy of pregnancy 
and preterm labour. Mediators of inflammation, 2012, 967629. doi: 10.1155/2012/967629
Tagore, s., & Kwek, K. (2010). comparative analysis of insulin-like growth factor binding protein-1 (IGfBP-1), 
placental alpha-microglobulin-1 (PaMG-1) and nitrazine test to diagnose premature rupture of membranes in 
pregnancy. J Perinat Med, 38(6), 609-612. doi: 10.1515/JPM.2010.099
Tanir, h. M., sener, T., & Yildiz, Z. (2009). cervical phosphorylated insulin-like growth factor binding protein-1 
for the prediction of preterm delivery in symptomatic cases with intact membranes. The journal of obstetrics 
and gynaecology research, 35(1), 66-72. doi: 10.1111/j.1447-0756.2008.00833.x
Taylor, B. d., holzman, c. B., fichorova, r. n., Tian, Y., Jones, n. M., fu, W., & senagore, P. K. (2013). Inflam-
mation biomarkers in vaginal fluid and preterm delivery. human reproduction. doi: 10.1093/humrep/det019
Teune, M. J., Bakhuizen, s., Gyamfi Bannerman, c., opmeer, B. c., van Kaam, a. h., van Wassenaer, a. G., . . . 
Mol, B. W. (2011). a systematic review of severe morbidity in infants born late preterm. am J obstet Gynecol, 
205(4), 374 e371-379. doi: 10.1016/j.ajog.2011.07.015
Tsiartas, P., holst, r. M., Wennerholm, u. B., hagberg, h., hougaard, d. M., skogstrand, K., . . . Jacobsson, 
B. (2012). Prediction of spontaneous preterm delivery in women with threatened preterm labour: a pro-
spective cohort study of multiple proteins in maternal serum. BJoG, 119(7), 866-873. doi: 10.1111/j.1471-
0528.2012.03328.x
Tucker, J., & McGuire, W. (2004). epidemiology of preterm birth. BMJ, 329(7467), 675-678. doi: 10.1136/
bmj.329.7467.675
Tworoger, s. s., & hankinson, s. e. (2006). collection, processing, and storage of biological samples in epi-
demiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. cancer 
epidemiology, biomarkers & prevention : a publication of the american association for cancer research, co-
sponsored by the american society of Preventive oncology, 15(9), 1578-1581. doi: 15/9/1578 [pii]10.1158/1055-
9965.ePI-06-0629
unal, e. r., cierny, J. T., roedner, c., newman, r., & Goetzl, l. (2011). Maternal inflammation in spontaneous 
term labor. am J obstet Gynecol, 204(3), 223 e221-225. doi: 10.1016/j.ajog.2011.01.002
Vadillo-ortega, f., & estrada-Gutierrez, G. (2005). role of matrix metalloproteinases in preterm labour. BJoG : 
an international journal of obstetrics and gynaecology, 112 suppl 1, 19-22. doi: BJo00579 [pii]10.1111/j.1471-
0528.2005.00579.x
roos, c., spaanderman, M. e., schuit, e., Bloemenkamp, K. W., Bolte, a. c., cornette, J., . . . Group, a.-I. s. (2013). 
effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a random-
ized controlled trial. JaMa, 309(1), 41-47. doi: 10.1001/jama.2012.153817
rose, c. h., McWeeney, d. T., Brost, B. c., davies, n. P., & Watson, W. J. (2010). cost-effective standardization of 
preterm labor evaluation. am J obstet Gynecol, 203(3), 250 e251-255. doi: 10.1016/j.ajog.2010.06.037
ruetschi, u., rosen, a., Karlsson, G., Zetterberg, h., rymo, l., hagberg, h., & Jacobsson, B. (2005). Proteomic 
analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic 
inflammation. J Proteome res, 4(6), 2236-2242. doi: 10.1021/pr050139e
saigal, s., & doyle, l. W. (2008). an overview of mortality and sequelae of preterm birth from infancy to adult-
hood. lancet, 371(9608), 261-269. doi: 10.1016/s0140-6736(08)60136-1
saito, s., nakashima, a., shima, T., & Ito, M. (2010). Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. 
am J reprod Immunol, 63(6), 601-610. doi: 10.1111/j.1600-0897.2010.00852.x
sanchez-ramos, l., delke, I., Zamora, J., & Kaunitz, a. M. (2009). fetal fibronectin as a short-term predic-
tor of preterm birth in symptomatic patients: a meta-analysis. obstet Gynecol, 114(3), 631-640. doi: 10.1097/
aoG.0b013e3181b47217
schuit, e., stock, s., Groenwold, r. h., Maurel, K., combs, c. a., Garite, T., . . . Mol, B. W. (2012). Progestogens to 
prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trials. 
BMc pregnancy and childbirth, 12, 13. doi: 10.1186/1471-2393-12-13
seong, h. s., lee, s. e., Kang, J. h., romero, r., & Yoon, B. h. (2008). The frequency of microbial invasion of the 
amniotic cavity and histologic chorioamnionitis in women at term with intact membranes in the presence or 
absence of labor. am J obstet Gynecol, 199(4), 375 e371-375. doi: 10.1016/j.ajog.2008.06.040
sharif, o., & Knapp, s. (2008). from expression to signaling: roles of TreM-1 and TreM-2 in innate immunity 
and bacterial infection. Immunobiology, 213(9-10), 701-713. doi: doI 10.1016/j.imbio.2008.07.008
simhan, h., Iams, J., & romer, r. (2007). Preterm birth. In s. G. Gabbe (ed.), obstetrics: normal and problem 
pregnancies (5 ed., pp. 1416). Philadelphia: churchill livingstone/elsevier.
smaill, f., & Vazquez, J. c. (2007). antibiotics for asymptomatic bacteriuria in pregnancy. cochrane database 
syst rev(2), cd000490. doi: 10.1002/14651858.cd000490.pub2
society for Maternal-fetal Medicine Publications committee, w. a. o. V. B. (2012). Progesterone and preterm 
birth prevention: translating clinical trials data into clinical practice. am J obstet Gynecol, 206(5), 376-386. doi: 
10.1016/j.ajog.2012.03.010
sotiriadis, a., Papatheodorou, s., Kavvadias, a., & Makrydimas, G. (2010). Transvaginal cervical length mea-
surement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis. ultra-
sound in obstetrics & gynecology : the official journal of the International society of ultrasound in obstetrics 
and Gynecology, 35(1), 54-64. doi: 10.1002/uog.7457
steer, P. (2005a). The epidemiology of preterm labor--a global perspective. J Perinat Med, 33(4), 273-276. doi: 
10.1515/JPM.2005.053
steer, P. (2005b). The epidemiology of preterm labour. Bjog-an International Journal of obstetrics and Gynae-
cology, 112, 1-3. 
180 181
re
fe
re
nc
es
references
Yonemoto, h., Young, c. B., ross, J. T., Guilbert, l. l., fairclough, r. J., & olson, d. M. (2006). changes in matrix 
metalloproteinase (MMP)-2 and MMP-9 in the fetal amnion and chorion during gestation and at term and 
preterm labor. Placenta, 27(6-7), 669-677. doi: 10.1016/j.placenta.2005.05.014
Youssef, r. e., ledingham, M. a., Bollapragada, s. s., o’Gorman, n., Jordan, f., Young, a., & norman, J. e. 
(2009). The role of toll-like receptors (Tlr-2 and -4) and triggering receptor expressed on myeloid cells 1 
(TreM-1) in human term and preterm labor. reproductive sciences, 16(9), 843-856. doi: 1933719109336621 
[pii]10.1177/1933719109336621
Yuan, M., Jordan, f., McInnes, I. B., harnett, M. M., & norman, J. e. (2009). leukocytes are primed in peripheral 
blood for activation during term and preterm labour. Molecular human reproduction, 15(11), 713-724. doi: 
gap054 [pii]10.1093/molehr/gap054
Yucel, a., Karakus, r., & cemalettin, a. (2007). effect of blood collection tube types on the measurement of hu-
man epidermal growth factor. J Immunoassay Immunochem, 28(1), 47-60. doi: 10.1080/15321810601026091
Zeitlin, J., draper, e. s., Kollee, l., Milligan, d., Boerch, K., agostino, r., . . . group, M. r. (2008). differences in 
rates and short-term outcome of live births before 32 weeks of gestation in europe in 2003: results from the 
MosaIc cohort. Pediatrics, 121(4), e936-944. doi: 10.1542/peds.2007-1620
Zhang, J., cao, Y. J., Zhao, Y. G., sang, q. X., & duan, e. K. (2002). expression of matrix metalloproteinase-26 and 
tissue inhibitor of metalloproteinase-4 in human normal cytotrophoblast cells and a choriocarcinoma cell line, 
JeG-3. Molecular human reproduction, 8(7), 659-666. 
Zhang, J., she, d., feng, d., Jia, Y., & Xie, l. (2011). dynamic changes of serum soluble triggering receptor 
expressed on myeloid cells-1 (sTreM-1) reflect sepsis severity and can predict prognosis: a prospective study. 
BMc Infect dis, 11, 53. doi: 10.1186/1471-2334-11-53
Vadillo-ortega, f., hernandez, a., Gonzalez-avila, G., Bermejo, l., Iwata, K., & strauss, J. f., 3rd. (1996). In-
creased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1 levels in am-
niotic fluids from pregnancies complicated by premature rupture of membranes. am J obstet Gynecol, 174(4), 
1371-1376. 
van Baaren, G. J., Vis, J. Y., Wilms, f. f., oudijk, M. a., Kwee, a., Porath, M. M., . . . Mol, B. (2013). The accuracy 
of fetal fibronectin and cervical length in women with signs of preterm labor before 34 weeks: a nationwide 
cohort study in The netherlands (aPosTel 1 study). Paper presented at the 33rd sMfM annual Meeting, san 
francisco.
Van haesebrouck, P., charon, a., devlieger, h., haumont, d., langhendries, J. P., Michel, M., . . . clercx, a. 
(2008). nIcaudit® synoptic report 2000-2007. Brussels: college of Physicians for the Mother and newborn, 
federal public service health, food chain safety and environment.
Van Parys, a. s., lucet, c., remacle, a., di Zinno, T., Verstraelen, h., Mambourg, f., . . . Temmerman, M. (2008). 
Maternal Intensive care in Belgium (pp. 157). Brussels: Belgian health care Knowledge centre.
Vanhaesebrouck, P., allegaert, K., Bottu, J., debauche, c., devlieger, h., docx, M., . . . extremely Preterm Infants 
in Belgium study, G. (2004). The ePIBel study: outcomes to discharge from hospital for extremely preterm 
infants in Belgium. Pediatrics, 114(3), 663-675. doi: 10.1542/peds.2003-0903-l
Villar, J., Papageorghiou, a. T., Knight, h. e., Gravett, M. G., Iams, J., Waller, s. a., . . . Goldenberg, r. l. (2012). 
The preterm birth syndrome: a prototype phenotypic classification. am J obstet Gynecol, 206(2), 119-123. doi: 
10.1016/j.ajog.2011.10.866
Vogel, I., Goepfert, a. r., Thorsen, P., skogstrand, K., hougaard, d., curry, a. h., . . . andrews, W. W. (2007). 
early second-trimester inflammatory markers and short cervical length and the risk of recurrent preterm birth. 
Journal of reproductive Immunology, 75(2), 133-140. doi: doI 10.1016/j.jri.2007.02.008
Wax, J. r., cartin, a., & Pinette, M. G. (2010). Biophysical and biochemical screening for the risk of preterm 
labor. clinics in laboratory medicine, 30(3), 693-707. doi: 10.1016/j.cll.2010.04.006
Wei, s. q., fraser, W., & luo, Z. c. (2010). Inflammatory cytokines and spontaneous preterm birth in asymptom-
atic women: a systematic review. obstet Gynecol, 116(2 Pt 1), 393-401. doi: 10.1097/aoG.0b013e3181e6dbc0
Weiss, a., Goldman, s., & shalev, e. (2007). The matrix metalloproteinases (MMPs) in the decidua and fetal 
membranes. frontiers in bioscience : a journal and virtual library, 12, 649-659. doi: 2089 [pii]
Widmer, M., Gulmezoglu, a. M., Mignini, l., & roganti, a. (2011). duration of treatment for asymptomatic bac-
teriuria during pregnancy. cochrane database syst rev(12), cd000491. doi: 10.1002/14651858.cd000491.pub2
Woessner, J. f., Jr. (2001). MMPs and TIMPs. an historical perspective. Methods in molecular biology, 151, 1-23. 
Wu, d., Zou, Y. f., Xu, X. Y., feng, X. l., Yang, l., Zhang, G. c., . . . Tang, J. l. (2011). The association of genetic 
polymorphisms with cerebral palsy: a meta-analysis. dev Med child neurol, 53(3), 217-225. doi: 10.1111/j.1469-
8749.2010.03884.x
Yadav, a. K., Madan, T., & Bernal, a. l. (2011). surfactant proteins a and d in pregnancy and parturition. front 
Biosci (elite ed), 3, 291-300. 
183
da
nK
W
oo
rd
DanKWOOrD
Ik herinner me nog heel goed het telefoontje van Prof. dr. Marleen Temmerman - ik was net drie weken beval-
len van Warre - met de vraag of ik interesse had om te doctoreren. Ik kreeg twee weken de tijd om te beslissen. 
Ik heb me vaak afgevraagd of het wel verstandig was om op een moment waarop de hormonen hoogtij vieren 
zo’n belangrijke beslissing te nemen, maar ik besefte ook dat ik deze kans geen twee keer zou krijgen. dus de 
beslissing was vrij snel genomen, al moet ik eerlijkheidshalve bekennen dat ik toen een voor mij heel onbe-
kende weg ben ingeslagen.
de voorbije vijf jaar waren zeer boeiend, met veel uitdagingen en opportuniteiten, maar ook zeer intensief, 
met ups-and-downs. het laatste half jaar leek de bergtop in zicht, maar de haarspeldbochten dienden nog 
genomen te worden vooraleer de finish binnen bereik kwam. het feit dat ik hier vandaag sta heb ik dan ook te 
danken aan de steun en begeleiding van een groot aantal mensen. omdat ik niet kan garanderen dat ik in mijn 
dankwoord niemand zal vergeten, wil ik eerst en vooral iedereen bedanken die op de een of andere manier 
heeft bijgedragen tot dit doctoraat.
een bijzonder woord van dank wil ik richten tot:
Prof. dr. Marleen Temmerman, mijn promotor, voor de mogelijkheid om bij u te doctoreren. Je gedrevenheid, 
enthousiasme en kritische kijk op de dingen waren een bron van inspiratie en motivatie. Bedankt om te gelo-
ven in mijn capaciteiten als onderzoekster en om de vrijheid die ik kreeg in de uitvoering van mijn doctoraats-
onderzoek. 
Prof. dr. Mario Vaneechoutte, mijn co-promotor, voor de vlotte samenwerking tijdens de verschillende studies, 
de constructieve feedback op de papers en de ondersteuning doorheen het doctoraat. 
Prof. dr. Bruno Verhasselt, voor het advies bij het valideren van de MMP-kit en de interpretatie van de immuno-
logische analyses alsook voor kritische revisie van de papers. 
Prof. dr. hans Verstraelen, voor zijn steun en dagdagelijkse begeleiding tijdens dit doctoraat. Je was vaak mijn 
eerste hulp bij ongevallen.
184 185
da
nK
W
oo
rd
danKW
oord
Prof. dr. Jean Plum, voorzitter van de examencommissie en de juryleden Prof. dr. Kristien roelens, Prof. dr. 
Koenraad smets, Prof. dr. George leclercq, Prof. dr. Yves Jacquemyn en Prof. dr. Bo Jacobsson, voor hun inte-
resse en tijd die ze aan deze thesis hebben besteed. I would like to thank all members of the jury for their effort 
in critically appraising this Phd thesis and for their valuable suggestions and detailed corrections to improve 
the quality of this thesis. 
Prof. dr. claus Bachert, voor het beschikbaar stellen van het labo en het luminex platform. 
Gabi holtappels, voor haar hulp bij de immunologische analyses. Gabi, jouw ruime labo-ervaring en deskundi-
ge begeleiding hebben bijgedragen tot het welslagen van de analyses. Je maakte ons wegwijs in het gebruik 
van de luminex technologie en stond steeds paraat bij vragen of problemen. 
dr. rita Verhelst, voor de inwijding in de wereld van de laboanalyses, een hele openbaring en uitdaging voor 
iemand die recht uit de praktijk komt. Je verrijkte mijn woordenschat met termen waar ik het bestaan niet 
eens van vermoedde. Vele spannende en leuke uren hebben we samen gespendeerd in het labo. Bedankt voor 
je begeleiding, je geduld en de vele schouderklopjes. 
Marijke Trog, mijn fijne collega study nurse op wie ik altijd kon rekenen en die probleemloos de studies van mij 
overnam tijdens mijn verlof.
dr. Ivo Kroes, arts-assistent gynaecologie en verloskunde, jij zette de ccPTB studie op de rails, toen ik het rus-
tiger aan diende te doen tijdens de zwangerschap van seppe. Ik herinner me nog goed dat je elke dag verslag 
kwam uitbrengen toen ik opgenomen was in het uZ met verkorte cervix en preterme ontsluiting (en dus bijna 
patiënt in eigen studie werd …). het was fijn samenwerken met jou! Veel succes nog met de opleiding tot 
gynaecoloog en met je latere loopbaan.
alle studenten die hun steentje hebben bijgedragen tot de studies, al dan niet in het kader van hun master-
proef of vrijwillig. Van harte bedankt nele, Klaar, hannelore, Tineke, Isabelle, liesbeth, …
alle vroedvrouwen en arts-assistenten van de Vrouwenkliniek, voor hun bereidwillige en zeer geapprecieerde 
medewerking aan de studie. Bedankt voor de extra inspanningen die jullie leverde bij het verzamelen van de 
bloedstalen en vaginale wissers. 
Bart, ellen, Guido, Piet, leen, … van het labo bacteriologie in Blok a. dank zij jullie maakte ik kennis met de 
voor mij onbekende en aparte wereld van de microbiologie. een extra welgemeende dank aan Bart die de elIsa 
analyses voor zijn rekening heeft genomen en hier ettelijke uren tijd heeft ingestoken. 
alain Visscher, voor de statistische ondersteuning en de talrijke, boeiende discussies hierover. Bij jou kon ik 
terecht met 1001 vragen over statistiek en telkens kreeg ik een zorgvuldig antwoord. 
alle mensen van het Icrh, voor hun collegialiteit met als kers op de taart de activiteiten georganiseerd door 
het fun-team die mij altijd zullen bijblijven. Bijzonder veel dank gaat uit naar an-sofie, collega vroedvrouw 
en doctoraatstudent, bij wie ik steeds terecht kon voor een leuke babbel, een luisterend oor en advies. Veel 
succes met de afwerking van jouw doctoraat! ook dikke merci aan cindy voor de logistieke en administratieve 
ondersteuning bij de voorbereiding van de doctoraatsverdediging.
de kersverse collega’s van Kaho sint lieven, voor hun steun en het begrip de voorbije maanden. Jullie leerde 
mij pas kennen toen ik al bezig was aan de beklimming van de cols… het vertrek na acht jaar uZGent/uGent 
was niet evident, maar jullie gaven mij een warm onthaal, waardoor ik mij meteen thuis voelde in het team. 
Bijzondere dank aan Katrien, voor het luisterend oor, voor het begrip wanneer het Kaho-werk eventjes op de 
tweede plaats kwam de laatste weken. Bedankt voor het nalezen van de thesis. Veel succes met de afwerking 
van jouw doctoraat! ook dank aan Marijke, voor de alle tips en suggesties in het beantwoorden van de com-
mentaren van de juryleden en voor de doctoraatsverdediging. 
Jeroen de Muynck voor de vormgeving van deze doctoraatsthesis en het laten van enkele uren slaap.
niet in het minst, alle zwangeren voor hun deelname aan de studie. Zonder hun bereidwillige medewerking 
was deze studie niet mogelijk. Zij vormden dan ook een grote motivatie om dit doctoraat tot een goed einde 
te brengen. 
Mijn (schoon)familie, voor alle steun en hulp. Jullie stonden steeds klaar om de kinderen op te vangen en 
regelmatig konden we de benen onder tafel steken. Mijn ouders wil ik in het bijzonder bedanken voor de 
kans die ze me gegeven hebben om te studeren (of beter te blijven studeren). examenperiodes waren voor 
jullie best stresserend, zeker met de faalangst die me parten speelde. Jullie stonden steeds klaar, iets wat ik 
enorm waardeer. een bijzonder woord van dank gaat naar mijn oma en meter Margriet, mijn tweede moeder, 
kotmadam en steun en toeverlaat tijdens mijn studies als vroedvrouw. Jammer genoeg kan je dit moment niet 
meer meemaken, want – in de woorden van seppe gezegd – je bent nu het mooiste sterretje van de hemel. 
last but not least, Jeroen, voor zijn onvoorwaardelijke en onmisbare steun tijdens de voorbije jaren. Zonder 
jouw hulp had ik de rit niet uitgereden en hier vandaag niet gestaan. Bedankt om er altijd te zijn voor mij en de 
kinderen. Je bent er steeds in blijven geloven. op moeilijke momenten gaf je mij een duwtje in de rug of pro-
beerde je mij op te vrolijken met jouw typische humor. Warre en seppe, jullie lach en knuffels zorgden ervoor 
dat ik van tijd tot tijd mijn zinnen kon verzetten. Jullie deden mij beseffen dat er meer is in het leven dan het 
schrijven van een doctoraat. ook dank je wel aan Warre en zijn klasgenootjes om deze thesis op te fleuren met 
tekeningen. Bedankt, Jeroen, Warre en seppe, jullie zijn mijn allerliefste sterren!
187
cu
rr
Ic
ul
uM
 a
nd
 P
uB
lI
ca
TI
on
s
CUrrICUlUM anD PUblICaTIOnS
Inge Tency graduated as a midwife in 1999. subsequently, she started a master in Medical social science, 
option health education and promotion at Ghent university (2002) and obtained a teaching certificate in 2003. 
she combined her studies with a job as midwife and became a scientific collaborator of the skills lab at the 
faculty of medicine of Ghent university. In 2005 she leaved clinical practice and worked on diverse scientific 
projects at the Women’s clinic of Ghent university hospital. since december 2012 she worked as a lecturer in 
midwifery education (Kaho sint lieven, sint-niklaas).
 a1-puBlications
Tency I, Verstraelen h, saerens B, Verhasselt B, Vaneechoutte M, degomme o, Verhelst r, Temmerman M.
elevated soluble triggering receptor expressed on myeloid cells (sTreM)-1 levels in maternal serum during 
term and preterm labor.
Plos one 2013;8(2): e56050. doi:10.1371/journal.pone.0056050
Tency I, Verstraelen h, Kroes I, holtappels G, Verhasselt B, Vaneechoutte M, Verhelst r, Temmerman M.
Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in 
maternal serum during preterm labor
Plos one. 2012;7(11):e49042. doi: 10.1371/journal.pone.0049042.
lopes dos santos santiago G, Tency I, Verstraelen h, Verhelst r, Trog M, Temmerman M, Vancoillie l, decat e, 
cools P, Vaneechoutte M.
longitudinal qPcr study of the synamics of l. crispatus, l. iners, a. vaginae, (sialidase positive) G. vaginalis, 
and P. bivia in the vagina.
Plos one. 2012 7(9): e45281. doi:10.1371/journal.pone.0045281
188 189
cu
rr
Ic
ul
uM
 a
nd
 P
uB
lI
ca
TI
on
scurrIculuM
 and PuBlIcaTIons
lopes dos santos santiago G, cools P, Verstraelen h, Trog M, Missine G, el aila na, Verhelst r, Tency I, claeys G, 
Temmerman M, Vaneechoutte M. 
longitudinal study of the dynamics of vaginal microflora during two consecutive menstrual cycles. 
Plos one. 2011 6(11): e28180. doi:10.1371/journal.pone.0028180
el aila na, Tency I, saerens B, de Backer e, cools P, lopes dos santos santiago G, Verstraelen h, Verhelst r, 
Temmerman M, Vaneechoutte M. 
strong correspondence in bacterial loads between the vagina and rectum of pregnant women.
res Microbiol. 2011 Jun;162(5):506-13. 
el aila na, Tency I, claeys G, Verstraelen h, deschagt P, decat e, lopes dos santos santiago G, cools P, Temmer-
man M, Vaneechoutte M.
comparison of culture with two different qPcr assays for detection of rectovaginal carriage of streptococcus 
agalactiae (group B streptococci) in pregnant women.
res Microbiol. 2011 Jun;162(5):499-505.
el aila na,# Tency I,# claeys G, saerens B, cools P, Verstraelen h, Temmerman M, Verhelst r, Vaneechoutte M. 
(# equal contribution)
comparison of different sampling techniques and differend culture methods for detection of group B strepto-
coccus carriage in pregnant women.
BMc Infect dis 2010 sep 29;10:285
el aila na,# Tency I,# claeys G, Verstraelen h, saerens B, lopes dos santos santiago G, de Backer e, cools P, 
Temmerman M, Verhelst r, Vaneechoutte M. (# equal contribution)
Identification and genotyping of bacteria from paired vaginal and rectal samples from pregnant women indi-
cates similarity between vaginal and rectal microflora. 
BMc Infect dis 2009 oct 14;9:167
el aila na,# Tency I,# claeys G, saerens B, de Backer e, Temmerman M, Verhelst r, Vaneechoutte M. (# equal 
contribution)
Genotyping of streptococcus agalactiaie (group B streptococci) isolated from vaginal and rectal swabs of wom-
en at 35-37 weeks of pregnancy.
BMc Infect dis 2009 sep 11;9:153
 a2-puBlications
delbaere I, cammu h, Martens e, Tency I, Martens G, Temmerman M.
limiting the caesarean section rate in low risk pregnancies is key to lowering the trend of increased abdominal 
deliveries: an observational study.
BMc Pregnancy childbirth. 2012 Jan 9;12:3
 a4-puBlications
Timmers l, Goemaes r, Moreels s, Pluymaekers M, Temmerman K, Tency I.
hand of voet, prik of snee? hoe zit het ermee? literatuuroverzicht over de Guthrietest.
Tijdschift voor vroedvrouwen, 2011, 17(6), 383-393.
Tency I, roets, e, coppens M, Temmerman M. 
laten we ’t nuchter houden. Pro’s en contra’s over voeding perpartum.
Tijdschrift voor vroedvrouwen, 2010, 16(5), 279-286.
Van Kerckhove K, Tency I.
Infecties als oorzaak van vroeggeboorte.
Tijdschrift voor vroedvrouwen, 2009, 15(5), 242-248.
Tency I, Martens e, Martens G, foidart JM, Temmerman M. 
Perinatale transer in België: een retrospectieve studie.
Tijdschrift voor vroedvrouwen, 2007, 13(4), 225-229.
Tency I, Grypdonck M. 
systematische voorlichting aan pasbevallen vrouwen in het postpartum: een kwalitatief onderzoek. 
Tijdschrift voor vroedvrouwen, 2003, 9(1), 6-14.
Tency I. 
Verpleegkundige theorieën en modellen in de vroedkunde: toepasbaarheid bij gezondheidsvoorlichting en 
–opvoeding (GVo). 
Tijdschrift voor vroedvrouwen, 2000, 6(5), 166-170.
190 191
cu
rr
Ic
ul
uM
 a
nd
 P
uB
lI
ca
TI
on
scurrIculuM
 and PuBlIcaTIons
 c3-puBlications
Tency I, Verstraelen h, degomme o, Verhelst r, saerens B, Verhasselt B, Vaneechoutte M, Temmerman M.
elevated sTreM-1 levels in maternal serum during term and preterm labor.
22nd european congress of obstetrics and Gynaecology (eBcoG), 9-12 mei 2012, Tallinn, estland.
Tency I, Verstraelen h, Verhelst r, Temmerman M.
Inflammatory response in maternal serum during preterm labour.
Wetenschapsdag, faculteit Geneeskunde en gezondheidswetenschappen, uGent, 14 maart 2012, Gent, België
Tency I, Verstraelen h, Kroes I, holtappels G, Vaneechoutte M, Verhelst r, Temmerman M.
Maternal matrix metalloproteinase (MMP)-3 and 9 levels in preterm birth.
7th european conference of european society for Infectious diseases in obstetrics and Gynaecology, 2-5 okto-
ber 2010, Trieste, Italië.
Tency I, daninck s.
one epidural and an orange juice please! Pros and cons of eating and drinking during labour.
25th International Winter symposium “Topics in anesthesia and algology” Midwifery symposium, 8 januari 
2010, leuven, België.
Tency I. 
laten we ’t nuchter houden: discussieworkshop over de zin en onzin van het nuchter blijven tijdens de arbeid.
Internationale dag van de vroedvrouw, 4 mei 2007, dworp, België
de Wispelaere c, haeck K, reniers J, Mariën B, Poelman T, hugelier f, Tency I, deveugele M, derese aGM. 
simulatie-instructiepatiënten in de training en toetsing Integrale consultvoering. 
nVMo-congres, 9-10 november 2006, amsterdam, nederland.
haeck K, reniers J, Tency I, Mariën B, Poelman T, deveugele M & derese a. 
consultations skills training and assessment with simulated instruction patients. 
The network: Towards unity for health, annual conference, 9-14 september 2006, Gent, België.
Tency, I.
Informatiebehoeften en gezondheidsvoorlichting: enkele theoretische concepten.
Minisymposium: het belang van voorlichting tijdens de zwangerschap”, expertisecentrum Kraamzorg lim-
burg, 25 april 2006, hasselt, België
Tency I, cosyns M, Goeman a, huysman M, laureys V, de Grave h, embo M, derese a. 
huisarts en zwangerschap: een praktijkgerichte opleidingssessie. 
nVMo-congres, 17-18 november 2005., amsterdam, nederland.
de Wispelaere c, Tency I, derese a, Van Zele e; lenaerts J. 
elektronische zelfstoetsing in het skillslab. 
nVMo-congres, 17-18 november 2005, amsterdam, nederland.
dewispelaere c, Tency I.
Workshop “Just in Time Teaching in het skillslab”
symposium “autonoom, multimediaal en interactief leren in het skillslab”, 10 juni 2005, Gent, België
derese a, Tency I, haeck K, hardy M, hugelier f, Present l. 
optimalisatie van het skillslabonderwijs: creëren van mogelijkheden tot actief zelfstandig leren. symposium 
“Technology in the learning process: visions for today and tomorrow”, 3 maart 2005, Gent, België.
 v-puBlications
Tency I, Martens e, Martens G, foidart JM, Temmerman M. 
Perinatal referral in Belgium. 
federal Public service (fPs) health, food chain safety and environment, college of physicians for Mother and 
newborn, Brussels, May 2007.
INFLAMMATORY RESPONSE IN MATERNAL 
SERUM DURING PRETERM LABOUR
INFLAM
M
ATORY RESPONSE IN M
ATERNAL SERUM
 DURING PRETERM
 LABOUR
INGE TENCY
Inge Tency
2013
Faculty of medicine and Health Sciences
Department of Obstetrics and Gynaecology
Inge_Thesis_Kaft_371x240.indd   1 20/06/13   23:34
